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Summary
To produce energy and maintain healthy function the brain requires a steady supply of
oxygen which if interrupted results in impaired function and tissue damage. Oxygen
metabolism is therefore presented as a desirable physiological function to measure as it
is closely linked with brain tissue function and health. Recently an MRI method was
introduced capable of measuring absolute oxygen metabolism in the brain [1–3]. The
technique is based on using both hypercapnic and hyperoxic respiratory challenges to
calibrate the blood oxygen level dependent (BOLD) functional MRI (FMRI) signal. The
aim of this thesis is to further develop this promising technique, referred to here as dual
calibrated FMRI (dcFMRI), proving its suitability for application in further studies of
oxygen metabolism in the brain.
Initially, in this thesis, the role of oxygen metabolism in energy production, brain func-
tion and disease is discussed. To motivate the development of dcFMRI a review of
current measurement techniques is presented followed by an introduction to the basic
MRI concepts underpinning the dcFMRI approach. The dcFMRI technique is then
described in detail.
The optimal ASL acquisition available in our centre for application in the dcFMRI
measurement was experimentally investigated, allowing a dcFMRI protocol to be imple-
mented. A comparison of dcFMRI respiratory designs, for detecting regional changes in
oxygen metabolism, was made and the within and between session repeatability of these
measurements were assessed. In order to make the technique more clinically feasible,
reductions in acquisition time were assessed using a retrospective analytical approach.
The ability of dcFMRI to detect global flow related changes in oxygen metabolism was
demonstrated and a novel dcFMRI approach was implemented. This availed of an R′2
based measure to replace the hypercapnic respiratory challenge in the dcFMRI protocol.
Potential areas for future work and further application of the dcFMRI technique are
then considered.
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Chapter 1
Energy Metabolism and the Brain
The brain serves as the centre of the nervous system providing centralised control
over the other organs in the body. As with all organs, energy metabolism is
vital to fuel basic cellular processes and maintain proper working function of the
brain and therefore the body. In this chapter motivation will be provided for the
measurement of physiological processes related to energy metabolism.
1.1 The Brain on a Cellular Level
The brain is composed mainly of glial cells and neurons. Glial cells are responsible
for the structural support, metabolism, insulation and guidance of development
whereas neurons are responsible for relaying information throughout the brain and
body. Neurons are electrically excitable cells that process and transmit information
through electrochemical signals. They form the basis of the vastly complicated
signalling system which allows the brain centralised control over the body. In
order to achieve this billions of interconnected neurons form the nervous system
and relay signals to and from the brain.
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1.1.1 The Neuron
A single neuron is composed of a number of different parts, each with a specific
function. The soma or cell body, contains the cell nucleus and serves to main-
tain the cell and keep the neuron functional. Dendrites branch outward from the
soma and act as receivers for neural signals communicated by connected neurons.
Neural signals are transported through the neuron via the axon, an elongated fi-
bre that extends from the cell body to terminal endings. The terminal endings
form connections with dendrites of other cells, which may be neurons, through
the synapse. The synapse allows the transmission of the electrochemical signals
from the terminal endings (pre-synaptic) to the dendrites (post-synaptic) using a
neurotransmitter. When an electrochemical signal has travelled the length of the
axon it stimulates the release of neurotransmitters into the synapse. The neuro-
transmitter crosses the synapse and attaches to receptors on the neighbouring cell.
These receptors can change the properties of the receiving cell and if the receiving
cell is also a neuron, the signal can continue the transmission to the next cell.
1.1.2 Neural Signalling
The signals transported by neurons are in the form of electrochemical pulses re-
ferred to as action potentials. These electrochemical signals are formed due to the
distribution of ions inside and outside the cell. Ions are atoms with a net positive
or negative electrical charge. The cell membrane is the division which divides the
interior and exterior of the cell and the membrane potential describes the electrical
potential or voltage across the cell membrane due to the presence of ions. As a
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result, the membrane potential depends on the intra / extra - cellular distribution
of ions across the cell membrane and the permeability of the membrane to those
ions. The membrane potential is the medium for neuronal signalling as it is the
property in the neuron which is altered when a signal is received from another
neuron.
The principle ions involved in neuronal signalling are sodium (Na+), potassium
(K+), calcium (Ca2+) and chloride (Cl−) with higher concentrations of K+ inside
the cell and Na+, Ca2+ and Cl− outside the cell. This leads to a net negative resting
potential. These ions cannot freely diffuse through the cell membrane but instead
their passage is controlled by ion channels. Importantly these ion channels can be
modulated to allow the passage of different ions through the membrane.
To form an initial action potential, a signal is sent, from the cell body to the neural
membrane, to open ion channels allowing positively charged ions inside the cell and
negatively charged ions out. This process causes a rapid increase in the positive
charge of the nerve fibre. When the charge reaches a threshold level the impulse
is propagated down the nerve fibre. This electrical impulse is carried down the
nerve through a series of action potentials. An action potential which arrives at a
synapse with another neuron initiates a process, releasing neurotransmitters from
vesicles in the pre-synaptic terminal which cause ion channels on the post-synaptic
neuron to open or close. Depending on the type of ion channels which are opened
or closed the membrane potential may depolarise again producing a propagation
of the action potential.
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A given neuron may receive signals from many other neurons at any given time,
creating fluctuations in the membrane potential on the dendritic tree. If a suf-
ficient cumulative current reaches the cell body, the membrane potential will be
depolarised, generating an action potential and sending a new signal to other neu-
rons. However it is important to note that there is likely to be a lot of synaptic
activity that does not lead to spiking or action potentials.
1.1.3 Restoring the Resting Potential
After the neuron has fired, there is a refractory period in which another action po-
tential is not possible and the cell must return to it’s original high energy resting
state. This allows the neuron to produce further action potentials. It is at this
stage where an energy source is required to perform work. The resting potential of
the neuron must be restored and the neurotransmitter returned to the vesicles in a
process which requires movement of atoms and molecules against their concentra-
tion gradients. As such, neuronal signalling can be considered a spontaneous but
controlled process. The neuron is stored in a high energy state where it is waiting
for a trigger to release this energy.
From this it can be seen that neurons require energy in order to maintain proper
function. Energy is required for basic cellular maintenance, the generation and
propagation of the action potential, pre-synaptic recovery involving the clearance
of ions and repackaging of neurotransmitter to the vesicles and post-synaptic recov-
ery involving restoration of the intra / extra - cellular ion distribution. How much
energy is required depends on the spiking rate and average number of synapses
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reached by each action potential. However, the most energy intensive process
involves the restoration of post-synaptic resting potential [4].
1.2 Oxygen Metabolism in the Brain
1.2.1 Adenosine Triphosphate
Adenosine triphosphate (ATP) is the main source of energy used by cells in the
body and is therefore the main source of energy used to fuel the cellular processes
associated with neural signalling and activity. It is estimated that at least half of
the ATP used in the brain is consumed in the restoration of post-synaptic resting
potential [5].
ATP can be produced in the brain through aerobic respiration, a process which
requires oxygen, and anaerobic respiration, in a process which does not require oxy-
gen. Aerobic respiration occurs when oxygen and hydrogen atoms bond together
to break down glucose, and facilitate an exchange of energy, producing by-products
of carbon dioxide and water. Anaerobic glycolysis, occurs when glucose is broken
down without the presence of oxygen and has lactic acid as a by-product.
Another distinguishing feature between the two processes is that aerobic respira-
tion produces considerably more ATP molecules, 38 per glucose molecule, com-
pared to anaerobic respiration, 2 ATP molecules per glucose molecule. The im-
portance of oxygen to the brain is therefore highlighted by the fact that virtually
all of the ATP used to fuel cellular work is derived from the metabolism of glu-
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cose and oxygen. If the brain is deprived of oxygen, energy production through
purely anaerobic means cannot meet the brain’s energy demands, leading to un-
consciousness and irreversible cellular death. Following on from this, as the brain
has no reserve supplies of oxygen and glucose it must be continuously supplied
with these raw materials in order to maintain sufficient production of ATP and
maintain proper cellular function.
1.2.2 Arterial Blood Gases
Oxygen Transport
Human blood is primarily comprised of plasma and red blood cells (RBC’s) which
carry haemoglobin. Since oxygen is only soluble in water in small quantities,
the main constituent of blood, an oxygen transport protein is required to carry
sufficient amounts of oxygen in the blood. In humans this oxygen transport protein
is haemoglobin. Haemoglobin is composed of four chains of proteins (globins), with
a haem group attached to each chain, each of which contains one iron ion. The
iron ion is the site of oxygen binding and as such each haemoglobin molecule is
capable of binding a total of four oxygen molecules.
The partial pressure of oxygen (pO2) determines how much oxygen is bound to
haemoglobin. The vast majority of oxygen present in blood is bound to haemoglobin,
with only a very small amount dissolved in plasma. The maximum amount of
oxygen that can be carried in the blood is therefore determined by the amount
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of haemoglobin present. When every oxygen binding site is occupied the blood is
said to be 100% saturated.
The oxygen-haemoglobin dissociation curve plots the proportion of haemoglobin
in its saturated form on the vertical axis against pO2 on the horizontal axis. The
curve typically follows a sigmoidal shape with higher pO2 values demonstrating
higher oxygen saturation. The oxygen-haemoglobin dissociation curve is essential
in understanding how blood carries and releases oxygen. Values of pO2 in the
lungs are typically 100 mmHg whereas pO2 in tissue capillaries are typically lower,
∼ 40 mmHg. Highly saturated arterial blood which has travelled from the lungs
to the tissue capillaries therefore releases oxygen to the tissue due to the gradient
in pO2 between lung and tissue capillaries. Tissue which is more active uses more
oxygen, dropping tissue pO2 and leading to a greater gradient causing larger oxygen
delivery to the active tissue.
Carbon Dioxide Transport
Carbon dioxide is produced in the tissue, and diffuses down its concentration
gradient into the extracellular fluid and then into the blood. Carbon dioxide is
not easily stored and transported in its original form, but reacts with water to
form bicarbonate ions that are dissolved in the plasma for removal.
The formation of bicarbonate is normally slow in blood plasma, however in RBC’s
the presence of enzymes dramatically accelerate this process through the transfor-
mation of diffusing carbon dioxide into bicarbonate and hydrogen ions. These end
products can greatly alter the local pH, and several proteins (including haemoglobin)
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help buffer the additional hydrogen ions to maintain stable pH. Haemoglobin
acts as a better buffer when deoxygenated thus the unloading of oxygen from
haemoglobin enables better absorption and removal of carbon dioxide from the
tissue.
Changes in respiration can affect the concentration gradient of gases in the lungs,
which in turn can affect the loading and unloading of both oxygen and carbon
dioxide throughout the circulatory system. Insufficient ventilation decreases the
concentration gradient of carbon dioxide in the lungs and reduces the amount of
carbon dioxide transferred from blood to air in the lungs. This causes a rise in
vascular carbon dioxide concentrations. Hyperventilation can increase the concen-
tration gradient of carbon dioxide in the lungs causing more carbon dioxide to
diffuse out of the blood and into the lungs, reducing the concentrations of carbon
dioxide throughout the vasculature.
Measurement of Blood Gases
The most direct way to measure arterial gas tensions is to sample the blood via
arterial puncture, however this method is highly invasive. Pulse oximetry enables
non-invasive measurement of oxygen saturation through spectrophotometry while
simultaneously monitoring the pulse amplitude and heart rate. Limitations with
this technique are associated with the oxygen dissociation curve that correlates
PaO2 with oxygen saturation and suggests that this method would not be very
sensitive to changes in PaO2 within the upper flat section of the sigmoid.
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Another non-invasive method for estimation of PaO2 and PaCO2 is to analyse
the gas content of expired air. Because these gases diffuse rapidly across biological
membranes, arterial partial pressures equilibrate rapidly with alveolar partial pres-
sures (becoming effectively identical). The measured end-tidal values represent the
averaging of alveolar gas levels, and are used as an approximation of PaO2 and
PaCO2. Several studies have supported this relationship [6, 7], and end-tidal val-
ues are commonly used in place of actual arterial values that require more invasive
sampling methods.
Effect of CO2 on Blood Flow
Changes in PaCO2 are known to cause changes in local CBF. Local concentrations
of carbon dioxide determine the local pH level and it is the altered levels of hy-
drogen ions that initiate a network of signalling resulting in changes in vascular
resistance. Changes in pH cause a range of pathways to be initiated, resulting in
an increase or decrease of CBF due to smooth muscle relaxation or constriction,
respectively.
1.2.3 Oxygen Extraction Fraction and Cerebral Blood Flow
By design glucose and oxygen are delivered to the brain in arterial blood. Glucose
is absorbed through the small intestine into the bloodstream through capillaries
and is transported to the brain in arterial blood. Once it has reached the capillary
beds in the brain, glucose diffuses from the high glucose concentration in the
arterial blood to the low glucose concentration in the capillary beds. It must then
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diffuse across the interstitial space separating blood vessels and cells and enter the
intracellular environment.
Similarly blood becomes oxygenated in the capillary rich, alveoli present in the
lungs. As previously described, oxygen does not dissolve in blood so readily and
instead becomes bound to haemoglobin in RBC’s with a small fraction dissolved
in blood plasma. The heart than pumps the oxygen rich blood to the brain via the
arteries. Oxygen diffuses into the tissue down a concentration gradient between
dissolved gas in capillary plasma and dissolved gas in brain tissue. The proportion
of oxygen extracted from arterial blood is referred to as the oxygen extraction
fraction (OEF) and is approximately 40% in a healthy human brain at rest. OEF
can be calculated if the arterial oxygen content (CaO2) and venous oxygen content
(CvO2) are known.
OEF =
CaO2 − CvO2
CaO2
(1.1)
Cerebral blood flow (CBF) refers to the amount of blood delivered to the brain or
a specific region of the brain in a given unit of time and is measured in millilitres of
blood delivered per 100g of tissue per minute (ml/100g/min). CBF is therefore a
vital physiological parameter that is tightly regulated to meet the brain’s metabolic
demands. Typical values of CBF in the resting human brain are approximately 50
ml/100g/min for grey matter with CBF in white matter being lower [8].
Once glucose and oxygen has been delivered to the capillary beds by CBF, carbon
dioxide, water and heat, the by products of ATP production, produced by oxygen
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and glucose metabolism, diffuse out of the cells into the blood and are carried off
to the lungs via venous blood.
OEF and CBF in Disease
Local OEF measures can be used to assess compensatory responses made by the
brain due to alterations in CBF. In healthy brain tissue, energy production and
consumption is closely matched to CBF with little regional variation in OEF.
In order to maintain acceptable oxygen levels within brain tissue, reductions in
CBF can lead to progressive increases in OEF. Severe reductions in CBF can
be implicated in chronic disease, brain trauma and particularly stroke [9] where
mismatches in OEF may mean that sufficient levels of oxygen are not maintained
leading to cell dysfunction and ischaemia. In conditions such as stroke, OEF
provides an important marker of tissue at risk from impaired blood supply, but
which is not yet ischemic.
1.2.4 Cerebral Metabolic Rate of Oxygen Consumption
The cerebral metabolic rate of oxygen consumption (CMRO2) refers to the amount
of oxygen consumed, in µmols, per 100g of tissue, per minute (µmols/100g/min).
Assuming all oxygen extracted from arterial blood is used to form ATP in brain
cells, CMRO2 can be related to OEF and CBF through Fick’s first law:
CMRO2 = OEF · CBF · CaO2 (1.2)
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Where CaO2 is the oxygen content of arterial blood and is typically 8 µmol/ml of
blood. Typical values of CBF and OEF in grey matter, previously discussed, would
therefore suggest a typical CMRO2 of 160 µmol/100g/min in grey matter.
CMRO2, Neural Activity and Disease
The brain is known to have a relatively high, constant rate of metabolism with
baseline brain activity having a large energy budget [10]. As previously discussed
the brain does not have a reserve supply of oxygen or glucose and due to this high
maintenance level of energy required, the brain must be continuously supplied
with oxygen and glucose rich blood, through CBF, in order to fuel general basal
activity in the brain. OEF is thought to be relatively uniform across the brain
despite a larger regional variation of the resting CMRO2 [11]. Considering Fick’s
principle, Equation 1.2, and a constant CaO2, changes in CMRO2 can be driven by
either changes in OEF, CBF or both. It follows from this that regional increases
in metabolism due to increased brain activity and neural signalling lead to an
increased ATP demand and therefore an increase in CMRO2.
CMRO2 is also an important indicator of brain tissue integrity, reflecting the
metabolic function of the underlying cells [12]. Perturbations in cerebral oxygen
metabolism are associated with neurodegenerative disorders such as Alzheimer’s
disease, Parkinson’s disease and multiple sclerosis [13–15] whilst directly measur-
ing CMRO2 can assist in assessing the extent of brain damage after stroke [16] and
aid in tumour management and outcome [17].
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1.3 Measurement of Cerebral Oxygen Metabolism
As CMRO2 is closely related to brain function and health and will change regionally
with disease or functional activation, a quantifiable measure of oxygen metabolism
in the brain will provide a valuable insight into the underlying metabolic changes
that accompany normal brain development, ageing and brain disease in which tis-
sue damage or dysfunction alters metabolic activity. Oxygen metabolism presents
a functional biomarker which could aid in the diagnosis and development of new
treatment pathways of such diseases.
1.3.1 Kety-Schmidt Approach
Among the first attempts to quantify oxygen metabolism in the human brain in-
volved the introduction of the Kety-Schmidt method [18]. The approach relies
on Fick’s principle, measuring CBF alongside arterio-venous differences of oxygen
content. The subject breathes nitrous oxide (N2O) continuously for several min-
utes. During this time the arterial and venous concentrations of N2O are sampled
frequently from the carotid artery and the jugular vein. This is done until the ar-
terial, venous and tissue N2O concentrations come into equilibrium. Information
regarding CBF can be calculated by the time it takes to reach this equilibrium
state and OEF can be calculated by measuring the arterial-venous difference in
oxygen content allowing global CMRO2 to be given using Fick’s principle (Equa-
tion 1.2). However, this technique is highly invasive, requiring substantial surgical
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set-up and the measure provided is of global CMRO2 and may be insensitive to
regional changes in metabolism.
This practical implementation of Fick’s principle paved the way for a number
of tracer based techniques. The most notable of these being Positron Emission
Tomography.
1.3.2 PET
Positron emission tomography (PET) is a nuclear imaging technique capable of
producing three-dimensional (3D) images of functional processes in the body. A
PET system detects pairs of gamma rays emitted indirectly by a positron-emitting
radionuclide that is introduced into the body on a biologically active molecule
allowing tissue concentrations of that molecule to be measured. By using the
isotope, 15O, imaging of CBF, cerebral blood volume (CBV), OEF and CMRO2
can be conducted using PET.
Triple oxygen Positron Emission Tomography (PET) is the current gold standard
for performing oxygen metabolism measurements in the brain [19]. This approach
involves three separate PET measurements [20–22]. Oxygen gas enriched with 15O
is inhaled into the human body and the spatial distribution and accumulation rate
of the labelled water (H2
15O2) metabolised from the inhaled
15O2 can be measured
to produce a three dimensional map of CMRO2 consumption in the brain providing
regional metabolic information. However 15O PET is unable to distinguish between
radioactive signals from 15O bound to haemoglobin and H2
15O2. To overcome
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this CBV is measured using the inhalation of C15O gas in addition to a CBF
measurement based on the intravenous injection of H2
15O2 allowing CMRO2 to be
measured accurately [21].
There are however a number of disadvantages to this technique which result from
the use of radionuclides and its overall expense. As 15O has a half-life of approxi-
mately two minutes it requires an on sight cyclotron. The technique does not lend
itself to repeat or longitudinal studies due to the radiation dose acquired by the
patient. It also requires an intravenous injection and the scan time is relatively
long as sufficient time between scans is necessary to ensure specificity taking ∼ 45
minutes to run.
1.3.3 Near Infrared Spectroscopy
Near Infrared Spectroscopy (NIRS) takes advantage of the optical window in which
skin, tissue, and bone are mostly transparent to NIR light in the spectrum of
700-900 nm, while haemoglobin and deoxygenated haemoglobin absorb this light.
Differences in the absorption spectra of oxygenated and deoxygenated haemoglobin
allow the measurement of relative changes in haemoglobin concentration through
the use of light attenuation at multiple wavelengths. Typically a light emitter and
detector are placed ipsilaterally on the subjects skull so recorded measurements
are due to reflected light. NIRS is cost effective and portable but cannot be
used to measure cortical activity more than 4 cm deep due to limitations in light
emitter power. The technique also has very limited spatial resolution, requires a
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separate measure of CBF and can only measure relative changes in CMRO2 from
an unknown baseline [23].
1.3.4 Magnetic Resonance Imaging
Magnetic Resonance Imaging (MRI) is a medical imaging technique that is widely
available in research and clinical settings and is capable of providing detailed
anatomical and functional images of the body in both health and disease. MRI
is a versatile technique with many intrinsic contrast mechanisms and as such MR
methods have begun to emerge for estimating absolute CMRO2. The measurement
of CMRO2 using MRI is not trivial, but this imaging modality offers excellent im-
age resolution, is non-invasive and avoids complications associated with radioiso-
topes. As such an MRI technique capable of producing whole-brain parameter
maps providing regional detail of oxygen metabolism is desirable and has applica-
tions in the longitudinal monitoring of ageing and development, disease diagnosis
and treatment as well as drug development and functional neuroimaging.
In Chapter 2 the basic concepts behind MRI are introduced alongside how MRI
can be applied to provide further information on the underlying physiological func-
tions of the brain. The pros and cons of the current MR techniques capable of
measuring absolute CMRO2 are discussed and a recently introduced, non-invasive
MR method will be described.
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Chapter 2
Magnetic Resonance Imaging
In this chapter, the principles of nuclear magnetic resonance (NMR) and MRI
are introduced. The MRI methods which are utilised throughout this thesis are
also discussed alongside a review of MR techniques capable of measuring oxygen
metabolism in the brain. For the purposes of this chapter and introducing the
concepts of NMR and MRI, classical mechanics provides a sufficient description of
the behaviour of the net magnetisation vector. However a more thorough deriva-
tion of the concepts of spin and its behaviour can be found by using a quantum
formalism.
2.1 Basic MRI Concepts
The human body is composed of approximately 80% water with each water molecule
consisting of two hydrogen and one oxygen atom. As a result hydrogen is the most
abundant element in the body and forms the basis for MRI. Each hydrogen atom
has a proton and an electron. The hydrogen proton has an electrical charge and
in the classical model ’spins’ around its own axis creating a magnetic field referred
to as a nuclear magnetic dipole. The gyromagnetic ratio refers to the ratio of
the magnetic dipole moment to angular momentum. For a hydrogen proton or
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’spin’ the gyromagnetic ratio is 42.56 MHz/Tesla. The spinning hydrogen protons
are analogous to tiny bar magnets which are randomly orientated throughout the
body. As a result the small magnetic component contributed by the spins cancel
each other out resulting in the body having no net magnetisation.
In the presence of an applied magnetic field, proton spins will align parallel or
anti-parallel to the direction of the field, representing a low and high energy state,
respectively. Slightly more protons align with the applied magnetic field, as this
is a lower energy state, leading to a net magnetisation of the body pointing in
the direction of the applied magnetic field. This effect is known as spin excess
and the ratio of protons in the high energy state (N+) compared to those in a low
energy state (N−) is described by a Boltzmann distribution (
N+
N−
= exp
(−∆E
kT
)
)
where ∆E is the energy difference between states, k is the Boltzmann constant
and T is temperature.
The net magnetisation vector ~M precesses as described by the equation:
d ~M(t)
dt
= γ( ~Mx~B) (2.1)
The frequency of this precession is dependent on the magnetic field strength | ~B|
and the gyromagnetic ratio of the proton γ. For a hydrogen proton experiencing
a 3 Tesla (3T) magnetic field the Larmor frequency is 127.6 MHz.
ω = γ · | ~B| (2.2)
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The magnetic moment of each of these precessing spins, present in the applied
magnetic field, can be split into longitudinal and transverse components.
The longitudinal component is static, pointing with or against the direction of the
applied field and is referred to as Mz. The transverse component, where present, is
perpendicular to the applied magnetic field and precesses in the laboratory frame
at the Larmor frequency. The transverse component is referred to as Mxy. The
net magnetisation magnitude, M0, of the ensemble of spins placed in the applied
magnetic field, is proportional to the excess of spins in the parallel state, the spin
density and the spin magnetic moment. Due to spin excess, M0 is in the direction
of the applied field, Mz. The protons, which M0 is composed of, will precess out
of phase and therefore M0 has no net transverse component.
When placed in an MRI scanner the magnetic field experienced by the protons in
the body are a combination of the local chemical environment, the main magnetic
field (B0) created by a superconducting magnet, inhomogeneities in this magnetic
field due to uniformity or susceptibility differences in the object and magnetic
fields produced by gradient coils (G) or radio frequency (RF) pulses.
2.1.1 Main Magnetic Field
The main magnetic field in an MRI scanner creates a bulk magnetisation in the
participant from head to foot along the z-axis. This static magnetic field is usu-
ally supplied by a superconducting magnetic allowing high field strengths to be
achieved. The ideal static field is strong, stable and homogenous. In reality the
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static magnetic field has some non-uniformities and shimming can be performed
to improve uniformity.
2.1.2 RF Excitation
RF pulses act to give M0 a transverse component (Mxy), perpendicular to the
z-axis, which rotates at the Larmor frequency and is detectable. M returns to
its original low energy, pre-RF pulse orientation at rates referred to as T1 and T2
relaxation. The difference in energy between the low and high energy spins, created
by the application of an external magnetic field, is given by ∆E = hflarmor where h
is Planck’s constant. As RF energy is delivered by photons, photons with exactly
the right energy, ∆E, can be used to excite protons from low to high energy. The
effect of RF energy on M is described in terms of flip angle (FA). As spins are
promoted from low energy states to high energy states the net magnetisation, M0,
changes direction in relation to the original spin excess state. An RF pulse with a
90◦ FA results in Mz = 0 and Mxy = M0. An RF with a 180◦ FA results in Mz =
-M0 and Mxy = 0.
2.1.3 RF Receive
Detectable MR signal is derived from the time varying, transverse component of the
magnetisation vector, Mxy and can be detected by an RF coil. The time varying
magnetic field induces a current in the coil proportional to the rate of change
of the magnetic flux. The amplitude of the detected signal is proportional to the
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amplitude of Mxy. The signal detected after an RF excitation decays exponentially
as Mz returns back to M0 and this is referred to as a free induction decay (FID).
As Mxy is a time varying magnetic field, FID results in an exponentially decaying
sinusoid.
2.1.4 Gradient System
Following the definition of the longitudinal and transverse axis it is beneficial to
define a coordinate system in terms of B0. In an MRI scanner set-up the patient
is usually positioned head to foot in the direction of the static magnetic field (B0)
lying on their back. The z-axis is therefore in the inferior-superior direction, the
x-axis refers to left-right and the y-axis in the anterior-posterior direction.
Gradients are designed to introduce small, transient, linear variations in the static
magnetic field in the x, y and z direction. These magnetic fields are generated by
resistive electromagnetic coils inside the body of the scanner with a separate set of
coils used for the three gradient directions. The net field in the bore is equivalent to
the sum of the main field and the gradient fields. The gradient strength determines
how much the gradient field varies the static field with distance from the isocentre
(x=0, y=0, z=0). As the Larmor frequency is dependent on field strength the
application of a gradient causes a positional variation in Larmor frequency.
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2.1.5 Image Localisation
The gradient system allows a controlled, spatially varying Larmor frequency to be
introduced across the imaging volume during a sequence. This aids with slice se-
lection, signal localisation (phase and frequency encode) and echo formation.
Slice Selection
To select a transverse slice (an xy-plane perpendicular to the z-axis) a slice select
gradient is used. This is a gradient which causes a spatial variation in the magnetic
field along the z-axis, resulting in protons which precess at a frequency dependent
on their position in the magnet. An RF pulse can selectively excite all spins in an
xy-plane at a particular z-axis location. The position of the slice along the z-axis
is determined by the frequency of the RF pulse and this process is referred to as
slice selective excitation. The thickness of the excited plane, in the z-direction,
is controlled by the bandwidth of the RF pulse (range of frequencies) and the
gradient strength.
Signal Encoding
Once the appropriate spins in a given slice have been selectively excited the RF
receiver simultaneously detects signal from all spins in that slice. In order to
spatially differentiate where the signals come from signal encoding is used. Each
excited spin has an amplitude, phase and frequency. The amplitude of the excited
spin provides contrast in the final image and therefore signal encoding is done
via frequency and phase encoding. A frequency encode gradient can be applied
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orthogonal to the slice select gradient. If the slice select gradient is considered
to be applied along the z-axis the frequency encode gradient is applied along the
x-axis. The frequency encode gradient causes a positional variation in frequency
dependent on the location of protons along the x-axis. A phase encode gradient can
also be applied orthogonal to both the slice select and frequency encode gradients,
in the y-direction. This causes protons to acquire a phase difference which is
dependent on their position along the y-axis. After signal encoding, the protons
present, in a given x-y position, in a given slice, have a unique phase and frequency
indicating their location. In a simple encoding implementation phase encoding is
performed first, then as the echo is forming frequency encoding is performed.
Signal localisation is discussed in more detail in Section 2.1.7
2.1.6 Relaxation
When an RF excitation pulse is applied some spins are flipped into a high energy
state, pointing anti-parallel to the static field and spins begin to rotate in phase
in the transverse plane. Once the RF is no longer applied two processes occur, M0
recovers back to its low energy state and spins begin to dephase.
Longitudinal Relaxation
T1 or longitudinal relaxation is the term used to describe the time it takes for
spins to return back to their original low energy state, aligned with the static
magnetic field. T1 is the time it takes for M0 to recover to 63% of its original
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pre RF value. Different tissues have different T1 values based on their molecular
environments.
Transverse Relaxation
RF forces spins into phase creating a transverse magnetisation component. Spins
quickly lose this transverse magnetisation through spin-spin relaxation and the
transverse magnetisation component soon returns back to zero when the RF is
no longer applied. This is referred to as transverse relaxation and is due to local
variations in the magnetic field. Local variations cause spins to precess at different
speeds and can be due to the thermal motion of molecules and imperfections in the
magnetic field. T2 relaxation describes dephasing as a result of thermal motion
whereas T∗2 describes the combined effect of thermal motion and imperfections in
magnetic field. As a result T∗2 dephasing is faster than T2.
2.1.7 Refocusing and Echo Creation
When an RF pulse has been applied there is an inevitable delay before the signal
from the excited spins can be acquired. Due to FID that occurs during the enforced
delay, this decayed signal is not ideal for making measurements. However the
effects of some dephasing can be reversed using an echo created by additional RF
pulses or the application of gradient pairs. Spin-echo creation can reverse the
effects of some dephasing, causing spins to return to nearly identical phase and
net transverse magnetisation to grow back to measurable values.
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Spin Echo
In the case of a spin echo (SE) an initial 90◦ RF pulse is followed by a 180◦ RF pulse,
called a refocusing pulse. The initial 90◦ pulse gives M0 a detectable transverse
component. As soon as the RF is switched off this transverse component decays
due to dephasing at a rate of T∗2. By applying a 180
◦ refocusing pulse the transverse
component is rotated around its own axis by 180◦. This has the effect of reversing
the process of dephasing, rephasing the dephased spins and eventually resulting
in the net transverse magnetisation being refocused. The refocussed transverse
magnetisation vector is referred to as an echo. Once the echo has formed the
spins will continue to dephase. Effects of spin-spin relaxation are not reversed
with SE and therefore the amplitude of the rephased transverse magnetisation will
be affected by T2-relaxation. In terms of timings the echo is formed at an echo
time (TE) from the original 90◦ pulse. To form the echo at TE the 180◦ pulse
must be applied at TE
2
. To summarise the process of spin echo creation, after a
90◦ pulse FID decay occurs where transverse magnetisation is dephasing. A 180◦
pulse is applied and spins rephase reaching the max echo amplitude at TE. Max
echo amplitude is not equal to the inital net transverse magnetisation as spin-spin
dephasing cannot be refocused by the 180◦ refocusing pulse. After TE the spins
continue to dephase with T∗2.
Gradient Echo
A gradient echo (GRE) employs bipolar gradients instead of a 180◦ RF pulse to
refocus transverse magnetisation. GRE acquisitions are typically faster than SE
acquisitions. As gradient rephasing cannot reverse dephasing due to magnetic field
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inhomogeneities, unlike a 180◦ refocusing pulse, gradient echoes show a sensitivity
to T∗2 rather than T2. After the inital 90
◦ excitation a negative transverse gradient
is applied to speed up dephasing. After this an equivalent positive transverse
gradient is applied to refocus this dephasing. The area under the positive gradient
is twice that of the negative gradient and TE occurs half way through this positive
gradient. These gradients are referred to as dephasing and rephasing gradients.
As discussed later in this chapter, the sensitivity of GRE to detect changes in T∗2
provide the basis for Blood Oxygen Level Dependent (BOLD), functional MRI
(FMRI).
K-space
K-space represents spatial frequency information and is related to MR image space
via a Fourier transform. K-space is a vital concept in MR image acquisition which
will be described here in detail.
A Fourier transform is a mathematical transformation used to transform signals
between the time (or spatial domain) and the frequency domain. Using a Fourier
transform any image may be decomposed into a spectrum of 2D spatial frequen-
cies. This spectrum of 2D spatial frequencies is known as k-space. A 2D spatial
frequency is essentially a sinusoidal grating which can be defined by two param-
eters, kx and ky, that describe the spatial frequencies in the x and y direction
respectively.
K-space is a 2D plane with axes kx and ky where each point in k-space (kx, ky) is a
spatial frequency component. The amplitude at a given point in k-space represents
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the amplitude of that spatial frequency in the image. Each point in k-space holds
data on the entire image with the centre of k-space responsible for low spatial
frequencies and the outer areas of k-space responsible for high spatial frequencies.
For an image with M-by-N pixels, k-space will have M rows and N columns. The
image frequency content is therefore approximated by M-by-N spatial frequency
components as described by k-space.
Filling K-space
MR signal localisation uses gradients to manipulate the MR signal allowing the
spatial frequencies necessary to form an image to be measured. In a 2D acquisition,
an RF excitation is performed during the application of a slice selection gradient
in order to excite the spins in a 2D plane that is the imaging slice.
A phase encoding gradient is applied orthogonally to the slice select gradient.
During the application of the phase encode gradient, spins will accumulate a phase
difference dependent on their position along the phase encode direction. When the
phase encode gradient is switched off this phase difference remains and spins are
said to be phase encoded. The amplitude of the MR detected signal, after phase
encoding, is dependent on the number of in-phase spins, which is in turn dependent
on the spatial frequency of protons in the phase encode direction. Each value of
phase encoding provides a probe of one spatial frequency (spatial distribution of
spins). To acquire enough information for a whole image the entire range of spatial
frequencies must be sampled. This involves multiple repetitions of the excitation
process followed by a different phase-encoding gradient until all spatial frequencies
are interrogated.
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However, phase encoding only allows us to probe the spatial frequency of MR
signals along the phase encode direction. In order to produce a 2D image, or
slice through an object, the spatial frequency of MR signals needs to be probed
orthogonal to the slice select and phase encode directions.
Frequency encoding acquires all the spatial frequency information needed from
one MR signal following one RF excitation. During the continuous application of
the frequency encode gradient the MR signal is continuously measured at discrete
time-points. At each time-point the MR signal is affected by a different amount of
gradient moment and therefore has a different amount of phase change. Each data
point reflects a different amount of ’phase encoding’ and corresponds to a different
spatial frequency. All spatial frequencies can be investigated in the frequency
encode direction in real time following a single RF excitation. To summarise,
frequency encoding and phase encoding are performed so that data is spatially
encoded by differences in frequency and phase, amenable to analysis by Fourier
transform.
The application of phase and frequency encode gradients allow us to traverse
through k-space, acquiring signal amplitudes from in-phase spins corresponding
to the spatial frequency imposed by these gradients. The phase encode gradi-
ent allows movement to a new row in the ky direction and the frequency encode
gradient allows movement along a new row in the kx direction. As previously
mentioned, to acquire enough information for a whole image the entire range of
spatial frequencies must be sampled. This involves choosing a point on the ky
axis using phase encoding and acquiring signal amplitudes for all relevant spatial
frequencies along the kx axis using a frequency encode readout. However taking
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this approach leads to lengthly acquisition times proportional to NPE×TR, where
NPE is the size of the phase-encoding matrix and TR is time between RF excites,
also referred to as repetition time. Methods such as echo planar imaging (EPI)
attempt to speed up this process by acquiring multiple lines of k-space from a
single RF excitation.
2.2 Functional MRI
MRI not only provides detailed structural images of the brain but also important
information about the physiological processes which contribute to the function of
the brain. FMRI is a class of MR techniques capable of providing information
on the physiological processes in the brain. A cornerstone of this technique is an
imaging method which allows fast image acquisition and high temporal resolu-
tion.
2.2.1 Echo Planar Imaging
EPI is an MR imaging technique that allows very rapid data acquisition [24].
Rather than acquiring a single line of k-space after each RF excitation, all of
k-space is acquired in one TR, in the case of single shot-EPI (SS-EPI). This is
achieved by using a series of bipolar readout gradients to generate a train of gra-
dient echoes. The positive and negative frequency encode gradients are equivalent
to scanning back and forth through k-space along the kx axis. With an accom-
panying blipped phase encoding gradient, the acquisition is moved onto the next
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line in k-space on the ky axis and k-space is effectively filled in a single TR by
rastering through the kx and ky axes. Each GRE is distinctively spatially encoded
so that multiple k-space lines can be sampled under the envelope of an RF-spin
echo (in the case of Spin Echo-EPI, T2-weighting) or FID (in the case of Gradient
Echo-EPI, T∗2 weighting).
K-space Trajectory, Spiral EPI
The k-space trajectory described previously refers to a blipped-EPI acquisition
and results in a Cartesian k-space trajectory. In an attempt to speed up image
acquisition and sample k-space more efficiently, spiral k-space trajectories have
been introduced [25]. The trajectory starts at the origin of k-space and spirals to
the edge of k-space. It is accomplished by applying an oscillatory gradient, which
increases in amplitude as a function of time with both frequency and phase gra-
dients oscillating simultaneously. Spiral acquisitions offer faster image acquisition
as both frequency and phase encode gradients are used to simultaneously track
through k-space. This is in contrast to the Cartesian trajectory which uses the
frequency encode gradient to do most of the work. The shorter readout reduces
off-resonance-induced geometric distortion (in EPI) and blurring (in spiral) as well
as signal dropout due to susceptibility differences [26, 27]. Spiral acquisitions are
however highly demanding on the gradient system and require complicated recon-
struction. Although these hardware limitations have mostly been overcome, the
availability of spiral acquisition sequences are still limited [28].
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GRE-EPI and T2*
By pairing GRE signal refocusing with an EPI readout, a rapid MRI imaging
technique with sensitivity to T∗2 weighting is possible.
2.2.2 Blood Oxygen Level Dependent Signal
BOLD FMRI is a functional neuroimaging procedure that takes advantage of the
high temporal resolution of GRE-EPI as well as its sensitivity to changes in T∗2
to map brain activity. It relies on an intrinsic contrast mechanism that is derived
from blood.
In its fully deoxygenated state haemoglobin is paramagnetic and disrupts the local
magnetic field homogeneity. As oxygen molecules begin to occupy the binding sites
in haemoglobin the paramagnetic nature of the molecule is reduced. As oxygen
is mainly transported in blood by haemoglobin the magnetic susceptibility of the
haemoglobin molecule is directly indicative of the blood oxygenation. The presence
of deoxyhaemoglobin induces magnetic field gradients that surround RBC’s and
affect the proximal extravascular tissue. The measurable result of these localised
field inhomogeneities is to shorten the T∗2 of the nearby tissue.
Although the intravascular compartment is a small fraction of total tissue volume
(∼ 4%) the intravascular and extravascular spins have been shown to contribute
a comparable amount to BOLD signal change at 1.5T [29]. This is as a result of
the intrinsic signal change in blood being of an order of magnitude larger than the
extravascular signal change. Large magnetic field gradients are present around the
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RBC’s carrying deoxyhaemoglobin and as a result the venous blood signal may
be reduced by as much as 50% when compared to fully oxygenated blood. This
provides a much wider dynamic range for intravascular signal when compared to
extravascular signal.
The fact that changes in the amount of de-oxygenated blood present has a mea-
surable effect on MR signal was discovered by Ogawa et al. [30]. The magnitude of
the signal change depends upon the change in T∗2 induced by neural activation and
the echo time, TE. The contrast to noise ratio is maximised when TE = T∗2 [31].
If TE is very short, the signal is insensitive to T∗2, and so the signal change with
activation is minimal. If TE is very long, most of the signal decays away before
it is measured, so again the sensitivity is low because the signal is lost in the
noise.
BOLD FMRI is used to identify regional areas of neural activation in the brain.
However the BOLD signal does not directly measure neural activity and is instead
reliant on metabolic and blood flow changes that accompany such activity and
modulate local concentrations of deoxyhaemoglobin. A schematic outlining the re-
lationship between neural activation, haemodynamic response, deoxyhaemoglobin
concentration and BOLD signal change is shown in Figure 2.1. With increased
neural activity, additional oxygen is extracted from the blood to support the ad-
ditional energy requirements associated with such increases. Typically, a large
increase in CBF and moderate increase in CBV accompany CMRO2 increases in
an active, local brain region. However the OEF drops with the increase in oxy-
gen rich blood brought to the local region, due to the magnitude of the CBF
response [32]. It is the dilution of venous deoxyhaemoglobin that gives us the
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BOLD contrast in an active region of the brain and it is the relative changes in
these distortions in the brain over time, imaged using GRE-EPI, that we exploit.
As a result the BOLD signal provides a non-quantitative, mapping tool for brain
activity. However a direct measure of these underlying physiological quantities
that contribute to the BOLD signal, would be considerably more useful in clinical
research and application across a wide range of diseases.
2.2.3 Arterial Spin Labelling and CBF
CBF delivers glucose and oxygen to the brain and is linked with neural activa-
tion. Arterial spin labelling (ASL) is a non-invasive FMRI technique allowing
quantitative measures of CBF to be made. Many variations on the ASL tech-
nique exist but are all based around a simple experimental design. This involves
perfusion-weighting the MR signal and converting it to units of CBF using an ap-
propriate model. Protons travelling in the blood vessels outside the imaging plane
are labelled using a 180◦ RF inversion pulse to flip the protons in arterial blood.
Following a delay to allow the labelled blood reach the brain tissue, images are
obtained of the tissue in a labelled state. This is then repeated without labelling
to acquire a control image. The goal of the control image is to create an image
where the arterial blood is not inverted but the signal from static spins in the slice
are precisely the same as in the tagged image. The difference signal directly re-
flects quantitative local perfusion. CBF maps can then be obtained by scaling this
tag-control difference image appropriately using techniques such as the General
Kinetic Model (GKM) [33].
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Figure 2.1: Schematic detailing the relationship between neural stimulation and
BOLD signal change. A stimulus evokes neuronal activity which in turn provokes
a haemodynamic response. This haemodynamic response is comprised of changes
in CBV, CBF and CMRO2 that are modulated by baseline haematocrit, OEF and
CBV. This in turn leads to a change in venous deoxyhaemoglobin concentration
which manifests as a BOLD signal change
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Two major classifications of ASL techniques are pulsed ASL (PASL) and continu-
ous ASL (CASL). The variations between these techniques lie within the method
used for spin preparation. The spin preparation or tagging in PASL is spatially
selective whereas CASL tags protons travelling through a plane for a given amount
of time and is therefore a temporally dependent tag.
PASL
PASL techniques are characterised by a single 180◦ RF pulse which is applied as
a spatially selective pulse that tips over all spins in a thick band proximal to the
image slice of interest. After a delay to allow the tagged blood to flow into the
slice and the labelled water to exchange into the tissue, the tag image is acquired.
There are a number of different PASL techniques including EPISTAR (echo planar
imaging and signal targeting with alternating radio frequency) [34] , FAIR (flow
sensitive alternating inversion recovery) [35] and PICORE (proximal inversion with
control for off resonance effects) [36]. These techniques differ in how the tag-control
images are acquired. PICORE works by applying a control pulse in the absence
of field gradients but shifted in frequency so that the image plane experiences
the same off resonance RF pulse in both control and tag images. In this way, any
asymmetry of magnetisation transfer effects is automatically balanced between tag
and control images. This technique has the advantage that venous blood entering
from the superior side of the image plane is not tagged, whereas with EPISTAR,
such blood appears as a negative signal, and with FAIR, it appears with a positive
signal.
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QUIPSS II
Due to the spatial nature of the PASL tag the temporal duration of the label is
not well defined. QUantitative Imaging of Perfusion using a Single Subtraction II
(QUIPSS II) [37] is a method designed to create a well-defined bolus duration which
aids in CBF quantification. The QUIPSS II modification to PASL is to add a 90◦
saturation pulse, after the inversion pulse and before the imaging excitation pulse,
that saturates the same tagging band as the inversion pulse. During labelling, the
initial tag is spatially applied below the imaging plane as previously described at
time = 0. A saturation band is then applied to the same tagging region at time
= TI1. This is referred to as the tag cut-off. During this time the spatially tagged
blood is travelling through the arteries towards the imaging plane. The tag cut-
off saturates any tagged arterial blood remaining in the tagging plane effectively
creating an arterial bolus with a well defined trailing edge which has a temporal
duration equal to TI1. The time between tagging and saturation becomes the
temporal bolus of the tag. This temporal component aids in accurate modelling
and quantification of the perfusion weighted images. At time = TI2 after the
initial tag was applied image acquisition happens. TI2 allows sufficient time for
the tagged blood to travel to the capillary beds in the imaging plane.
CASL
While many routine examinations use PASL techniques due to their easier imple-
mentation, CASL has been shown to obtain perfusion images of the human brain
with a higher signal to noise ratio (SNR) [38, 39]. CASL uses long RF irradia-
tions in the presence of a slice select gradient to adiabatically label the inflowing
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blood before it reaches the imaging slice. The labelling duration and post labelling
delay (PLD) are key timing parameters in a CASL acquisition. The PLD refers
to the amount of time that has elapsed between labelling and image acquisition.
The primary drawback of CASL is the requirement of continuous RF transmitting
hardware that is not commonly available on most MRI scanners.
PCASL
Pseudo continuous ASL (PCASL) [40] is a sub category of the CASL techniques
and was introduced to overcome hardware limitations associated with CASL with-
out compromising labelling efficiency. To circumvent these problems PCASL
breaks the RF and gradient pulses into a series of short pulses ∼ 500 µs in duration
with a spacing of ∼ 1500 µs between pulses. This has the same effect of producing
an adiabatic inversion of the magnetisation of blood as it flows through the zero
plane of the gradient. However, the gradient used during each pulse is stronger
than the constant gradient used in traditional CASL, and this means that the
slice to be imaged is farther off resonance, with reduced magnetisation transfer
effects. Because the RF is pulsed, it is highly compatible with the majority of
MR scanner hardware. Moreover, it does not require any additional hardware and
provides high labelling efficiency, as in standard CASL, whilst possessing the same
high SNR advantage over PASL. The control tagging procedure is performed by
alternating the sign of the RF from pulse to pulse and ensuring that there is zero
average gradient between each pair of pulses. In the acquired control image, the
average field strength of the RF pulses is zero, but the averaged RF power, and
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hence the magnetisation transfer effects, will be matched between the control and
label sequences.
2.2.4 CBF Quantification
In order to convert the perfusion weighted subtraction images to absolute units of
CBF they must be appropriately scaled. The GKM was introduced by Buxton et
al. [40] to model the kinetics of the tagged blood throughout the vasculature and
brain tissue. It offers a method to quantify CBF using slightly modified models
for PASL and CASL.
The GKM
∆M is considered the perfusion weighted signal (tag minus control) in a given voxel
that is described by three components in the GKM. The delivery function, c(t),
describes the amount of tagged blood arriving in the voxel at time t, the residue
function, r(t), describes the amount of tagged blood left in the voxel at time t and
the magnetisation relaxation function, m(t), describes the amount of remaining
longitudinal magnetisation of the tagged blood after relaxing over time t. M0B is
the equilibrium magnetisation of arterial blood.
∆M is now described as ∆M(t), an integral of the history of tag delivery weighted
by the fraction of those tagged spins that remain in the voxel.
∆M(t) = 2M0B · CBF
∫ t
0
c(t′) · r(t− t′) ·m(t− t′) · dt′ (2.3)
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Aeff , is a term used to summarise the effect of these functions and can be used to
translate local perfusion values into magnetisation signal that is observed.
∆M(t) = CBF · Aeff ; Aeff = 2M0B
∫ t
0
c(t′) · r(t− t′) ·m(t− t′) · dt′ (2.4)
The amount of time it takes for the tagged blood to reach the voxel of interest
is called the arterial arrival time (AAT). AAT describes the delay in the arrival
of tagged blood in the voxel and during this time the tagged spins experience
longitudinal relaxation. The tag also has a finite duration, which is better defined
by the QUIPSS II cut-off in the case of PASL, and as such the delivery function
can be described as Equation 2.5 where α is the tagging efficiency, τ is the tag
duration and T1B is the longitudinal relaxation of tagged blood. Separate terms
are included in the partition function to describe the different characteristics of
PASL and CASL tags. This is due to the continuous nature of the CASL tag as
it reaches a steady state in the voxel, unlike the PASL tag.
c(t) =

0 [0 < t < AAT ]
αe−t/T1B (PASL) [AAT < t < AAT + τ ]
αe−AAT/T1B (CASL) [AAT < t < AAT + τ ]
0 [AAT + τ < t]
(2.5)
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The residue function r(t) is described using single compartment kinetics as a de-
caying exponential, where λ is the partition coefficient for water.
r(t) = e(−CBF ·t)/λ (2.6)
Once labelled spins have reached the capillary bed in the voxel of interest, spins
will exchange with the tissue and relax with the tissue relaxation rate T1T .
m(t) = et/T1T (2.7)
Combining Equations 2.3, 2.5, 2.6 and 2.7 leads to Equations which can be used
to describe pulsed or continuous ASL. For Pulsed ASL the difference signal can
be described as:
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∆M(t) = 0 [0 < t < AAT ]
= 2M0B · CBF (t− AAT ) · α · e−t/T1B · qp(t) [AAT < t < AAT + τ ]
= 2M0B · CBF · τ · α · e−t/T1B · qp(t) [AAT + τ < t]
qp(t) =
ekt(e−k·AAT − e−kt)
k(t− AAT ) [AAT < t < AAT + τ ]
=
ekt(e−k·AAT − e−k(τ+AAT )
kτ
[AAT + τ < t]
k =
1
T1B
− 1
T ′1
1
T ′1
=
1
T1T
+
f
λ
For Continuous ASL the difference signal can be described as:
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∆M(t) = 0 [0 < t < AAT ]
= 2M0B · CBF · T ′1 · α · e−AAT/T1B · qss(t) [AAT < t < AAT + τ ]
= 2M0B · CBF · T ′1 · α · e−AAT/T1B · e−(t−τ−AAT )/T
′
1 · qss(t) [AAT + τ < t]
qss(t) = 1− e−(t−AAT )/T ′1 [AAT < t < AAT + τ ]
= 1− e−τ/T ′1 [AAT + τ < t]
Equilibrium Magnetisation Estimation
M0 is the equilibrium magnetisation of brain tissue and can be estimated using an
EPI, equivalent to the ASL control acquisition, with an infinite TR.
M0B = R ·MCSF · e
( 1
T∗
2,CSF
− 1
T∗
2,Blood
)·TE
(2.8)
MCSF is the mean signal intensity measured from this image from a region of
interest in the lateral ventricles. R is the ratio of the proton density of blood in
the sagittal sinus to CSF and is taken as 0.87 [41], T∗2,CSF is the T
∗
2 of CSF and
T∗2,Blood is T
∗
2 of blood which are 43.6 ms and 74.9 ms respectively at 3T.
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Coil Sensitivity Correction
Coil sensitivity correction can be performed to correct for nonuniform receiver
coil sensitivity. Such background modulation, if not properly accounted for, can
confound flow quantification [42]. A low resolution, minimal contrast image is ac-
quired which provides a map of signal non-uniformity with low-spatial frequency.
This is directly related to non-uniformity caused by coil sensitivity and the mini-
mum contrast image can be divided into the perfusion map to remove these non-
uniformities.
2.2.5 ASL Acquisitions to Detect Simultaneous CBF and BOLD Signals
ASL can be used to collect multiple tag-control volumes in an appropriate scan
time, ∼ 5 minutes. The tag-control subtractions are usually averaged together, to
improve SNR, and a CBF parameter map produced from the perfusion weighted
image through kinetic modelling. However ASL tag-control runs can also be pro-
cessed to produce CBF and BOLD weighted time-series. In an ASL FMRI ex-
periment, a series of tag-control images are acquired in an interleaved manner.
The time course of signal differences (control − tag) is flow weighted and can be
used to calculate a CBF time-series. However, as these images are typically ac-
quired with GRE-EPI readout sequence they will have sensitivity to T∗2 changes
and therefore contain some BOLD signal contrast. This influence of BOLD con-
trast on the acquired time-series can be optimised by acquiring at a TE ∼ 30 ms
and the influence of the ASL tag can be minimised by averaging the tag-control
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time course ( control+tag
2
) [43]. Conversely the influence of BOLD weighting on the
CBF measure can be reduced by minimising the TE and acquisition time of the
readout sequence.
Dual-Echo Acquisition
Dual-echo GRE acquisitions allow image acquisition at different echo times, TE1
and TE2. Two successive GRE readouts are used to acquire echoes under the
T∗2 decay envelope. Dual-echo acquisition can be optimised for simultaneous CBF
and BOLD sensitivity by acquiring TE1 at a short echo time to increase perfusion
SNR [44] and TE2 can be acquired at∼ 30 ms to optimise BOLD weighting [31]. As
spiral readouts provide accelerated acquisition they are ideal for implementation
in a dual-echo pulse sequence in particular as they can provide a very short TE1
maximising CBF signal and minimising BOLD weighting.
2.2.6 Calibrated BOLD
The calibrated BOLD methodology was introduced to improve interpretability
of task related changes in BOLD. This is achieved by estimating the maximum
BOLD signal change, M, for the current physiological baseline state allowing es-
timates of relative change in CMRO2 to be inferred from task related changes
in BOLD and CBF. To measure M a calibration scan is performed where BOLD
signal changes are induced by manipulating venous deoxyhaemoglobin concentra-
tions. This can be done by inducing mild hypercapnia [45] or hyperoxia [46] in the
participant.
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Hypercapnia
Hypercapnia is an increase in the concentration of carbon dioxide in arterial blood.
This can be achieved by increasing the amount of inspired carbon dioxide. Hyper-
capnia causes an assumed isometabolic increase in CBF [47,48] which reduces the
deoxyhaemoglobin concentration on the venous side of the vasculature.
Hyperoxia
Similarly hyperoxia is an increase in the concentration of oxygen oxygen in arterial
blood above normal levels. The concentration of oxygen in arterial blood can be
referred to as the arterial oxygen content (CaO2). Hyperoxia can be achieved by
increasing the amount of inspired oxygen and causes a reduction in the amount of
deoxyhaemoglobin on the venous side of the vasculature.
BOLD Signal Model
The BOLD signal changes induced by hypercapnia and hyperoxia can be inter-
preted using a simple BOLD signal model derived by Davis et al. [45] and Hoge et
al. [49].
BOLD signal changes depend on changes in the amount of deoxyhaemoglobin
present. Due to it’s paramagnetic nature and presence in blood vessels, deoxy-
haemoglobin (dHb) creates a susceptibility difference with surrounding brain tis-
sue resulting in local signal decreases due to the enhanced relaxation rate. This is
dependent on the volume of blood present, described as CBV [29], and the con-
centration of deoxyhaemoglobin ([dHb]) in the blood which can be related to R∗2,
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the transverse relaxation rate (R∗2 =
1
T ∗2
). R∗2 is also dependent on the volume of
blood present. Considering a voxel with a normal resting R∗2, removing all dHb
from that voxel causes a change in R∗2 that can be described by δR
∗
2, Equation 2.9,
where constants κ and β are both field dependent constants and β is dependent
on vessel size and geometry.
δR∗2 = κ · CBV0 · [dHb]β0 (2.9)
Maximum BOLD signal change, M, can then be calculated.
M = TE · κ · CBV0 · [dHb]β0 = TE · δR∗2 (2.10)
Changes in BOLD signal can be described as ∆R∗2.
∆R∗2 = κ · CBV · [dHb]β − κ · CBV0 · [dHb]β0 (2.11)
Small changes in ∆R∗2, such as those that are experienced during an FMRI exper-
iment can be approximated by Equation 2.12 where ∆S
S0
is the fractional increase
in BOLD signal which takes the echo time (TE) of the acquisition sequence into
account.
∆S
S0
= e−TE·∆R
∗
2 − 1 ≈ −TE ·∆R∗2 (2.12)
Substituting Equation 2.11 for ∆R∗2 in Equation 2.12 gives:
∆S
S0
= TE · κ · CBV0 · [dHb]β0
(
1−
(
CBV
CBV0
)(
[dHb]
[dHb]0
)β)
(2.13)
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Substituting Equation 2.10 into Equation 2.13, the term for maximum BOLD
signal change can be incorporated into the model.
∆S
S0
= M
(
1−
(
CBV
CBV0
)(
[dHb]
[dHb]0
)β)
(2.14)
In the case of hypercapnia, Equation 2.14 reduces to Equation 2.15 where increases
in inspired CO2 are assumed to cause isometabolic CBF changes. α is the Grubb
constant [50], a value taken from literature that relates changes in CBF to changes
in CBV as [ CBF
CBF0
]α = [ CBV
CBV0
].
∆S
S0
= M
(
1−
(
CBF
CBF0
)α−β)
(2.15)
In the case of hyperoxia an isometabolic increase in CaO2 is assumed to have no
effect on CBF and Equation 2.14 is simplified to:
∆S
S0
= M
(
1−
(
1 +
∆[dHb]
[dHb]0
)β)
(2.16)
[dHb]0 is calculated by assuming haemoglobin concentration [Hb] and venous oxy-
gen saturation, SvO2.
[dHb]0 = [Hb](1− SvO2) (2.17)
∆[dHb] is inferred from increases in CaO2. CaO2 is estimated from arterial partial
pressure of oxygen (PaO2), which in subjects with normal pulmonary function
can reasonably be represented with only a small systematic error by measuring
the partial pressure of end-tidal oxygen (PETO2) [51]. CaO2 is calculated using
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a variation of Fick’s principle, Equation 2.19, after calculating arterial oxygen
saturation (SaO2) from PaO2 as described by the Severinghaus equation:
SaO2 =
(
1
23400
(PaO2)3+150(PaO2)
+ 1
)
(2.18)
CaO2 = φ[Hb]SaO2 + PaO2. (2.19)
where  is the coefficient of solubility of oxygen in blood (0.0031 ml O2/(dl blood
mmHg)) and φ is the O2 carrying capacity of haemoglobin (1.34 ml O2/gHb).
Both equations can then be solved for M with all other parameters being measured
or assumed. However it is important to note that hyperoxic calibration requires
a value for SvO2 to be assumed. It is also important to note that assuming fully
saturated arterial blood, OEF=1-SvO2.
With the experiment calibrated by determination of M, the normalised time courses
of perfusion, CBF
CBF0
, and BOLD, S
S0
, can be used to compute dynamic oxidative
metabolism maps (rCMRO2(t)) relative to baseline.
rCMRO2(t) =
(
CBF
CBF0
)1−α/β (
1−
S
S0
− 1
M
)1/β
(2.20)
Limitations of Calibrated BOLD
As previously mentioned, calibrated BOLD relies on the assumption that hyper-
capnia and hyperoxia do not modulate baseline CMRO2. Currently there are
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contrasting results in the literature due to the limited availability and sensitivity
of suitable techniques to measure CMRO2 changes in vivo. Hyperoxia has been
observed to cause increases [52], decreases [53, 54] and no change [55] in oxygen
metabolism. Similarly hypercapnia has been observed to cause increases [47,48,56],
decreases [57–60] and no change [18, 61, 62] in oxygen metabolism. These studies
were conducted over a range of species, techniques, states and pathologies which
may explain the wide range of results. The most relevant MR studies [53,57] sug-
gest a decrease in oxygen metabolism with hyperoxia and hypercapnia. However
as a result of the global nature of the measurements applied in these studies it is
difficult to interpret the effect of hyperoxia or hypercapnia on brain metabolism
particularly in grey matter, the region of focus in calibrated FMRI techniques.
Changes in CBF with hyperoxia have also been in observed in some cases [51,59].
Further investigation is required, but if indeed hypercapnia and hyperoxia were
found to modulate baseline CMRO2 (and CBF in the case of hyperoxia), and these
changes were correctly characterised, terms could be introduced into the BOLD
signal model to account for this.
Other limitations associated with this technique are related to the relative nature of
the measurement. As these methods are based on calibrating the BOLD signal and
result in estimates of relative changes in CMRO2 from an unquantified baseline,
the interpretation of these relative changes prove problematic where the baseline
may be altered in disease or drug studies [63]. As such MRI methods capable of
measuring absolute CMRO2 would be more effective for the longitudinal study of
metabolism changes in brain.
49
Chapter 2 ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Section 2.3
2.3 MRI for Measuring OEF and Absolute CMRO2
MRI methods capable of measuring absolute CMRO2 have been developed in or-
der to offer an MR alternative capable of measuring metabolism in the brain
non-invasively. These methods fall into two broad categories. Techniques which
provide global or bulk measures of CMRO2 for the whole brain and those capable
of producing parameter maps capable of regionally distinguishing areas of varying
metabolism. Techniques capable of producing regional measurements are prefer-
able and offer a true alternative to the ’gold standard’ PET techniques.
2.3.1 Phase Based Methods
Phase based susceptibility methods, such as PROM (Phased-based Regional Oxy-
gen Metabolism) [64], are based on measuring the susceptibility differences between
veins and surrounding tissue using phase based images. Phase based images can
be acquired using a GRE with a fixed TE. These approaches require mean re-
gion of interest (ROI) measures from an appropriate vein and surrounding tissue
to calculate the average phase difference (∆φ) between these ROI’s. Under the
assumption that the selected vein segment is an infinite cylinder (length is much
greater than diameter), the phase difference estimate is combined with an estimate
of the angle between the vein and the direction of the static magnetic field and an
estimate of susceptibility difference (∆χ) is calculated between the vein and tis-
sue. ∆χ can be related to OEF allowing absolute CMRO2 to be calculated using
an additional CBF measure such as ASL. However this class of techniques has a
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number of disadvantages related to the lack of spatial sensitivity (global measure)
and the manual identification of a suitable vein. Vein size may heavily influence
the results achieved as small veins may be susceptible to partial voluming effects
and larger veins will reflect oxygenation in many capillary beds. This means the
territory that is drained may not be well identified making it hard to calculate
local OEF changes.
Extravascular R′2 Based Methods
Quantitative BOLD style techniques [65–67] relate the reversible relaxation rate
(R′2 =
1
T ′2
= 1
T ∗2
− 1
T2
) to deoxyhaemoglobin induced signal loss. This class of
techniques can employ a number of different acquisitions to acquire the MR signal
required to calculate R′2, using a combination of GRE and SE MR sequences with
T∗2 and T2 sensitivity respectively, as well as hybrid SE-GRE sequences providing
sensitivity to both types of dephasing or asymmetric spin echoes (ASE), directly
sensitive to R′2. These techniques assume no diffusion effects are present in the
capillaries. This allows deoxyhaemoglobin concentration to be related to R′2 and
through signal modelling whole brain maps of CBV and SvO2 can be measured.
However the distinction between CBV and SvO2 is quite challenging under nor-
mal experimental conditions and multi-parametric qBOLD approaches have been
introduced [68] in an attempt to increase the spatial resolution of the acquisitions
and improve the accuracy of the oxygenation estimates by using independent mea-
surements of model parameters. It is also important to note that R′2 is sensitive
to [dHb] and CBV. It has recently been proposed [69] that R′2 could therefore be
related to maximum BOLD signal change, M. As M is dependent on both CBV
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and SvO2, issues related to separating these two terms can be sidestepped and over
fitting can be avoided.
Intravascular T2 Based Methods
Intravascular T2 measurements attempt to directly measure the effect of deoxy-
haemoglobin induced signal loss in intravascular blood. This relates the T2 of blood
directly to its oxygenation using a T2-oxygenation calibration curve. However in
order to measure SvO2, the T2 signal must be localised to venous blood.
Initial studies focused on measuring T2 in large veins similar to the approach
described in Section 2.3.1. TRUST (T2 relaxation under spin tagging) provides a
measure of T2 in a large draining vein, such as the sagittal sinus, by using an ASL
style tagging scheme to tag venous blood as opposed to inflowing arterial blood.
A tag-control subtraction is then used to better isolate the signal in the vein of
interest and the signal is acquired at multiple TE’s to characterise the T2 of venous
blood. Combining this with a global CBF measure acquired using phase contrast
MR, global absolute CMRO2 can be calculated.
QUIXOTIC (QUantitative Imaging of eXtraction of Oxygen and TIssue Consump-
tion) [70] and VSEAN (Velocity Selective Excitation with Arterial Nulling) [71]
are extensions of the TRUST methodology using the same venous tagging ap-
proach as TRUST. Velocity-selective spin labelling is then applied to isolate the
signal to venous blood and the oxygenation of the signal can be estimated using a
T2-oxygenation calibration curve. These techniques are currently limited to single
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slice acquisitions but have the scope for larger brain coverage with the addition of
a 3D acquisition.
The main difficulty with this class of technique is related to confidently localising
the signal to the venous vasculature requiring intricate tagging and vessel selective
pulses. The VSEAN approach in particular is promising but is still a new technique
in the development stage and the ease of implementation and application still
remains to be seen. Mapping techniques based on venous T2 also inherently suffer
from low SNR due to the small compartment under investigation.
2.4 Dual Calibrated FMRI
Recently the approach of Davis et al. [45] and Hoge et al. [49] has been extended
to use both hypercapnia and hyperoxia induced CBF and BOLD signal changes
to estimate venous deoxyhaemoglobin concentration and thus regional OEF and
absolute CMRO2 [1–3].
Dual calibrated FMRI (dcFMRI) effectively uses a two point calibration, inducing
BOLD and CBF changes, by hypercapnic and hyperoxic respiratory manipulations
performed in the same session. In it’s simplest form, as described by Bulte et al. [1],
M can be calculated using the hypercapnic calibrated BOLD approach, meaning
SvO2 no longer needs to be assumed in the hyperoxic calibration. Instead the
equation can now be solved for SvO2. Assuming arterial blood is fully saturated
the oxygen extraction fraction can be calculated using Fick’s equation.
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The approach of Gauthier et al. [2] and Wise et al. [3] to dcFMRI differ only in
the application of the BOLD signal model. Instead of estimating M independently
using hypercapnic calibration and determining SvO2 using hyperoxic calibration,
the Davis/Hoge model (Equation 2.14) is expanded to accommodate simultaneous
modulations of CBF and CaO2. The model reduces to the hypercapnic (Equa-
tion 2.15) and hyperoxic (Equation 2.16) based models when arterial oxygen levels
and CBF are held constant respectively. However M and SvO2 are estimated by
simultaneously optimising these parameters to the data through the expanded
model.
2.4.1 Expanded BOLD-Signal Model
An expanded BOLD signal model was presented by Wise et al. [3]. The full
derivations, from this paper, leading to Equation 2.21 are presented in the Ap-
pendix A. The assumptions for hypercapnia and hyperoxia are that with phys-
iologically moderate modulation of CBF through hypercapnia and CaO2, brain
tissue oxygen consumption remains unaltered. With hyperoxia additional oxygen
is largely dissolved in arterial blood plasma and therefore manifests as increased
venous oxygen saturation (SvO2). The conservation of oxygen allows us to de-
rive an expression for the venous deoxyhaemoglobin concentration with respect to
baseline conditions denoted by subscript zero (0):
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[dHb]
[dHb]0
=
CBF0
CBF
− 1
[dHb]0
(
1
φ
(
CaO2 −
(
CBF0
CBF
)
CaO2|0
)
+ [Hb]
(
CBF0
CBF
− 1
))
(2.21)
By combining the Grubb equation to relate CBF to CBV and Equations 2.14 and
2.21 estimates of M and SvO2 can be produced.
By simultaneously varying arterial concentrations of carbon dioxide and oxygen
the relationship between the Grubb equation, Equation 2.14 and Equation 2.21
can be exploited to concurrently produce estimates of α and β as well as M and
[dHb]0. Essentially BOLD signal changes resulting from modulation of arterial
oxygen content are simultaneously modulated by hypercapnia induced changes in
CBF. Considering two different levels of CBF, CBF1 and CBF2, produced as a
result of two different arterial carbon dioxide levels, the ratio of the superimposed
arterial oxygen induced changes in BOLD signal can be approximated by:
∆S1,O2
∆S2,O2
=
(
CBF1
CBF2
)1+α−β
where ∆Si,O2 =
∆Si
∆CaO2|i
(2.22)
2.5 Thesis Outline
The aim of this thesis is to further develop and optimise dcFMRI for the mea-
surement of oxygen metabolism, proving its suitability for application in further
clinical and research studies of oxygen metabolism in the brain.
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In Chapter 1 an introduction to energy metabolism in the brain is provided. The
role of oxygen metabolism in energy production, brain function and disease is dis-
cussed. To motivate the development of dcFMRI, a review of current measurement
techniques is also presented.
Chapter 2 introduces a background to basic MRI concepts followed by a descrip-
tion of the FMRI techniques which underpin the dcFMRI approach. Current MRI
methods capable of producing absolute oxygen consumption measures are dis-
cussed and the background and theory involved in measuring oxygen metabolism
using dcFMRI is described.
Chapter 3 aims to choose the optimal ASL acquisition available in our centre for
application in the dcFMRI measurement.
Chapter 4 compares hypercapnic-hyperoxic respiratory designs for detecting re-
gional changes in oxygen metabolism. This allows the sensitivity of dcFMRI for
detecting regional changes in oxygen metabolism to be assessed, where regional
changes in metabolism are induced using continuous visual and motor stimulation
throughout the dcFMRI measurement.
Chapter 5 investigates the within and between session repeatability of resting
oxygen metabolism measurements made using dcFMRI.
Chapter 6 uses a retrospective analytical approach to optimise the acquisition
time of dcFMRI with an aim to provide a more time efficient measure.
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Chapter 7 demonstrates the ability of dcFMRI to detect CBF related changes in
OEF suggesting that the technique is appropriate for clinical application in areas
such as stroke or vascular dysfunction in which flow is impaired.
Chapter 8 introduces a novel dcFMRI approach for the measurement of absolute
oxygen metabolism. This is achieved by replacing the hypercapnic challenge in the
dcFMRI protocol with an R′2 based measure of maximum BOLD signal change,
M. The concept and techniques used have the potential for a fast and effective
method of producing whole brain, absolute CMRO2 maps in a short scan time
without hypercapnia.
Chapter 9 discusses the experimental work presented, considers potential areas
of application and future work required to further progress this technique.
Throughout the main experimental work (Chapter 4 to 8) there is some repetition
of theory and methods to improve readability and subsets of data from a given
experiment are presented in more than one chapter.
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Chapter 3
Comparison of Acquisition Techniques
for Detecting Task-Related Changes in
CBF and BOLD
3.1 Introduction
FMRI experiments typically use blood oxygen level dependent (BOLD) signal
contrast to probe the regional and spatial extent of task-related neural activity.
However BOLD signal changes are measured from an unknown baseline and are a
function of underlying haemodynamic processes such as cerebral blood flow (CBF)
and oxygen metabolism. Techniques such as calibrated BOLD [45,46] attempt to
measure these underlying physiological processes to better interpret BOLD signal
changes and provide a clearer understanding of brain physiology. This is achieved
by inducing isometabolic CBF and BOLD signal changes using hypercapnic [45]
or hyperoxic [46] respiratory manipulations and relating them to the cerebral rate
of oxygen metabolism (CMRO2) through a BOLD signal model.
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3.1.1 Arterial Spin Labelling
In order for this technique to be feasible, it is beneficial to use a scanning protocol
capable of detecting changes in CBF and BOLD simultaneously. Consequently
the application of ASL to task based FMRI experiments and the ability to process
the acquisition in such a way as to provide simultaneous, non-invasive measures of
CBF and BOLD has made it a cornerstone of the calibrated BOLD methodology.
In an ASL FMRI experiment, a series of control and tag images are acquired in an
interleaved manner. Control images are acquired in which arterial blood is fully
relaxed. Tag images are then made, in which arterial blood is magnetically in-
verted and the tag image acquired after waiting an appropriate amount of time for
the tagged blood to perfuse into the tissue. The time course of signal differences
(control - tag) is flow weighted and can be used to calculate CBF. These images are
typically acquired with a rapid imaging sequence such as an echo-planar imaging
(EPI) readout sequence. The sensitivity of the rapid imaging sequence to changes
in T∗2 means that the ASL acquisition also contains some influences from BOLD
signal contrast. This influence of BOLD contrast on the acquired time-series can
be optimised by acquiring at a TE ≈ 30 ms and the influence of the ASL tag
can be minimised by averaging the tag-control time course ( control+tag
2
) [43]. Con-
versely the influence of BOLD weighting on the CBF measure can be reduced by
minimising the TE and acquisition time of the readout sequence.
Comparison of ASL Techniques
Although most ASL techniques are capable of being processed in such a way as to
provide both CBF and BOLD signal time-series, techniques are often optimised
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for either BOLD or CBF acquisition, not both. Moreover, different variations of
ASL (i.e. pulsed, continuous or pseudo-continuous) each offer specific benefits and
disadvantages.
Figure 3.1: Schematic showing the timings of the single echo PCASL with Carte-
sian EPI readout and dual-echo PASL spiral EPI readout ASL acquisitions.
In this study we aim to compare two ASL acquisition schemes available in our
centre, shown in Figure 3.1, that are capable of detecting task related changes
in CBF and BOLD. The two ASL acquisition schemes used for comparison were
a dual-echo pulsed ASL (PASL) acquisition with a spiral EPI readout (supplied
by University of California at San Diego (UCSD) [44]) and a single-echo pseudo-
continuous ASL (PCASL) with Cartesian EPI readout (supplied by the National
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Institutes of Health (NIH), Bethesda, Maryland, USA). The benefits and disad-
vantages of the different elements of each acquisition are discussed below.
As previously mentioned, ASL is based on the difference between a tag and con-
trol image, the subtraction of which can be directly related to CBF. The tagging
preparation module used can directly affect the signal-to-noise ratio (SNR) of the
perfusion signal [37]. The spin preparation or tagging of arterial blood performed
by PASL is spatially selective whereas continuous ASL (CASL) tags protons trav-
elling through a plane for a well defined period of time and is therefore temporally
dependent. In general, temporal tagging schemes lead to a higher amount of
tagged arterial blood and therefore CASL techniques usually afford a higher SNR
perfusion signal compared to PASL. However the primary drawback of CASL is
the requirement of continuous radio frequency (RF) transmitting hardware that is
not commonly available on most MRI scanners. PCASL is a subcategory of CASL
developed to circumvent the hardware limitations that are encountered. This is
achieved by breaking the RF and gradient pulses into a series of rapid pulses.
Dual-echo protocols allow data to be acquired at two different TE’s and therefore
can be optimised for the acquisition of CBF and BOLD data. CBF measurements
are preferably made with a TE as short possible, improving the SNR of the ASL
measurement and minimising T∗2 influences. Conversely, BOLD signal contrast can
be optimised by imaging at a more optimal, longer TE (≈ 30 ms). With a spiral
trajectory through k-space, the effective TE (i.e. the time at which the centre of
k-space is acquired) can be very short (a few ms), improving the SNR of the ASL
measurement. The second echo is optimised for the BOLD signal, generally at ∼
30 ms [44]. By way of contrast, single echo techniques require a compromise on
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TE usually at ∼ 20 ms. This leads to a reduction in the SNR of the CBF signal
and a loss of BOLD signal contrast due to the reduced echo time [31].
Ideally a comparison of techniques for detecting task-related changes in CBF and
BOLD would be performed in a systematic manner comparing each feature of the
pulse sequence including pulsed and pseudo-continuous tagging modules, single-
echo and dual-echo acquisitions and Cartesian EPI with spiral EPI readouts for
detecting task-related changes in CBF and BOLD. However, the comparison pre-
sented in this chapter was limited to ASL techniques available in our centre. The
multi-echo pulse sequence is limited to a PASL tagging module with a spiral EPI
readout allowing short readout times. The other available technique used a PCASL
tagging module, offering improved perfusion-related SNR compared to PASL, but
limited to a single echo acquisition with Cartesian EPI readout.
The aim of this study is to choose the pulse sequence most sensitive to simultaneous
detection of stimulus induced changes in both CBF and BOLD signal. The chosen
pulse sequence will be applied in a calibrated BOLD style protocol where the mea-
surement of hypercapnic and hyperoxic induced changes in CBF and BOLD signals
are essential. In order to assess the sensitivity of the two techniques for detect-
ing stimulus induced changes in CBF and BOLD, both ASL acquisition schemes
were used to acquire CBF and BOLD time-series during an on/off visual stimu-
lus paradigm. CBF and BOLD time-series were calculated from both acquisitions
and analysed to identify the statistical significance of visually induced changes in
CBF and BOLD signals using a linear modelling approach. The number of task
correlated ’active’ voxels and mean z-score of these voxels was assessed in the vi-
sual cortex at a number of significance levels for CBF and BOLD time-series that
62
Chapter 3 ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Section 3.2
were acquired using both techniques. Correlation between CBF and BOLD time-
series was also assessed at the same thresholding levels using different functionally
localised ROI’s to assess the correspondence between task related changes in the
CBF and BOLD time-series. As positive BOLD signal change is intrinsically linked
with increases in CBF a high correlation is expected between these two physio-
logical measures. Comparing correlations in this manner has the added benefit
of making the comparison independent of the task model and provides a useful
measure even if the activity time-course is not what would be expected.
3.2 Methods
3.2.1 Participants
Five normal healthy participants (aged 27-39; mean age 34.2 ± 4.4; 1 female) were
recruited and scanned having given written consent. Experimental procedures
were approved by the local institutional ethical review committee.
3.2.2 Scanning Protocol
Scanning was performed on a 3T GE HDx MRI (GE Healthcare, Milwaukee WI)
with a body transmit coil and 8-channel head receive only coil. All participants had
previous whole brain T1-weighted structural scans available (fast spoiled gradient
recalled echo, 1x1x1 mm voxels, TI/TR/TE = 450/7.8/3 ms).
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PASL and PCASL techniques were limited to 10 minute acquisition runs during
which the participant viewed a 90 second on/off visual stimulus consisting of a re-
versing checkerboard pattern (8 Hz). Comparing dual-echo PASL and single-echo
PCASL acquisitions, the repetition time (TR) or time taken to acquire a single
volume was longer for PCASL (TR = 3.1 s) than PASL (TR = 2.2 s). Due to this
difference in TR the total acquisition time was used as the limiting factor. This
was considered a fair comparison as the intended application of the acquisition was
to a calibrated BOLD protocol containing hypercapnic and hyperoxic challenges
with a predetermined acquisition time already decided upon. The imaging pre-
scriptions, including orientation and coverage of slices were consistent between the
two techniques (Flip angle 90◦, FOV 22 cm, matrix 64x64, 12 slices of 7 mm thick-
ness with an inter-slice gap of 1 mm acquired in ascending order). The sequence
in which ASL scans were acquired was randomised to control for order effects.
A separate single shot, M0 scan (TR = ∞) with the same parameters as each
functional run was used to measure the equilibrium brain tissue magnetisation for
purposes of quantifying CBF.
Perfusion and BOLD imaging time-series were acquired during the on/off visual
paradigm using the following acquisitions:
Dual-Echo PASL with Spiral EPI Readout
PASL, proximal inversion and control for off-resonance effects (PICORE), quan-
titative imaging of perfusion using a single subtraction (QUIPSS II) [37] imaging
sequence was used with a dual-echo, single-shot, gradient echo (GRE) readout
and spiral k-space acquisition [72] (TE1 = 3 ms, TE2 = 29 ms, TR = 2.2 s, flip
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angle 90◦, TI1 = 700 ms, TI2 = 1600 ms for the most proximal slice and was
incremented by 54.6 ms for subsequent slices, tag thickness = 20 cm, adiabatic
hyperbolic secant inversion pulse, 10 mm gap between labelling slab and bottom
slice, 10 cm QUIPSS II saturation band thickness with an EPI acquisition time
of 600 ms). During the 10 minute task, 272 volumes (136 tag-control pairs) were
acquired.
Single-Echo PCASL with Cartesian EPI Readout
PCASL labelling [40] was used with GRE echo-planar imaging, full k-space, Carte-
sian EPI readout (TR = 3.1 s, TE = 22 ms, EPI readout flip angle 90◦, no ac-
celeration factor). A TE of 22 ms was chosen as it was considered short while
still maintaining a good proportion of maximum possible BOLD weighting [31].
A labelling duration of 1.5 seconds was accompanied by a post-labelling delay of
1 second for the most proximal slice and incremented for the subsequent slices by
54.6 ms and leading to an EPI acquisition time of 600 ms. During the 10 minute
task 192 volumes (96 tag-control pairs) were acquired.
As the positioning of the labelling plane for PCASL affects the labelling efficiency
[73], a 3D time-of-flight angiogram was acquired in order to choose the position
of the PCASL labelling plane. This enables optimal placement of the labelling
plane in the straight portion of the carotid arteries avoiding twists and kinks in
the arteries that may affect the labelling efficiency Figure 3.2.
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Figure 3.2: A 3D time-of-flight angiogram showing the position of the PCASL
labelling plane in relation to the internal carotids and vertebral arteries.
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3.2.3 Analysis
The AFNI (Analysis of Functional NeuroImages) [74] and FSL (FMRIB Software
Library) [75] libraries of analysis tools are used extensively throughout this thesis
for image manipulation.
Image time-series were motion corrected using 3dvolreg and brain extracted using
3dAutomask [74].
CBF and BOLD Time-Series
Interpolated surround subtraction was performed on the PASL (first-echo) and
PCASL tag-control image time-series to yield a perfusion-weighted time-series [43].
From the M0 calibration image an ROI in the ventricles was produced to calculate
the mean M0 of CSF and related to the M0 of blood. This value was used to
calculate CBF image time-series from the perfusion-weighted PASL and PCASL
data using the PASL and CASL general kinetic model (GKM) [33] respectively
whilst correcting for slice timing delays. Interpolated surround averaging of the
tag-control images was performed to yield a BOLD weighted time-series. In the
case of dual-echo PASL, the second echo was used for the calculation of the BOLD
time-series.
General Linear Model
The CBF and BOLD time-series for both ASL techniques were analysed to identify
significant visual task induced changes in CBF and BOLD signals using a linear
modelling approach. A boxcar regressor with on/off periods of 90 seconds each was
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convolved with a single haemodynamic response function and fitted to the CBF and
BOLD image time-series, for both methods, in each subject, using 3dDeconvolve
[74]. Parameter estimates were converted to z-scores and thresholded at varying
levels of significance (p = 5x10−2, p = 1x10−2, p = 1x10−3, p = 1x10−4). No
clustering was performed as it could potentially introduce a degree of nonlinearity
and complexity to the comparison and instead the measures were restricted to the
occipital lobe (OL). An OL mask, as defined by the MNI152 (Montreal Neurlogical
Institute) atlas [76], was registered back to the native space of each of the CBF
and BOLD time-series through the high-resolution structural image using FLIRT
[77]. This was used to constrain the following calculations to OL as no clustering
was used. The number of voxels and mean z-score below each of the probability
thresholding levels, in OL, was then calculated for CBF and BOLD using both
ASL acquisitions. The OL anatomical ROI and the CBF and BOLD functional
ROI’s at each thresholding level were used to investigate how well CBF and BOLD
signal time-series correlated during the paradigm for both ASL techniques. This
was performed by extracting CBF and BOLD signal time-series using three pairs
of functionally localised ROI’s. The BOLD functional localiser was used to extract
CBF and BOLD time-series allowing a comparison of BOLD localised CBF and
BOLD. In a similar manner, the CBF functional localiser was used to extract CBF
and BOLD time-series allowing a comparison of CBF localised CBF and BOLD.
A third comparison was performed from the previously extracted time-series using
CBF extracted using the CBF functional localiser and BOLD extracted using the
BOLD functional localiser.
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3.3 Results
The number of significantly active voxels in the occipital lobe at each thresholding
level for CBF and BOLD using both PASL and PCASL techniques are shown
in Figure 3.3. The group mean (± standard deviation) number of active voxels
are displayed for differing levels of significance allowing the spatial extent of the
activation in each technique to be demonstrated.
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Figure 3.3: PASL (Blue) and PCASL (Red) were used to investigate the spatial
extent of CBF (solid line) and BOLD (dashed line) changes with a visual stimulus
paradigm. The mean number of active voxels (± standard deviation) across the
five subjects are displayed for differing levels of significance (x-axis labels) allowing
the spatial extent of the activation in each technique to be demonstrated.
The mean z-score at each thresholding level for CBF and BOLD using both tech-
niques are shown in Figure 3.4. This allows the sensitivity of the response to the
visual paradigm to be assessed. A higher z-score suggests better correlation with
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the signal model and therefore better sensitivity to task related changes in CBF
and BOLD.
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Figure 3.4: PASL (Blue) and PCASL (Red) were used to investigate the sensitiv-
ity of CBF (solid line) and BOLD (dashed line) changes with a visual stimulus
paradigm. The mean z-score (± standard deviation) across the five subjects are
displayed for differing levels of significance (x-axis labels) allowing the sensitivity
of the response to the visual paradigm to be assessed. A higher z-score suggests
better correlation with the signal model and therefore better sensitivity to task
related changes in CBF and BOLD.
Figure 3.5 shows the correlation coefficient, R, between the BOLD and CBF signal
time-series extracted using an anatomical ROI (OL) and three different combina-
tions of the functional localisers for both techniques. R values in each ROI are
compared between PASL and PCASL.
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Figure 3.5: Correlation coefficients, R, representing the similarity between CBF
and BOLD signal time-series during the on/off visual paradigm. Mean R (± stan-
dard deviation) across the five subjects were calculated for the OL anatomical
ROI (Black) and three different functionally localised ROI’s. These were used to
extract the time-series as follows: BOLD localised CBF and BOLD time-series
(Blue), CBF localised CBF and BOLD time-series (Red) and CBF localised CBF
time-series and BOLD localised BOLD time-series(Green). The functional lo-
calisers were thresholded at four different levels and the mean group correlation
coefficients compared for PASL and PCASL techniques.
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3.4 Discussion
Two characteristically different ASL acquisition schemes, a dual-echo PASL with
spiral EPI readout and single-echo PCASL with Cartesian EPI readout, were as-
sessed for their sensitivity to detecting task related changes to an on/off visual
paradigm lasting ten minutes in five participants.
By determining the correlation between the expected response to a visual paradigm
and the CBF and BOLD time-series on a voxel-wise basis, the number of task cor-
related ”active” voxels and mean z-score of these voxels were assessed in OL at
a number of significance levels. By investigating the number of voxels at each
thresholding level it can be inferred which technique provides a larger number of
significantly correlated voxels. A larger spatial activation suggests greater sensi-
tivity to detect changes, however the mean z-score of the remaining voxels at each
thresholding level was also calculated to assess the sensitivity of the technique
to detecting significant correlation with the task. Correlation between CBF and
BOLD time-series was also assessed, using both techniques, at the same threshold-
ing levels, using different functionally localised ROI’s to investigate which method
provided best correspondence between CBF and BOLD responses to task.
It can be seen from Figure 3.3 that CBF measured using dual-echo PASL produces
a higher number of significantly correlated voxels with task when averaging across
the five subjects at all thresholded levels. The opposite is true when considering the
BOLD related changes to task with PCASL providing consistently more activated
voxels at all thresholding levels. In both cases the group standard deviation is
comparable across techniques when CBF or BOLD is considered. In all cases
72
Chapter 3 ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Section 3.4
the number of active voxels decrease as the significance thresholding decreases, as
expected.
The quality of the activation can be measured by calculating the z-score. A higher
z-score suggests stronger task related activation and a more sensitive technique.
Mean z-scores across the group, calculated in OL at the varying thresholding levels
are presented in Figure 3.4. It can be seen that group mean z-score increases with
thresholding. This is to be expected as voxels with weaker correlations to the ac-
tivation are removed with thresholding, thus increasing z-scores. CBF activation
detected with dual-echo PASL provides a consistently higher z-score when com-
pared to PCASL as well as considerably lower standard deviations. Group mean
z-score calculated using BOLD contrast is higher using the PCASL technique with
the standard deviation being smaller.
The main aim of this initial study is to choose an available acquisition method
which has the greatest sensitivity to detecting changes in CBF and BOLD for use
in calibrated BOLD experiments. Some other considerations that warrant dis-
cussion mainly focus around the measurement of CBF. As the signal difference
between ASL tag-control images is ∼ 1% and requires some form of subtraction to
weight the time series to perfusion, the intrinsic SNR and temporal resolution of
ASL is worse than with BOLD imaging. Therefore detecting task related changes
in CBF should be viewed as challenging and a technique proving more capable in
this aspect should be given more weight. The short TE of the dual-echo PASL
technique provides CBF measures with a marginally higher number of significantly
correlated voxels with higher mean z-score at all thresholding levels. This would
suggest that PASL with a short TE, acquired as close to TE = 0 ms as possible, is
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more sensitive at detecting task-related changes in CBF than a higher SNR tag-
ging module, as in PCASL, with a longer, suboptimal TE. During the 10 minute
acquisition time, 272 PASL volumes were acquired compared to 192 PCASL vol-
umes. This is as a result of the shorter TR of the PASL technique when compared
to PCASL giving the PASL approach a better temporal resolution which may be
an important factor.
It is also important to note that PASL may be favourable to PCASL when choosing
a method to measure CBF changes during hypercapnic respiratory manipulations
as is the case in calibrated BOLD. Hypercapnia is known to induce changes in the
velocity of arterial blood. This change in velocity has been demonstrated using
phase-contrast MRI in areas of the arterial tree such as the internal carotid and
vertebral arteries where the PCASL labelling plane is typically positioned [73].
This can cause the use of hypercapnia to decrease the tagging efficiency of the
PCASL technique and lead to inaccurate estimates of CBF. Failure to correct for
decreases in tagging efficiency due to increased velocity of arterial blood lead to
overestimation of the tagging efficiency and underestimation of CBF calculated
during hypercapnia. Due to the spatial nature of the PASL tag it should be
insensitive to such changes. For the QUIPSS II approach used in this study, this
assumes that the tag thickness is large enough that the cut-off saturation pulse,
used to provide a well defined bolus, does not miss the back of the tagging slab.
Methods for correcting changes in PCASL tagging efficiency are available but
require additional phase-contrast scans to be performed [73].
Surprisingly the PCASL technique proved more sensitive to detecting task re-
lated changes in BOLD. This may be due to the Cartesian EPI readout offering
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improved sensitivity to BOLD changes over the spiral readout. The Cartesian sam-
pling scheme samples k-space in a more thorough fashion which involves a longer
readout when compared to the spiral readout. To investigate this further, group
mean percentage BOLD increase and group mean coefficient of determination were
calculated over the OL as determined by the anatomical ROI previously described.
Group mean percentage increase were similar for both techniques, PASL = 0.34
± 0.21 % and PCASL = 0.32 ± 0.15 %. However the PCASL technique demon-
strated a higher group mean coefficient of determination (R2), PASL = 0.08 ± 0.04
and PCASL 0.10 ± 0.04. This would suggest that the improved BOLD sensitivity
afforded by the Cartesian EPI readout is due a noiser spiral readout.
Figure 3.5 demonstrates that higher correspondence between CBF and BOLD
time-series is achieved when using CBF to localise the signal time-series in both
techniques. One reason for this may be the fact that ASL measures the delivery
of arterial blood to the capillary beds and better localises the BOLD signal to this
region. BOLD signal changes are less specific and arise from venous oxygenation
changes. At all thresholding levels, equivalent or better correlation is demonstrated
by PASL when compared to PCASL. The improved correlation between CBF and
BOLD is also shown by the OL anatomical, ROI. This anatomical ROI analysis has
the advantage of not constraining the signal to only task-like voxels and instead
includes all signal from the OL.
To summarise the results in Figures 3.3 and 3.4, the dual-echo PASL technique
allows CBF measures which are more sensitive to task-related changes with a
higher number of active voxels whereas the single-echo PCASL acquisition allows
more sensitive BOLD related changes with task. Taking this into consideration
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the improved correlation between task-related changes in CBF and BOLD signal
afforded by the dual-echo PASL technique can be put down to its superior CBF
measure. Although a higher SNR is provided by a PCASL tagging module, the
dual-echo PASL approach allows a CBF measurement to be made with a TE as
short possible, improving the SNR of the ASL measurement and minimising T∗2
influences. The dual-echo PASL acquisition also allows an improved temporal
resolution, with a TR of 2.2 s compared to 3.1 s, which may contribute towards
the better CBF and BOLD correlations.
3.5 Conclusion
The sensitivity of two ASL techniques, a dual-echo PASL with spiral EPI read-
out and a single-echo PCASL Cartesian EPI readout, were compared for detect-
ing task-related changes in CBF and BOLD with a visual task. The optimised
echo time and superior temporal resolution of the PASL technique offered better
sensitivity in terms of detecting task related CBF changes whereas the PCASL
technique offered better BOLD sensitivity. Better correspondence between CBF
and BOLD time-series is achieved when using CBF to localise both perfusion and
BOLD task related time-series with PASL again demonstrating higher correla-
tion.
From these results and the fact that PASL tagging is largely insensitive to CBF
misestimation related to velocity dependent tagging efficiency errors [78], the dual-
echo PASL technique would appear to be the more appropriate acquisition for ap-
plication in calibrated BOLD, respiratory manipulation style experiments.
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Chapter 4
Comparison of Dual Calibrated FMRI
Respiratory Designs for the Detection of
Regional Alterations in Absolute
CMRO2
4.1 Introduction
Oxygen is essential in the supply of energy to the brain. The brain has minimal
energy and oxygen reserves so it must be continuously supplied with oxygen rich
blood in order to maintain proper, healthy function. The rate at which oxygen is
consumed by the brain is referred to as the cerebral metabolic rate of O2 consump-
tion (CMRO2) and is a direct indicator of cerebral activity under the assumption of
largely oxidative metabolism [12]. CMRO2 is closely related to brain function and
health and can change regionally with disease or functional activation [19]. The
coupling of CMRO2 with CBF and its relationship with CBV make it an impor-
tant component in the formation of BOLD contrast, commonly exploited to map
neural activity in the brain [32]. Perturbations in cerebral oxygen metabolism are
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directly linked to neurodegenerative disorders such as Alzheimer’s, Parkinson’s and
multiple sclerosis [13–15] whilst directly measuring CMRO2 can assist in assessing
the extent of brain damage after stroke [16] and aid in tumour management and
outcome [17]. As a result, techniques capable of producing non invasive, absolute,
quantitative maps of CMRO2 in the brain provide us with a unique tool to inves-
tigate the regional and spatial extent of cerebral oxygen consumption and have
a wide range of applications. With appropriate development a technique allow-
ing a robust absolute CMRO2 measure would provide a valuable insight into the
underlying metabolic changes that accompany normal brain development, ageing
and brain disease in which tissue damage or dysfunction alters metabolic activ-
ity. Oxygen metabolism presents a functional biomarker which could aid in the
diagnosis and development of new treatment pathways of such diseases. A direct
measure could also be applied to studies of task-related brain activity by providing
a measure of baseline from which brain activity levels are changing, aiding in the
interpretation of traditional FMRI studies.
4.1.1 PET
Currently triple oxygen Positron Emission Tomography (PET) is the gold standard
for providing detailed oxygen metabolism maps of the brain [19]. This technique
requires three separate PET radio-tracer studies to be performed allowing whole
brain CMRO2 maps to be produced. However this technique is time consuming
taking ∼ 45 minutes to acquire the relevant data, requires an on-site cyclotron due
to the short half-life of the radioisotope used, is expensive to perform and most
78
Chapter 4 ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Section 4.1
importantly exposes the subject to a radiation dose which compromises the ability
of PET to be used in longitudinal studies of disease or ageing.
4.1.2 MRI
A number of MRI alternatives have been developed in an attempt to avoid using
radioisotopes to measure CMRO2 in the human brain [45,46].
Relative CMRO2 and Calibrated BOLD
Calibrated BOLD is an established technique used to determine changes in CMRO2
associated with a task by calibrating the blood oxygen level dependent (BOLD)
signal using measurements acquired during a respiratory manipulation. As dis-
cussed in Chapter 3, arterial spin labelling (ASL) can be acquired and processed
in a manner which allows simultaneous measures of BOLD and cerebral blood flow
(CBF) to be made during a respiratory manipulation such as hypercapnia [45] or
hyperoxia [46]. Using an appropriate BOLD signal model and relevant assumptions
about the respiratory manipulation, changes in CMRO2 can be quantified relative
to baseline. However as this technique produces estimates of relative changes in
CMRO2 from an unknown baseline and is dimensionless, the interpretation of these
changes prove problematic where the baseline may be altered in disease or drug
states [63].
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Absolute CMRO2
MR methods have started to emerge allowing estimates of absolute CMRO2 to be
made in µmol of O2 consumed per 100g of tissue per minute (µmol/100g/min).
Methods yielding bulk or whole brain absolute CMRO2 are based on measure-
ments of CBF and venous oxygen saturation via relaxation measurements of T2
of venous blood [79] or the pattern of magnetic field distortions around major
veins [64]. Velocity selective methods have also been proposed to isolate the T2 of
venous blood and estimate its oxygenation based on a T2-oxygenation calibration
curve [70, 71]. However, these techniques have low SNR and currently suffer from
limited brain coverage. Methods capable of producing whole brain parametric
maps capable of detecting regional differences in absolute CMRO2 are preferable
in detecting the extent of disease or functional activation and are analogous to
the PET technique discussed previously. A quantitative or qBOLD approach has
been demonstrated in which R′2 is sensitive to CBV and deoxyhaemoglobin con-
centration [69]. However the distinction between CBV and deoxyhaemoglobin
concentration is challenging under normal experimental conditions [68].
4.1.3 Dual Calibrated FMRI
By performing dual hypercapnic-hyperoxic manipulations of CBF and BOLD sig-
nals in the same session, it has recently been shown that calibrated BOLD can be
extended to estimate absolute CMRO2 [1, 2]. The technique measures the max-
imum BOLD signal (M) and estimates the baseline oxygen extraction fraction
(OEF0) through dual calibration. As this is an absolute measure it provides a
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quantitative FMRI measurement for investigating longitudinal changes in cere-
bral metabolic behaviour, with use as a potential biomarker of disease which has
applications in both research and clinical settings.
Further study of the dual calibrated FMRI (dcFMRI) technique involved the inves-
tigation of the respiratory manipulation design and the sensitivity of the technique
to detecting regional changes in metabolism [3]. Interleaved respiratory manipula-
tions were performed with periods of normocapnia with hyperoxia and hypercapnia
with normoxia interleaved with periods of normocapnia with normoxia, similar to
the original studies [1, 2]. This respiratory design, lasting 19.5 minutes, was then
used in a dcFMRI protocol to detect regional changes in absolute CMRO2 due to
a sustained visual stimulus. The study also introduced a simultaneous respiratory
manipulation with periods of hyperoxia which were simultaneously modulated us-
ing periods of hypercapnia, lasting 13.5 minutes in total. By simultaneously modu-
lating hyperoxia using hypercapnia, the simultaneous dcFMRI approach provided
additional information about the exponents, α and β, used in the BOLD signal
model. α is the exponent relating relative increases in CBF to relative increases
in CBV and β is the exponent relating deoxyhaemoglobin concentration to the
transverse relaxation rate R∗2. Both of these model parameters are dependent
on cerebrovasculature, have the potential to change depending on the underlying
physiology and are assumed in the interleaved dcFMRI approach.
The focus of this study is to compare an interleaved respiratory manipulation
design to a simultaneous design for the detection of regional changes in metabolism.
This study offers a number of refinements to that presented by Wise et al. [3]. Both
interleaved and simultaneous respiratory manipulations are used to investigate
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regional elevations in oxygen metabolism, a visual and motor stimulus is used to
regionally elevate oxygen metabolism and optimised interleaved and simultaneous
respiratory manipulations are presented.
The interleaved and simultaneous hypercapnic-hyperoxic respiratory manipula-
tions are modified versions of those presented by Wise et al. [3]. Modifications
made to the interleaved design are shown in Figure 4.1. Periods of normocap-
nia/normoxia and hyperoxia/normocapnia last one minute each and periods of
hypercapnia/normoxia last 2.5 minutes. The reliance on arterial spin labelling
(ASL) to measure changes in CBF is considered to be a limiting factor in the
dcFMRI routine as the measure of CBF using ASL suffers from low SNR. It can
also be seen from Figure 4.1 that changes in CBF are only expected during periods
of hypercapnia. In order to increase the SNR of the ASL measure of CBF change,
the length of the hypercapnia/normoxia blocks were increased. As no such SNR
limitations are placed on the detection of BOLD changes induced during periods of
hyperoxia, more frequent, shorter blocks of hyperoxia and normocapnia/normoxia
were used. The symmetry and interleaved nature of the design, were also thought
to be beneficial in dealing with any drift that may occur during the long scan time
duration. To aid in extrapolating measurements of the α and β exponents from
the simultaneously modulated design it was considered best to have many levels of
simultaneously varying hypercapnia and hyperoxia in the 18 minute time-course,
as shown in Figure 4.2. It was also designed symmetrically to counteract drift
with baseline measures being conducted at the beginning, middle and end of the
respiratory design. The acquisition time of both respiratory designs was set at 18
minutes.
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Figure 4.1: Schematic detailing, from top to bottom, target PETO2 and PETCO2
time courses and expected perfusion and BOLD responses for the interleaved res-
piratory manipulation.
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Figure 4.2: Schematic detailing, from top to bottom, target PETO2 and PETCO2
time courses and expected perfusion and BOLD responses for the simultaneous
respiratory manipulation.
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Interleaved and simultaneous dcFMRI approaches were then used to investigate re-
gional changes in metabolism due to continuous visual and motor stimulation. This
allows us to investigate the sensitivity of the dcFMRI technique for the detection
of regional metabolic changes and therefore assess the suitability of the technique
for application in the detection, monitoring and treatment of disease.
4.2 Methods
4.2.1 Participants
8 normal healthy participants (aged 24 - 39; mean age 33.5 ± 5.0; 2 female)
were recruited and scanned. Experimental procedures were approved by the local
institutional ethical review committee.
4.2.2 MRI
Scanning was performed on a 3T GE HDx MRI (GE Healthcare, Milwaukee WI)
with a body transmit coil and 8-channel head receive coil. All participants had
previous whole brain T1-weighted structural scans available (fast spoiled gradient
recalled echo, 1x1x1 mm voxels, TI/TR/TE = 450/7.8/3 ms). Each participant
was scanned in two sessions on separate days with protocols lasting approximately
50 minutes. On each day a functional localiser, dcFMRI acquired during base-
line and dcFMRI acquired during elevated baseline were acquired. The dcFMRI
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acquired during baseline and elevated baseline allowed quantification of absolute
CMRO2 at baseline and elevated baseline during each session. During the first ses-
sion the dcFMRI protocol used an interleaved hypercapnic-hyperoxic respiratory
manipulation and the second session used a simultaneous hypercapnic-hyperoxic
respiratory manipulation, as detailed in Figure 4.3.
Figure 4.3: Schematic detailing the protocol used to assess the suitability of the
interleaved and simultaneous dcFMRI techniques for detecting regional changes
in metabolism. Session 1 involved an interleaved dcFMRI acquisition at rest and
during continuous visual and motor stimulation while Session 2 consisted of si-
multaneous dcFMRI acquisition at rest and during continuous visual and motor
stimulation. Not shown is the acquisition of the functional localiser (5.5 mins)
which was acquired at the start of each session during normocapnia and normoxia.
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CBF and BOLD Acquisition
Simultaneous ASL and BOLD imaging data was collected for the functional lo-
caliser and for each of dcFMRI acquisitions in each session using a PASL proximal
inversion and control for off-resonance effects (PICORE), quantitative imaging of
perfusion using a single subtraction (PICORE QUIPSS II) [37] imaging sequence
with a dual-echo gradient echo (GRE) readout and spiral k-space acquisition (TE1
= 3 ms TE2 = 29 ms, TR = 2.2 s, flip angle 90
◦, FOV 22 cm, matrix 64 x 64, 12
slices of 7 mm thickness with an inter-slice gap of 1 mm acquired in ascending or-
der, TI1 = 700 ms, TI2 = 1600 ms for the most proximal slice and was incremented
by 54.6 ms for subsequent slices, tag thickness = 20 cm, adiabatic hyperbolic se-
cant inversion pulse, 10 mm gap between labelling slab and bottom slice, 10 cm
QUIPSS II saturation band thickness). This resulted in the acquisition of 248 vol-
umes (124 tag-control pairs) for the functional localiser and 488 volumes (244 tag -
control pairs) for each of the absolute CMRO2 acquisitions. A separate single shot
(M0) scan was acquired (TR=∞) with the same parameters as the functional run
to measure the equilibrium brain tissue magnetisation for purposes of quantifying
CBF. A minimum contrast image was also acquired to correct for coil sensitivity
with the same acquisition parameters as the ASL run except for TE = 11 ms, TR
= 2 s, and 8 interleaves.
4.2.3 Stimulus Design
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Functional Localiser
The functional localiser, lasting 51
2
minutes, was used to create ROI’s of activated
voxels. This consisted of a 30 second baseline, 30 second motor stimulation and
30 second visual stimulation repeated three times ending with a baseline period.
The motor stimulation consisted of numbers from 1 to 4 appearing on the screen
with the participant responding by pressing the corresponding button on a button
box. The button box was positioned in the subjects right hand with index finger
corresponding to button 1, middle finger corresponding to button 2 and so on to
button 4. Visual stimulation consisted of a full contrast reversing checkerboard
pattern. The frequency of the reversing checkerboard was 8 Hz and the motor task
2 Hz.
Baseline and Elevated Baseline CMRO2 Conditions
Each participant was then scanned during an 18 minute respiratory challenge for
separate rest and continuous task conditions allowing baseline and elevated base-
line CMRO2 to be measured. The elevated baseline condition consisted of a con-
tinuous visual and motor task performed for the duration of the entire scan. The
task was comprised of the reversing checkerboard pattern overlaid with the chang-
ing numbers task that was used in the functional localiser as motor stimulation.
During the baseline condition scan, the participant was told to fixate on a cross
hair overlaid on a black background. The functional task protocol provided a re-
gional variation in CMRO2 in corresponding visual and motor regions of the brain
between baseline and elevated baseline acquisitions essentially, simulating a disease
or treatment-like condition where metabolism changes regionally. The order with
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which the baseline and elevated baseline conditions were scanned was randomised
to control for order effects.
4.2.4 Respiratory Manipulations
Respiratory challenges were administered using a system of end-tidal forcing [63]
which offers independent control of partial pressures of end-tidal oxygen and car-
bon dioxide (PETO2 and PETCO2 respectively). The end-tidal forcing system
comprised a laptop personal computer using BreatheDmx software (Department
of Physiology, Anatomy and Genetics, Oxford University, UK) to monitor end-
tidal expired gas levels and calculate the inspired partial pressures required to
achieve the desired target. The gas mixtures were delivered at a total flow rate
of 30 litres per minute (lpm) through a fast gas mixing system connected to a
tight-fitting face-mask worn by the volunteer (Quadralite, Intersurgical, Woking-
ham, Berkshire, UK). The respiratory circuit included a reservoir on the expired
limb to permit re-breathing in the event that the instantaneous inspiratory rate
exceeded 30 lpm. Supplies of 10% CO2 (balance air), 10% O2 (balance N2), 100%
O2 and medical air were delivered from cylinders to the gas mixing chamber which
was placed as close as possible to the volunteer (on the chest) to minimise delays
in switching to a new inspiratory mixture. Gas delivery was controlled by four
mass flow controllers (MKS Instruments, Wilmington, MA, USA). Tidal gases
were sampled from the volunteers facemask and PETO2 and PETCO2 were mea-
sured using rapidly responding gas analysers (AEI Technologies, Pittsburgh, PA,
USA). During the functional localiser PETO2 and PETCO2 were monitored for the
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volunteer. Resting PETO2 was used as the PETO2 target for normoxic periods and
resting PETCO2 + 1mmHg was used as the target PETCO2 for normocapnia to
allow the end-tidal forcing system to provide control of end-tidal CO2. During the
functional localiser scan the volunteer breathed medical air only without control
of end-tidal CO2 and O2.
Interleaved and Simultaneous Hypercapnic-Hyperoxic Respiratory De-
signs
Target profiles for PETO2 and PETCO2 are shown in Figures 4.1 & 4.2. Figure 4.1
shows an interleaved hypercapnic and hyperoxic respiratory manipulation whereas
Figure 4.2 demonstrates a simultaneous hypercapnic and hyperoxic manipulation.
Each participant was scanned once with the interleaved design and once with
the simultaneous design producing whole brain CMRO2 measures at baseline and
elevated baseline for both designs.
4.2.5 Analysis
Preprocessing
All image time-series were motion corrected using 3dvolreg [74]. Time-series image
data acquired from the first echo of the PASL technique were used to calculate
CBF, while the data from the second echo was used to examine changes in BOLD
signal. Physiological noise correction (a modified RETROICOR), was applied
by regressing the first and second harmonics of both the cardiac and respiratory
90
Chapter 4 ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Section 4.2
cycles from the data along with the interaction term of the first cardiac and respi-
ratory harmonics [80, 81]. Interpolated surround subtraction of the first-echo, tag
and control image time-series was performed to yield a perfusion-weighted time-
series [43] which was corrected for coil sensitivity by dividing the CBF time-series
by a normalised version of the minimum contrast image [82]. CBF images were
calculated using the M0 of blood (estimated from the cerebrospinal fluid signal in
the ventricles of the M0 image) and the general kinetic model (GKM) [33]. The
CBF estimates were adjusted for the likely reduction of the T1 of arterial blood
with increasing plasma concentration of dissolved paramagnetic O2, according to
the measured partial pressure of arterial O2 and blood T1 values quoted in Bulte
et al. [51]. Interpolated surround averaging of the tag and control images was
performed to yield a BOLD weighted time-series.
Anatomical ROI Timeseries
Subject specific ROI’s of global grey matter (GM) were produced using FAST seg-
mentation [83] and registered to the native space of CBF and BOLD images using
FLIRT [77]. A binary mask was then created by thresholding the GM mask in
native space to keep voxels above 0.5. Occipital lobe (OL, MNI152 atlas (Montreal
Neurlogical Institute)) and precentral gyrus (PG, Harvard-Oxford cortical struc-
tural atlas) ROI’s were transformed to the native space of the CBF and BOLD
time-series by registering the relevant whole brain standard space images to the
high resolution anatomical in each subject and then registering the high resolu-
tion anatomical image to the native space of the CBF and BOLD time-series. The
transforms of these registrations were concatenated and applied to the OL and PG
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ROI’s, as determined in standard space, to transform them from standard space
to native space. The OL and PG ROI’s, in native space, were then thresholded
to produce binary masks and combined with the subject specific GM masks. This
analysis was localised to GM as the measurement of white matter perfusion using
ASL suffers from low SNR and is therefore unreliable.
Functionally Localised ROI Timeseries
The CBF time-series for the functional localiser run were analysed to identify sig-
nificant visual and motor stimulus-induced changes in CBF using a linear modelling
approach (3dDeconvolve [74]). CBF was chosen to localise the area of activation
as Leontiev et al. [84] demonstrated that selecting ROI’s according to flow activa-
tion significantly improves the robustness of measurements available with fMRI. A
box-car regressor with on/off periods corresponding to the on/off visual and motor
tasks used in the functional localiser task were convolved with gamma haemody-
namic response functions and fitted to the data. The resulting visual and motor
task activation maps were thresholded at p<0.001 level to correct for multiple com-
parisons. Only clusters of voxels greater than 50 were included using 3dclust [74].
The OL GM and PG GM ROI’s were then used to further anatomically constrain
the visual and motor activation ROI’s respectively.
Block Averaging
Averaging over the native-space ROI voxels, mean CBF and BOLD time-series
were produced for each of the five ROI’s. GM, OL and PG ROI’s were determined
from a standard atlas and functional ROI’s in visual cortex (fVC) and motor cortex
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(fMC) were determined by the functional localiser as described above. For each
ROI, relative CBF signal time-series normalised by baseline ( CBF
CBF0
) and BOLD
signal time-series normalised by baseline (∆S
S0
) were block averaged. Baseline was
calculated by taking the 10th percentile CBF and BOLD values from the ROI time-
series. Block-averaging was conducted to produce fewer time-points with higher
SNR. This was particularly beneficial when fitting the BOLD signal model to the
CBF time-series. Block averaging also excluded time-points that were considered
to be in transition by only including CBF and BOLD time-points that were con-
sidered to have reached steady state. For the interleaved design block averaging
periods were calculated for each final 30 second period of each 60 second respi-
ratory block (normocapnia with normoxia and normocapnia with hyperoxia) and
120 seconds of each 150 second block (hypercapnia with normoxia). The final 30
second period of each 60 second respiratory block was used when block averaging
the simultaneous design. The mean arterial oxygen content, CaO2, was calculated
from the PETO2 data for the same time periods.
Absolute CMRO2 Quantification
The BOLD model described in Wise et al. [3] was fitted to the global GM and
regional data using a simple bayesian framework (written in house using Matlab
(MathWorks Inc., Natick, MA)) to yield estimates of M and SvO2 (interleaved
design) and M, SvO2, α and β (simultaneous design) for each of the baseline and
elevated baseline conditions. Where α and β were held constant, M and SvO2
fitting was repeated for two combinations of previously used α and β: (α, β) =
(0.38 [50], 1.5 [45]) and (0.14, 0.91 [85]). Priors for M and SvO2 were generated as
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normal probability density functions centred around initial estimates of 0.08 and
0.5 with broad standard deviations of 0.02 and 0.1. When fitting for M, SvO2, α
and β normal probability density functions centred around initial estimates of 0.3
and 1.4 with standard deviations of 0.1 and 0.2 were used as priors for α and β.
By applying Bayes’ rule to the first time points of averaged data ∆S
S0
, CBF
CBF0
and
CaO2, posterior probability distributions of the variables, [M and SvO2] and [M,
SvO2, α and β], were generated after integrating over the ranges 0.01− 0.15 (M),
0.2− 0.8 (SvO2), 0.1− 0.5 (α) and 0.8− 2.0 (β). These were chosen to be beyond
the extremes of physiologically plausible values. The posterior distributions were
used as the priors for calculations with the second time points of averaged data and
so on until a final posterior distribution for each of the two variables was obtained.
The maxima of these probability distribution functions provided the estimates of
M and SvO2 and M, SvO2, α and β for each subject. Absolute CMRO2 was then
calculated using the equation:
CMRO2 = (1− SvO2) · CBF · CaO2 (4.1)
.
Statistical Testing
Testing for significant group increases between baseline (non-stimulated) and el-
evated baseline (continuously stimulated) were performed in the structural and
functional ROI’s for CBF, SvO2 and CMRO2 using one-tailed, paired t-tests.
3dttest++ [74] was used to test for significant regional differences between baseline
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and elevated baseline M, CBF, SvO2 and CMRO2. This was achieved by register-
ing the individual whole brain parameter maps of M, CBF, SvO2 and CMRO2 to
MNI152 space [76] through the hi-resolution structural image using FLIRT.
4.3 Results
The number of task related voxels identified by the functional localiser in the visual
and motor cortex used to make the fVC and fMC ROI’s for both the interleaved
and simultaneous sessions are shown in Figure 4.4. Group mean number of voxels
localised for the interleaved design in visual and motor tasks are 366 ± 284 and
658 ± 544 and for the simultaneous design in visual and motor are 647 ± 322 and
714 ± 770.
fVC Int fVC Sim fMC Int fMC Sim
0
500
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um
be
r o
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el
s
Figure 4.4: Details of the number of voxels identified by the functional localiser
to create the fVC and fMC ROI’s in the interleaved (Int) and simultaneous (Sim)
dcFMRI sessions. Each point represents a single subject. A line connects the
corresponding interleaved and simultaneous ROI voxel count for that subject (N
= 8).
95
Chapter 4 ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Section 4.3
By estimating SvO2 and measuring CBF and CaO2, estimates of absolute CMRO2
were made using Equation 4.1 on all 8 subjects for both respiratory designs.
Measurements of CBF, M, SvO2 and consequently CMRO2 were made in the five
regions of interest detailed above at baseline and elevated baseline for both the
interleaved and simultaneous design.
Tables 4.1 (α= 0.38, β = 1.5) and 4.2 (α= 0.14, β = 0.91) show estimates of M and
SvO2 made using different combinations of α and β values present in the literature
for the interleaved respiratory design. Significant differences between baseline and
elevated baseline CBF were found in OL, fVC and fMC and are marked with
(*). No significant differences were found between baseline and elevated baseline
measures of the remaining parameters.
Table 4.3 shows estimates of M, SvO2, α and β for the simultaneous respiratory de-
signs again for the five ROI’s. Significant differences between baseline and elevated
baseline CBF were found in OL, fVC, PG and fMC and are again marked with (*).
Significant increases in CMRO2 were detected in the functionally localised visual
and motor ROI’s.
Figure 4.5 shows group averaged, whole brain parameter maps of CBF, M, SvO2
and CMRO2 in standard space at baseline and elevated baseline for the interleaved
design. Figure 4.6 shows the equivalent whole brain parameter maps for the simul-
taneous design of CBF, M, SvO2 and CMRO2 with the addition of α and β. These
whole brain maps were produced by performing the analysis routine described in
96
Chapter 4 ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Section 4.3
R
O
I
C
B
F
M
S
v
O
2
α
β
C
M
R
O
2
(m
l/
10
0g
/m
in
)
(µ
m
ol
/1
00
g/
m
in
)
G
M
-R
es
t
51
.8
±7
.7
0.
03
5±
0.
01
3
0.
53
±0
.1
8
0.
38
1.
50
19
6.
1±
85
.6
-T
as
k
53
.6
±5
.3
0.
03
2±
0.
01
0
0.
60
±0
.1
3
16
9.
6±
54
.7
O
L
-R
es
t
56
.7
±8
.7
0.
03
2±
0.
01
4
0.
53
±0
.0
9
20
9.
7±
46
.2
-T
as
k
64
.2
±9
.5
*
0.
03
0±
0.
01
0
0.
55
±0
.0
9
22
2.
5±
37
.1
fV
C
-R
es
t
62
.3
±1
1.
9
0.
04
5±
0.
01
0
0.
50
±0
.0
7
24
7.
8±
58
.6
-T
as
k
84
.0
±1
8.
5*
0.
03
6±
0.
00
3
0.
58
±0
.1
7
26
5.
3±
83
.6
P
G
-R
es
t
45
.9
±8
.4
0.
02
4±
0.
01
6
0.
59
±0
.2
0
15
2.
6±
85
.7
-T
as
k
48
.1
±7
.1
0.
02
4±
0.
01
4
0.
60
±0
.2
0
15
4.
3±
84
.6
fM
C
-R
es
t
46
.7
±1
8.
8
0.
02
6±
0.
02
3
0.
58
±0
.1
4
14
2.
4±
61
.4
-T
as
k
62
.3
±9
.5
*
0.
02
5±
0.
01
0
0.
70
±0
.1
7
14
3.
9±
73
.6
T
ab
le
4.
1:
In
te
rl
ea
ve
d
d
es
ig
n
,
es
ti
m
at
in
g
M
an
d
S
v
O
2
w
it
h
tr
ad
it
io
n
al
(α
=
0.
38
,
β
=
1.
5)
α
an
d
β
va
lu
es
.
*
in
d
ic
at
es
si
gn
ifi
ca
n
t
d
iff
er
en
ce
,
p
<
0.
05
,
b
et
w
ee
n
b
as
el
in
e
(r
es
t)
an
d
el
ev
at
ed
b
as
el
in
e
(t
as
k
)
co
n
d
it
io
n
s.
T
h
is
w
as
te
st
ed
fo
r
al
l
R
O
I’
s
fo
r
C
B
F
,
S
v
O
2
an
d
C
M
R
O
2
97
Chapter 4 ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Section 4.3
R
O
I
C
B
F
M
S
v
O
2
α
β
C
M
R
O
2
(m
l/
10
0g
/m
in
)
(µ
m
ol
/1
00
g/
m
in
)
G
M
-R
es
t
51
.8
±7
.7
0.
05
0±
0.
01
7
0.
55
±0
.1
7
0.
14
0.
91
18
7.
5±
79
.4
-T
as
k
53
.6
±5
.3
0.
04
6±
0.
01
3
0.
61
±0
.1
2
16
4.
6±
50
.7
O
L
-R
es
t
56
.7
±8
.7
0.
04
5±
0.
02
0
0.
53
±0
.0
9
20
7.
7±
41
.4
-T
as
k
64
.2
±9
.5
*
0.
04
3±
0.
01
4
0.
56
±0
.0
9
21
8.
9±
36
.0
fV
C
-R
es
t
62
.3
±1
1.
9
0.
06
2±
0.
01
3
0.
51
±0
.0
7
24
3.
4±
57
.9
-T
as
k
84
.0
±1
8.
5*
0.
05
1±
0.
00
5
0.
60
±0
.1
8
25
3.
5±
83
.6
P
G
-R
es
t
45
.9
±8
.4
0.
03
4±
0.
02
3
0.
59
±0
.2
0
15
3.
2±
84
.3
-T
as
k
48
.1
±7
.1
0.
03
4±
0.
01
9
0.
62
±0
.1
9
14
7.
0±
77
.5
fM
C
-R
es
t
46
.7
±1
8.
8
0.
03
5±
0.
03
1
0.
58
±0
.1
3
14
0.
8±
54
.0
-T
as
k
62
.3
±9
.5
*
0.
03
6±
0.
01
4
0.
70
±0
.1
7
14
0.
6±
74
.0
T
ab
le
4.
2:
In
te
rl
ea
ve
d
d
es
ig
n
,
es
ti
m
at
in
g
M
an
d
S
v
O
2
w
it
h
u
p
d
at
ed
(α
=
0.
14
,
β
=
0.
91
)
α
an
d
β
va
lu
es
.
*
in
d
ic
at
es
si
gn
ifi
ca
n
t
d
iff
er
en
ce
,
p
<
0.
05
,
b
et
w
ee
n
b
as
el
in
e
(r
es
t)
an
d
el
ev
at
ed
b
as
el
in
e
(t
as
k
)
co
n
d
it
io
n
s.
T
h
is
w
as
te
st
ed
fo
r
al
l
R
O
I’
s
fo
r
C
B
F
,
S
v
O
2
an
d
C
M
R
O
2
98
Chapter 4 ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Section 4.3
R
O
I
C
B
F
M
S
v
O
2
α
β
C
M
R
O
2
(m
l/
10
0g
/m
in
)
(µ
m
ol
/1
00
g/
m
in
)
G
M
-R
es
t
49
.6
±1
0.
2
0.
07
0±
0.
01
9
0.
64
±0
.1
1
0.
45
0±
0.
11
7
0.
92
±0
.2
7
13
7.
7±
38
.0
-T
as
k
52
.4
±1
1.
0
0.
06
4±
0.
02
2
0.
67
±0
.1
1
0.
44
2±
0.
10
9
1.
04
±0
.1
9
13
9.
8±
55
.9
O
L
-R
es
t
54
.1
±1
0.
6
0.
06
4±
0.
02
5
0.
64
±0
.1
2
0.
45
8±
0.
11
2
1.
00
±0
.2
4
15
2.
5±
40
.4
-T
as
k
63
.8
±1
6.
1
*
0.
06
6±
0.
02
6
0.
69
±0
.0
8
0.
46
7±
0.
06
2
1.
06
±0
.2
9
15
9.
3±
59
.3
fV
C
-R
es
t
57
.2
±1
3.
1
0.
07
4±
0.
02
4
0.
65
±0
.1
1
0.
49
2±
0.
09
7
0.
94
±0
.2
2
15
2.
0±
26
.0
-T
as
k
79
.3
±2
1.
0
*
0.
08
0±
0.
01
7
0.
65
±0
.0
8
0.
41
7±
0.
09
9
1.
00
±0
.2
7
21
3.
9±
43
.2
*
P
G
-R
es
t
43
.6
±1
0.
7
0.
07
4±
0.
02
3
0.
64
±0
.0
8
0.
53
3±
0.
09
4
0.
83
±0
.2
2
12
1.
8±
31
.1
-T
as
k
47
.0
±1
1.
0
*
0.
06
2±
0.
02
5
0.
70
±0
.0
8
0.
51
7±
0.
09
9
0.
98
±0
.2
4
11
6.
5±
51
.8
fM
C
-R
es
t
39
.7
±1
4.
3
0.
07
6±
0.
04
1
0.
66
±0
.1
3
0.
51
7±
0.
09
3
0.
75
±0
.2
2
10
4.
4±
45
.5
-T
as
k
59
.0
±1
8.
1
*
0.
07
6±
0.
02
9
0.
68
±0
.0
8
0.
47
5±
0.
07
9
0.
88
±0
.2
6
14
8.
9±
61
.3
*
T
ab
le
4.
3:
S
im
u
lt
an
eo
u
s
d
es
ig
n
,
fi
tt
in
g
fo
r
M
,
S
v
O
2
,
α
an
d
β
.
*
in
d
ic
at
es
si
gn
ifi
ca
n
t
d
iff
er
en
ce
,
p
<
0.
05
,
b
et
w
ee
n
b
as
el
in
e
(r
es
t)
an
d
el
ev
at
ed
b
as
el
in
e
(t
as
k
)
co
n
d
it
io
n
s.
T
h
is
w
as
te
st
ed
fo
r
al
l
R
O
I’
s
fo
r
C
B
F
,
S
v
O
2
an
d
C
M
R
O
2
99
Chapter 4 ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Section 4.4
the Methods section on a voxel wise basis throughout the brain. Regional eleva-
tions in CBF and CMRO2 are particularly evident in the visual cortex for both
techniques.
T-statistic maps produced as a result of the voxelwise t-test analysis are presented
in Figure 4.7 reflecting the ROI analysis presented in Tables 4.1, 4.2 and 4.3.
4.4 Discussion
In this study a noninvasive, dcFMRI protocol is used to produce absolute, whole
brain measures of oxygen metabolism. A BOLD signal model [3] allows esti-
mates of SvO2 and in turn CMRO2 to be made from perfusion and BOLD data
acquired during a dual hypercapnic-hyperoxic challenge. A simple motor and vi-
sual task was used to regionally elevate oxygen metabolism to simulate a disease
or treatment-like condition and demonstrate the ability of the technique to de-
tect regional changes in baseline CMRO2. The implementation of interleaved and
simultaneous hypercapnic-hyperoxic challenges allowed the optimisation of the res-
piratory manipulation to be investigated, at the same time assessing the protocol’s
ability to detect changes in other physiological parameters which may be affected
by the altered metabolic state. Measurements using the interleaved respiratory
manipulation are comparable in principal to the work shown by Gauthier et al. [2]
and Bulte et al. [1] and both the interleaved and simultaneous designs are exten-
sions of the work presented by Wise et al. [3].
100
Chapter 4 ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Section 4.4
F
ig
u
re
4.
5:
G
ro
u
p
av
er
ag
ed
,
w
h
ol
e
b
ra
in
p
ar
am
et
er
m
ap
s
ac
q
u
ir
ed
u
si
n
g
in
te
rl
ea
ve
d
h
y
p
er
ca
p
n
ic
-h
y
p
er
ox
ic
re
sp
ir
a-
to
ry
m
an
ip
u
la
ti
on
s.
R
eg
io
n
al
d
iff
er
en
ce
s
b
et
w
ee
n
b
as
el
in
e
an
d
el
ev
at
ed
b
as
el
in
e
ca
n
b
e
cl
ea
rl
y
as
se
ss
ed
d
u
e
to
go
o
d
w
h
ol
e
b
ra
in
co
ve
ra
ge
.
M
ea
su
re
s
ar
e
li
m
it
ed
to
gr
ey
m
at
te
r
as
a
re
su
lt
of
li
m
it
at
io
n
s
as
so
ci
at
ed
w
it
h
m
ea
su
ri
n
g
C
B
F
in
w
h
it
e
m
at
te
r
u
si
n
g
A
S
L
.
101
Chapter 4 ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Section 4.4
F
ig
u
re
4.
6:
W
h
ol
e
b
ra
in
p
ar
am
et
er
m
ap
s
p
ro
d
u
ce
d
u
si
n
g
si
m
u
lt
an
eo
u
s
h
y
p
er
ca
p
n
ic
-h
y
p
er
ox
ic
re
sp
ir
at
or
y
m
an
ip
u
la
-
ti
on
s.
In
ad
d
it
io
n
to
eq
u
iv
al
en
t
p
ar
am
et
er
m
ap
s
to
th
os
e
sh
ow
n
in
F
ig
u
re
4.
5,
si
m
u
lt
an
eo
u
s
re
sp
ir
at
or
y
m
an
ip
u
la
ti
on
al
lo
w
s
fo
r
th
e
es
ti
m
at
io
n
α
an
d
β
102
Chapter 4 ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Section 4.4
F
ig
u
re
4.
7:
T
-s
ta
ti
st
ic
m
ap
s
p
ro
d
u
ce
d
as
a
re
su
lt
of
th
e
vo
x
el
w
is
e,
p
ai
re
d
t-
te
st
an
al
y
si
s
co
n
d
u
ct
ed
b
et
w
ee
n
th
e
b
as
el
in
e
an
d
el
ev
at
ed
b
as
el
in
e
p
ar
am
et
er
m
ap
s
fo
r
b
ot
h
th
e
in
te
rl
ea
ve
d
an
d
th
e
si
m
u
lt
an
eo
u
s
re
sp
ir
at
or
y
d
es
ig
n
s.
103
Chapter 4 ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Section 4.4
In all 8 subjects, consistent CBF baseline values in the predicted range were
achieved across the group in both the rest and task conditions. Spatial varia-
tion of CBF values are consistent with literature [3]. In both scan sessions, OL
demonstrated the highest regional CBF with respect to the regions measured, ∼55
ml/100g/min, with PG showing lowest, ∼45 ml/100g/min, and GM perfusion val-
ues of ∼50 ml/100g/min at rest.
Direct comparison of CMRO2 measurements made in GM to values established
with dcFMRI show the interleaved design, 187.5 ± 79.4 µmol/100g/min, overesti-
mates resting CMRO2 when compared to values reported by Bulte et al. [1], 158
± 39 µmol/100g/min and Gauthier et al. [2], 145 ± 30 µmol/100g/min. CMRO2
estimates made using simultaneous design agree well with ranges from PET lit-
erature of 128-149 µmol/100g/min [17] (age and region dependent) and 136 ±
10 µmol/100g/min [19] in an older cohort. However it is important to note that
the measurement is localised to GM as a result of limitations associated with
using ASL to measure CBF. This coupled with the improved spatial resolution
afforded by MRI and a relatively young cohort would lead to the expectation that
the simultaneous CMRO2 measures would be higher than those associated with
PET.
M is the fractional, maximum BOLD signal change that can occur due to removing
all deoxyhemglobin from a given voxel and is a function of the amount of deoxy-
hemoglobin present in a given physiological state. Estimates of M made using
the simultaneous design, 0.070 ± 0.019, agree well with established values in the
range of 0.06 − 0.088 [46]. However, measures of M made using the interleaved
design, 0.050±0.017 and 0.035±0.013, seem low in comparison. It is interesting to
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note the differences between M estimated using different combinations of α and β.
As these parameters are fixed in the interleaved model and changes in these fixed
parameters result in different estimated M’s, this would suggest that there is some
collinearity between M and α and β.
At rest, arterial blood is nearly fully oxygenated with approximately 40% of the
oxygen extracted during its transit across the capillary bed [86, 87]. Venous oxy-
genation saturation (SvO2) represents the amount of oxygen remaining in the blood
after it has passed through the capillaries into the venous vasculature. Assuming
arterial blood is fully saturated, SvO2 is equivalent to 1−OEF. Therefore SvO2
values in the range of 0.55−0.65 are expected in GM. Measures of SvO2 using the
interleaved, 0.55 ± 0.17, and simultaneous design, 0.64 ± 0.11, are within the ac-
ceptable range of estimates but at opposite ends of the spectrum. The estimates of
SvO2 using the interleaved design lead to measures of CMRO2 that are considered
high for GM (∼ 200 µmol/100g/min). The simultaneous design leads to more
agreeable estimates of SvO2 and CMRO2 in GM. This is probably due to the extra
degrees of freedom available to the simultaneous design for measuring α and β.
It is important to note that unrealistic parameter estimates of M, SvO2, α and
β were produced when trying to fit for all four parameters using the interleaved
design (results not presented here). This is due to the lack of information provided
by the single hypercapnic modulation, meaning α and β cannot be properly deter-
mined by the BOLD signal model. As a result, the most likely explanation for the
difference between the SvO2 values, produced by the interleaved and simultaneous
designs, is that the extra degrees of freedom used in the simultaneous design not
only allow α and β to be measured, but also capture some other sources of vari-
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ation. These sources of variation are not accounted for in the interleaved model
where α and β are fixed
In a given brain region, it is changes in CBF and OEF that dictate the extent
of the BOLD signal. In an activated brain region where CMRO2 increases, it
is expected that increases in SvO2 and CBF also accompany a rise in metabolic
demand when compared to the same region at rest. No significant changes were
detected for CMRO2 in the functional ROI’s between rest and task conditions
for the interleaved design. Significant changes (p<0.05) were detected between
baseline and elevated baseline conditions in the visual and motor cortex using the
simultaneous design. In the visual cortex a group average increase in CMRO2
of 61.9 µmol/100g/min (40%) with task accompanied a significant increase of
22.1 ml/100g/min (38.5%) in CBF. A significant increase in CMRO2 of 44.5
µmol/100g/min (43%) and CBF of 19.3 ml/100g/min (49%) in the motor cor-
tex was detected with task. Percentage CMRO2 increases in the visual and motor
cortex are larger than expected when compared with calibrated BOLD studies,
usually ∼30% [45] and ∼25% [88] respectively. The larger than expected CMRO2
responses may be due to the constant duration and combined nature of the task
coupled with the strength of the flashing checkerboard. The significant regional
changes detected using the simultaneous design may again be due to the extra
degrees of freedom afforded by this approach.
As previously discussed, the simultaneous approach not only allows α and β to be
measured, but the extra degrees of freedom may allow other sources of variation
to be captured. This may make the simultaneous approach more sensitive to
detecting changes in CMRO2 by allowing the BOLD signal model to correctly
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deal with changes in α, β or other variations that may accompany the regional
changes in metabolism. No significant changes in SvO2 were detected in either
functional ROI suggesting that task related increases in CMRO2 are mainly driven
by increased CBF. This may be because the biological changes in OEF are small
compared to the changes in CBF and the proposed technique does not have the
required sensitivity to detect such small changes.
The ratio of the fractional changes with activation between CBF and CMRO2 is
often referred to as the coupling of these two terms and can be defined as n =
( ∆CBF%
∆CMRO2%
). Calibrated BOLD studies have reported n in the range of 1.7 - 4.5
for cortical regions including the motor and visual cortex. In the functionally
defined ROI’s, the simultaneous design produces values of n ≈ 1. These coupling
values measured in the functional ROI’s are lower than that currently established
in literature for similar tasks and are not surprising as we do not detect significant
group differences between rest and task SvO2 estimates with very small if any group
average differences calculated. This would again suggest that CMRO2 changes with
task are mostly CBF driven and the technique requires improvements in sensitivity
or a larger cohort of subjects to detect the small changes in SvO2 that may occur
with the tasks used in this experiment.
For the interleaved design, slightly lower variability in CMRO2 across subjects was
demonstrated for α, β = 0.14, 0.91 with estimates of M and SvO2 that are more
agreeable with literature produced when compared to estimates made using α, β
= 0.38, 1.5. As such values of α, β = 0.14, 0.91 are used in the following Chapters
when values of α and β are assumed. However parameter estimates did not change
drastically when using these different α, β combinations. The largest differences
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in CMRO2 found between the two α, β combinations were ∼5% found in global
GM.
By simultaneously varying arterial concentrations of carbon dioxide and oxygen,
the BOLD signal model was exploited to produce estimates of α and β as well
as M and SvO2. Interpreting the simultaneous hypercapnic-hyperoxic data using
the BOLD signal model leads to estimates of α=0.45±0.12 and β=0.92±0.27 for
whole brain GM at rest. The traditional combination of α = 0.38 and β = 1.5
were proposed by [50] and [45]. α was originally measured by altering inspired
CO2 in monkeys and measuring global changes in flow and volume, whereas β
was based on approximations made using Monte Carlo simulations of a BOLD
signal model. More recently, Griffeth et al. [85] proposed a new combination
of values, α=0.14 and β=0.91, based on the optimisation of the exponents in
relation to a complex, compartmental BOLD model for a range of BOLD and
CBF signal changes. However, these comparisons with a complex signal model
suggest α and β potentially lose their original physiological meanings as intended
in the Davis model. Instead, α and β are effectively capturing several sources
of variation arising in the detailed model, and they should just be regarded as
fitting parameters. It is therefore difficult to make a physical interpretation of the
α and β values presented in Table 4.3. The main focus should instead be on the
fact that the simultaneous design allows a certain degree of flexibility by allowing
the α and β terms to be determined through the model. This is advantageous as
these exponential terms may take account of a number of underlying physiological
processes which the BOLD signal model cannot take into account when α and
β are fixed. This allows for changes in these underlying, unknown effects due to
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altered states of activation, disease or treatment to be accounted for by adding an
additional degree of freedom. However as estimating these parameters may not
have a direct physiological interpretation there may be room for optimisation of
the BOLD signal model presented inWise et al. [3].
The group averaged, whole brain parameter maps presented in Figures 4.5 and 4.6
demonstrates the potential of this technique to detect regional, localised changes
in physiological parameters. Increases in CMRO2 can be seen in visual cortex
between baseline and elevated baseline images in both Figures 4.5 and 4.6. To
investigate this further groupwise T-statistic maps are shown in Figure 4.7. For
both the interleaved and simultaneous designs, differences in the visual and motor
cortex can be seen in the CMRO2 T-statistic maps as regions of blue and with
differences more evident in the simultaneous design. On visual inspection of the
CBF and SvO2 T-statistic maps it is interesting to note that the task related
changes detected in CMRO2 seem to be driven by CBF and that larger more
significant task related group changes were detected in visual and motor cortex
with the simultaneous design. There does not appear to be a strong group, regional
change in SvO2 detected with either technique. The T-statistic maps demonstrate
the ability of this technique to provide detailed regional information about changes
in cerebral metabolism and related haemodynamic parameters which reflect the
ROI analysis presented in Tables 4.1, 4.2 and 4.3.
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4.5 Conclusion
We have demonstrated the use of an absolute CMRO2 quantification routine by
implementing a dual hypercapnic-hyperoxic manipulation during which BOLD and
CBF time courses are measured. When compared to an interleaved respiratory
manipulation, a simultaneous approach is capable of detecting significant regional
alterations in absolute CMRO2 (induced using sensory and motor stimulus of the
visual and motor cortex respectively) that produces agreeable estimates of CMRO2
in global grey matter compared with a range of established values. The technique
also circumvents the complication of pre-allocating values to the exponents of the
BOLD signal model, α and β, by allowing them to be made using the signal
model and simultaneous hypercapnic-hyperoxic manipulation. The ability to infer
absolute measures of CMRO2 using FMRI-based methods increases the potential of
FMRI to quantify an important clinical biomarker that is implicated in numerous
neurological diseases and, at the same time, can improve our understanding of
metabolic processes in the brain. However, in order for this technique to become
clinically relevant, it is important to make the measure as robust as possible.
This requires the investigation of within and between session reproducibility and
repeatability which is the subject of the following chapters.
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Chapter 5
Test-Retest Repeatability of Dual
Calibrated FMRI Measures of Oxygen
Metabolism in the Brain.
5.1 Introduction
The brain requires an uninterrupted supply of oxygen in order to extract the
energy it needs from glucose. The rate at which oxygen is consumed in the brain
to produce this energy is referred to as the cerebral metabolic rate of oxygen
consumption (CMRO2). CMRO2 can be related to oxygen concentration levels
in blood, cerebral blood flow (CBF) and oxygen extraction fraction (OEF) and
therefore can be measured if these parameters are known. CMRO2 can become
altered due to activation, disease and drug related interventions and is therefore
a good indicator of cerebral health. This makes CMRO2 a desirable biomarker to
quantify and map in the human brain.
An established class of PET techniques using oxygen isotopes (15O) [19] are cur-
rently considered the gold standard for producing whole brain, oxygen metabolism
maps. However these techniques are invasive and expose the subject to a radiation
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dose meaning they are not ideal for conducting longitudinal tracking of cerebral
metabolic variables.
Recently, dual calibrated FMRI (dcFMRI) has been demonstrated as being capable
of producing whole brain maps of absolute CMRO2 by measuring venous oxygen
saturation, SvO2, cerebral blood flow (CBF) and maximum BOLD signal change,
M [1–3]. The measurement relies on detecting CBF and BOLD signal changes
made during a dual respiratory manipulation, using arterial spin labelling (ASL).
The induced signal changes are interpreted using a BOLD signal model. The
dual respiratory manipulation involves increasing levels of inspired carbon dioxide
(CO2) and oxygen (O2), inducing hypercapnia and hyperoxia respectively. These
calibrated FMRI techniques are therefore an extension of the methods introduced
by Davis et al. and Chiarelli et al. [45, 46]. The BOLD signal model used for the
absolute quantification of CMRO2 is an amalgamation of the models presented
in these studies and can be found in [3]. dcFMRI has the potential to become a
robust clinical and research tool. With no radiation burden attached this technique
would lend itself to the longitudinal study and monitoring of metabolic changes
in the brain associated with development and ageing, disease, trauma and drug
efficacy and targeting.
However, before dcFMRI can be applied to longitudinally monitor metabolic changes
in the brain, it is important that the test-retest repeatability of the technique is first
assessed to understand the limitations of the technique. Test-retest repeatability
studies have been conducted for 15O PET [89, 90] and a recently introduced re-
gional MR technique named TRUST (T2-relaxation-under-spin-tagging) [91]. The
aim of this study is to establish reference data on the test-retest repeatability
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of absolute CMRO2 measures made using dcFMRI. The test-retest repeatability
of the CBF, M and SvO2 measures allowing the calculation of CMRO2 will also
be assessed. Two respiratory manipulation designs were compared, an interleaved
hypercapnic-hyperoxic design and a simultaneous hypercapnic-hyperoxic design as
presented in Chapter 4. Resting measures of oxygen metabolism related parame-
ters made using dcFMRI were compared in a cohort of subjects for each technique,
within session where subjects were scanned back-to-back with the same protocol
and between session where resting measures were repeated on a separate scan
day. This allowed the intrasession, intersession and intersubject variability to be
investigated. The repeatability of the interleaved and simultaneous designs were
compared by calculating intraclass correlation coefficient’s (ICC’s).
5.2 Methods
5.2.1 Participants
8 normal healthy participants (aged 24 - 39; mean age 33.5 ± 5.0; 2 female) were
recruited and scanned having given written consent. Experimental procedures
were approved by the local institutional ethical review committee.
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5.2.2 MRI
Scanning was performed on a 3T GE HDx MRI (GE Healthcare, Milwaukee WI)
with a body transmit coil and 8-channel head receive coil. All participants had
previous whole brain T1-weighted structural scans available (fast spoiled gradient
recalled echo, 1x1x1 mm voxels, TI/TR/TE = 450/7.8/3 ms). dcFMRI acquisi-
tions lasted 18 minutes each. Details of the dual echo PASL protocol, including M0
and minimum contrast (Min Con) ASL calibration scans, used to simultaneously
measure CBF and BOLD signal time-series during localiser and dcFMRI scans
can be found in Chapter 4 alongside details of the interleaved and simultaneous
hypercapnic-hyperoxic respiratory manipulations.
5.2.3 Acquisition Overview
Each participant was scanned during three scanning sessions performed on sepa-
rate days. Each session consisted of two dcFMRI acquisitions. In the first session
a dcFMRI acquisition was performed using an interleaved hypercapnic-hyperoxic
respiratory manipulation during rest and combined, continuous visual/motor stim-
ulation. The second session was equivalent to the first apart from using a simulta-
neous hypercapnic-hyperoxic respiratory manipulation during the dcFMRI acqui-
sition. A comparison of interleaved and simultaneous respiratory manipulations
for the quantification of oxygen metabolism related parameters is demonstrated
in Chapter 4. During the third session a repeat measure of the interleaved and
simultaneous dcFMRI acquisition at rest was performed. During rest scans the
participant was presented with a crosshair on a black background and instructed to
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keep their eyes open. This allowed the baseline state of the physiological variables
to be measured. During combined visual and motor stimulation the subject was
presented with a continuous flashing checkerboard and finger tapping task corre-
sponding to numbers between 1 and 4 presented on the screen. This allowed an
elevated baseline state of the physiological variables to be measured in visual and
motor cortex. During session 1 and 2 a functional localiser, lasting 51
2
minutes,
was used to create ROI’s of activated voxels during visual and motor stimulation.
This consisted of a 30 second baseline, 30 second motor stimulation and 30 second
visual stimulation repeated three times ending with a baseline period. A schematic
layout of the 3 scan sessions, excluding the functional localiser runs in session 1
and 2 can be seen in Figure 5.1.
To investigate test-retest repeatability all dcFMRI scans would ideally be con-
ducted at rest. However a subset of the data (session 1 and 2) was used to
investigate the sensitivity of dcFMRI for detecting regional changes in physio-
logic parameters. In an attempt to manufacture a second intrasession ”rest”
measure, processing steps described in Section 5.2.5 were performed to remove
significantly activated voxels from the task datasets in sessions 1 and 2 as shown
in Figure 5.1.
5.2.4 Data Preprocessing
The image time-series produced by the dual-echo PASL sequence were motion cor-
rected using 3dvolreg [74]. Time-series image data acquired from the first echo of
the PASL technique were used to calculate CBF, while the data from the second
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Chapter 5 ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Section 5.2
echo were used to examine changes in BOLD signal. Interpolated surround sub-
traction of the ASL tag and control image time-series was performed to yield a
perfusion-weighted time-series [43] which was corrected for coil sensitivity. CBF
images were calculated using the M0 of blood, estimated from the cerebrospinal
fluid signal of the M0 image and the general kinetic model (GKM) [33]. The
CBF estimates were adjusted for the likely reduction of the T1 of arterial blood
with increasing plasma concentration of paramagnetic O2, according to the blood
T1 values quoted in [51]. Interpolated surround averaging of the tag and control
images was performed to yield a BOLD weighted time-series.
5.2.5 Regions of Interest (ROI’s)
ROI’s of global grey matter (GM) were produced using FAST segmentation [83] of
the high resolution anatomical images. A second modified GM ROI was produced
in an attempt to gain useful information about intrasession repeatability. This
was done by removing voxels from GM that were deemed to respond significantly
to the visual and motor tasks.
Two functional localisers were performed on each subject during session 1 and 2.
The BOLD time-series acquired during each functional localiser task was fitted
with baseline, drift and activation regressors using 3dDeconvolve [74] in order to
produce β-weight maps of visual and motor activation. All β-weight maps were
registered to MNI152 space (Montreal Neurlogical Institute) [76] through the hi-
resolution structural image using FLIRT. 3dttest++ [74] was used to test on a
voxel-wise basis whether the mean across the group significantly differed from zero.
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This significance map was liberally thresholded at p = 0.01 and was transformed
back to the native space of the subject through the high-resolution anatomical
image. This mask was then removed from the global GM mask to produce a mask
of GM without task (GM-NoTask) and transformed to native space of the CBF
and BOLD time-series.
Quantification of Physiological Parameters
CBF and BOLD time-series were produced in GM and GM-NoTask ROI’s for each
subject. For each ROI’s time-series, time averaged relative CBF ( CBF
CBF0
) and BOLD
signal (∆S
S0
) were block averaged. For the interleaved design block averaging periods
were calculated for each final 30 second period of each 60 second respiratory block
(normocapnia with normoxia and normocapnia with hyperoxia) and 120 seconds of
each 150 second block (hypercapnia with normoxia). The final 30 second period of
each 60 second respiratory block was used when block averaging the simultaneous
design. The mean arterial oxygen content, CaO2, was calculated from the PETO2
data for the same time periods. The model described by Wise et al. [3] was fitted
to the CBF and BOLD time-series using a simple bayesian framework to yield
estimates of M and SvO2 for the interleaved design and M, SvO2, α and β for
the simultaneous design. This was done in both the interleaved and simultaneous
respiratory designs, permitting calculation of absolute CMRO2. Where α and β
were held constant in the interleaved design, M and SvO2 fitting was performed
using α, β = 0.14, 0.91 [85]. Priors for M and SvO2 were generated as normal
probability density functions centred around initial estimates of 0.08 and 0.5 with
broad standard deviations of 0.02 and 0.1. When fitting for M, SvO2, α and β
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for the simultaneous design, normal probability density functions centred around
initial estimates of 0.3 and 1.4 with standard deviations of 0.1 and 0.2 were used
as priors for α and β and the same priors were used for M and SvO2 in the
simultaneous design. By applying Bayes’ rule to the first time points of averaged
data ∆S
S0
, CBF
CBF0
and CaO2, posterior probability distributions of the variables M and
SvO2 (interleaved design) and M, SvO2, α and β, were generated after integrating
over the ranges 0.01−0.15 (M), 0.2−0.8 (SvO2) and 0.1−0.5 (α) and 0.8−2.0 (β)
where relevant in the simultaneous design. These were chosen to be beyond the
extremes of physiologically plausible values. The posterior distributions were used
as the priors for calculations with the second time points of averaged data and so
on until a final posterior distribution for each of the two variables was obtained.
The maxima of these probability distribution functions provided the estimates of
M and SvO2 for each subject. Assuming that arterial blood is fully saturated with
oxygen, oxygen extraction fraction (OEF) = 1-SvO2 and absolute CMRO2 can be
calculated using the equation:
CMRO2 = OEF · CBF · CaO2 (5.1)
5.2.6 Statistical Analysis
Coefficients of variation
For dcFMRI acquisitions using both interleaved and simultaneous respiratory
manipulations, intrasession, intersession and intersubject coefficients of variation
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(CV) were calculated for M, SvO2, CBF and CMRO2 from the data collected in
the three sessions as shown in Figure 5.1.
Intrasession CV was calculated as:
CVintrasession =
1
N
∑
n
|Mn1 −Mn2|√
2 ·Mean(Mn1 ,Mn2)
(5.2)
where Mn1 and Mn2 represent measurement #1 and #2 made in the same session
for Subject #n (n = 1, 2 . . . , N). When referring to interleaved dcFMRI this
is calculated using the two measures made in Session 1 and when referring to
simultaneous dcFMRI this refers to the two measures made in Session 2.
Intersession CV was calculated as:
CVintersession =
1
N
∑
n
|Mnk1 −Mnk2 |√
2 ·Mean(Mnk1 ,Mnk2)
(5.3)
where Mnk1 and Mnk2 represent the rest measurements from separate sessions. In
the case of the interleaved design this refers to rest measures made in Session 1
(k1) and 3 (k2) and for the simultaneous design this is the rest measures made in
Session 2 (k1) and 3 (k2).
Intersubject CV was calculated as:
CVintersubject =
1
N ·K
∑
n
∑
k=1,2,3
SDn(Mnk)
Meann(Mnk)
(5.4)
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where SDn and Meann represent standard deviation and mean across subjects.
These were calculated across all subjects for the relevant measures made in Sessions
1 (k1, k2) and 3 (k3) for the interleaved design and Sessions 2 (k1, k2) and 3 (k3)
for the simultaneous design.
As presented by Liu et al. [91], the value of CVintersession is expected to contain
additional variance due to subject repositioning and day-to-day differences in phys-
iological state compared to CVintrasession and can be calculated as CVDay−to−Day =√
CV 2intersession − CV 2intrasession. An additional confound in the case of this study
is that intrasession measures compare a rest condition scan with a task condition
scan. However as mentioned previously processing steps were taken to remove
the influence of the task on the measure. Similarly, compared to CVintersession,
CVintersubject contains additional intersubject physiological differences and can be
calculated as CVIntersubPhysiology =
√
CV 2intersubject − CV 2intersession.
Intraclass Correlation
ICC’s were used to assess the intra- and inter- session repeatability of measure-
ments of M, SvO2, CBF and CMRO2 using the same groupings as described for
the CV calculations for both interleaved and simultaneous hypercapnic-hyperoxic
dcFMRI. There are multiple forms of the ICC. ICC(2,1) was chosen and its cal-
culation is described in detail by Shrout and Fleiss [92]. ICC’s reflect the ratio
between the variability of measurement on the same subject (intra or inter - session
in this case) and the total data variance across all subjects and all measurements.
These comparisons were performed within technique, that is intra or inter - session
for both the interleaved and simultaneous dual calibrated approaches.
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5.3 Results
Eight participants were scanned during three sessions. Each session involved two
dcFMRI acquisitions. This resulted in each subject having three dcFMRI ac-
quisitions acquired using both the interleaved and the simultaneous respiratory
manipulations.
5.3.1 Coefficients of Variation
Intrasession, intersession and intersubject CV’s, calculated using Equations 5.2, 5.3
and 5.4, are presented for the measured physiological parameters in both global
GM and GM-NoTask, Table 5.1. Lower CV’s represent less variance in the mea-
sure with the interleaved design demonstrating lower CV’s for intra and intersession
CMRO2 measures. In all cases inter subject variance is higher than intersession
variance suggesting that the technique has sensitivity to detect intersubject differ-
ences.
5.3.2 Intraclass Correlation
Intrasession and intersession comparisons are presented in Figure 5.2 (GM) and 5.3
(GM-NoTask). ICC’s are calculated for these relations and presented in Table 5.2
with the interleaved design demonstrating superior intra and intersession ICC’s for
all parameters except for CBF. ICC’s of higher value represent better repeatability
with values above 0.6 showing good repeatability.
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Figure 5.2: Scatterplots of measured physiological variables, M, SvO2, CBF and
CMRO2 presented intra- and inter- session for both the interleaved and simulta-
neous dcFMRI acquisition. Scatterplots presented in this figure were produced
using global GM ROI. ICC’s describing the relations demonstrated in these plots
are presented Table 5.2
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Figure 5.3: Scatterplots of measured physiological variables, M, SvO2, CBF and
CMRO2 presented intra- and inter- session for both the interleaved and simultane-
ous dcFMRI acquisition. Scatterplots presented in this figure were produced using
GM-NoTask ROI. ICC’s describing the relations demonstrated in these plots are
presented Table 5.2.
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Intrasession (ICC) Intersession (ICC)
INT SIM INT SIM
GM
M 0.90* 0.52 0.21 0.78*
SvO2 0.51 -0.16 0.26 -0.05
CBFbase 0.60* 0.89* 0.71* 0.96*
CMRO2 0.62* -0.02 0.58 0.10
GM-NoTask
M 0.97* 0.66* 0.36 0.52
SvO2 0.57 -0.18 0.25 -0.11
CBFbase 0.60* 0.88* 0.60* 0.95*
CMRO2 0.68* -0.01 0.50 0.01
Table 5.2: Intraclass correlation coefficient’s (ICC) calculated intra- and inter-
session for the measured physiological variables, M, SvO2, CBF and CMRO2. ICC’s
are calculated for both GM and GM-NoTask ROI’s and *’s mark ICC’s ≥ 0.6 (See
Section 5.4.2 for information on interpreting ICC’s).
5.4 Discussion
dcFMRI is a technique capable of producing whole-brain maps of CMRO2 as well
as other physiological parameters associated with oxygen metabolism in the brain.
It has been shown to produce similar estimates of CMRO2 when compared to
other quantitative techniques and is sensitive to detecting regional changes in
oxygen metabolism, [1–3] and Chapter 4. dcFMRI has the potential to provide
a practical technique capable of implementation in clinical and research settings
to investigate regional and longitudinal changes in CMRO2. However before this
technique can be implemented into such studies it is important to assess it’s test-
retest repeatability.
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5.4.1 CV’s
Intrasession, intersession and intersubject CV’s are presented in Table 5.1 for
both interleaved and simultaneous hypercapnic-hyperoxic dcFMRI using GM and
GM-NoTask ROI’s. Calculating the CV’s in this manner provides an impor-
tant reference for future studies. It also presents a useful comparison with other
CMRO2 measurement techniques which have investigated test-retest repeatabil-
ity using these indices. These studies investigated test-retest repeatability of 15O
PET [89, 90] and a recently proposed MR protocol, TRUST [91]. For compari-
son with Table 5.1 a summary of CV’s from these studies is presented in Table
5.3.
It can be seen that the CV’s presented in this study are larger than those pre-
sented in Table 5.3. However as intersubject CV is greater than intersession CV
in both cases the technique should have some sensitivity allowing it to determine
differences between subjects taking into account intersession variability. dcFMRI
also provides some distinct advantages over these techniques. TRUST is limited in
terms of spatial resolution and only provides a whole brain measure. It therefore
is not useful for investigating regional changes in oxygen metabolism. 15O PET
techniques are capable of producing whole brain maps of oxygen metabolism re-
lated parameters such as CMRO2 but suffer from disadvantages associated with
the use of radioisotopes. 15O PET requires an on site cyclotron for the prepara-
tion of specialised radiotracers with a short half-life, is expensive to perform and
invasive. Longitudinal studies of metabolism using PET are also limited as such
studies require participants to receive multiple radiation doses.
127
Chapter 5 ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Section 5.4
PET [89] PET [90] TRUST [91]
OEF (%)
Intrasession CV 5.7 ± 4.4 - 3.2 ± 1.2
Intersession CV - 9.3 8.2 ± 4.5
Intersubject CV 7.3 ± 1.2 21.4 15.6
CBF (ml/100g/min)
Intrasession CV 8.4 ± 7.6 - 2.8±0.8
Intersession CV - 8.8 7.4 ± 3.0
Intersubject CV 13.5 ± 1.4 13.1 17.4
CMRO2 (µmol/100g/min)
Intrasession CV 5.3 ± 3.9 - 3.8 ± 1.4
Intersession CV - 5.3 6.6 ± 1.6
Intersubject CV 12.8 ± 1.1 7.1 8.8
Table 5.3: Intrasession, intersession and intersubject CV’s calculated in test-retest
repeatability studies of quantitative oxygen metabolism techniques involving 15O
PET [89,90] and MR TRUST [91]
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5.4.2 ICC’s
Variations on the dcFMRI, hypercapnic-hyperoxic respiratory manipulation used
for absolute CMRO2 quantification were introduced by Wise et al. [3]. The in-
terleaved design performs hyperoxia during normocapnia and hypercapnia during
normoxia whilst the simultaneous design concurrently varies levels of hypercapnia
and hyperoxia as shown in Fig. 5.1 and described in more detail in Chapter 4.
The simultaneous design also has the advantage of being able to measure values
of α and β which must be assumed when using the interleaved respiratory design,
as discussed in Chapter 4.
To investigate if the type of respiratory manipulation used is advantageous in terms
of repeatability, ICC’s were calculated for the measured physiological parameters
intrasession and intersession for both respiratory designs. For the interpretation
of ICC’s the stratification approach suggested by Cicchetti et al. [93] is considered.
This proposed ICC groupings of poor (<0.4), fair (0.41-0.59), good (0.60-0.74)
or excellent (>0.75) repeatability. This approach has previously been adopted
by [94–96].
Considering the global GM and GM-NoTask ROI’s, intrasession measures are more
relevant for the GM-NoTask whereas intersession is most relevant in GM. GM-
NoTask ROI is required for the intrasession comparison as one of the measurements
is confounded by a task as shown in Figure 5.1 and the mask attempts to exclude
regions engaged in the task. Both intersession measures were conducted at rest
and therefore GM is appropriate for use here.
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Intrasession, interleaved measurements of CMRO2 (GM-NoTask) are considerably
more reproducible than simultaneous measurements which do not seem to have
any appreciable correlation (≈ 0). As CMRO2 is calculated from SvO2 and CBF,
these parameters also show high significant, or close to significant ICC’s (p≈0.05)
when compared to the simultaneous approach. Comparing GM calculations to
GM-NoTask, it is interesting to note that the measured ICC’s generally increase
slightly when the task is removed, as is expected intrasession, demonstrating that
the task-related areas are confounding the results.
Intersession ICC’s (GM) are better, in the case of the simultaneous design, than
the intrasession ICC’s. This is surprising, as intersession comparisons would be
expected to contain extra sources of variance when compared to intrasession mea-
sures. It is a possibility that the intrasession comparisons, particularly in the case
of the simultaneous design, are influenced by the presence of the task leading to
the higher intrasession ICC’s. For the interleaved design an expected decrease in
ICC’s is seen between intra and intersession except for the case of CBF. This may
be due to the smaller ROI (reduced SNR) used to calculate the GM-NoTask.
The initial impression given by the ICC’s, shown in Table 5.2, suggest that SvO2
is considerably more reproducible using the interleaved design leading to more
reproducible measures of CMRO2 at rest. However it is interesting to note that
in Chapter 4 the simultaneous design detected significant differences between
baseline (rest) and elevated baseline states (continuous task) in visual and motor
cortex for CMRO2 where the interleaved design did not. This might suggest that
the interleaved design demonstrates higher repeatability due to the insensitivity
of the technique to detect changes in CMRO2 possibly related to fixing the α and
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Figure 5.4: Difference between resting CMRO2 measures made in global GM
(Black) compared to elevated baseline CMRO2 measures, from Chapter 4, that
were functionally localised in the visual cortex (Red) for both the interleaved and
simultaneous HC-HO design. This visually demonstrates the argument that the
interleaved design has better repeatability (ICC) but may not be sensitive enough
to detect changes in CMRO2, demonstrated by the overlap between GM and fVC
measures. For the simultaneous design there is less overlap between GM and fVC
and it is therefore more sensitive to detecting changes in CMRO2.
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β parameters. Figure 5.4 attempts to visualise this in terms of intersession resting
CMRO2 GM measures compared to the elevated baseline measures that were func-
tionally localised to the visual cortex (made in Chapter 4). However, in order
to thoroughly investigate this, a test-retest repeatability investigation of regional
and global changes in oxygen metabolism would need to be conducted. This could
be done by performing back to back baseline and elevated baseline dcFMRI mea-
sures, essentially repeating within session the experiment that was conducted in
Chapter 4. This procedure would then be repeated on a separate scanning day
allowing intrasession and intersession repeatability of baseline and elevated base-
line measures to be assessed. This would allow the sensitivity of the techniques
to detecting changes in absolute CMRO2 to be assessed. The repeatability of the
task itself must be investigated and the ideal elevated baseline paradigm may not
necessarily be a continuous visual or motor task as used in Chapter 4.
It is also important to note that the sample size and number of repeat measure-
ments used in this study is small. 8 subjects had 3 acquisitions of each type,
interleaved and simultaneous, repeated once within session and once between ses-
sion. A more thorough approach could be taken, similar to that used to investigate
the test-retest repeatability of TRUST [91], where 7 subjects were scanned in 5
different sessions and within sessions were two repeats of the same measure. By
increasing the number of subjects and/or the number of measurements a more
rigorous characterisation of the distribution of measures intersubject, intra and
inter -session would be provided.
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5.5 Conclusion
Test-retest repeatability of dcFMRI using interleaved and simultaneous hypercapnic-
hyperoxic respiratory manipulations was assessed by scanning 8 participants in
three separate sessions. Each session consisted of two separate dcFMRI acquisi-
tions. Intrasession, intersession and intersubject variation was determined for both
interleaved and simultaneous designs and provides useful reference data for future
studies. Physiological parameters measured at rest using interleaved and simulta-
neous designs were further compared for intrasession and intersession repeatabil-
ity using ICC’s. The interleaved design results in more reproducible measures of
CMRO2. However, questions remain over the sensitivity of the technique to detect
changes in oxygen metabolism and associated parameters.
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Chapter 6
Optimisation of Acquisition Time for a
Dual Calibrated FMRI Protocol
6.1 Introduction
Dual calibrated FMRI (dcFMRI) is a promising technique capable of providing
whole brain maps of absolute CMRO2 and related physiological variables. The
technique is an extension of the calibrated BOLD methodology [45, 46] and uses
a BOLD signal model to quantify baseline SvO2 from induced changes in cerebral
blood flow (CBF) and BOLD using combined hypercapnic and hyperoxic respi-
ratory challenges. As dcFMRI is a recently introduced technique limited litera-
ture presenting its use is available. The duration and design of the hypercapnic-
hyperoxic respiratory manipulations presented in these studies differ somewhat
with total acquisition times as short as 13.5 minutes and as long as 19.5 minutes
being presented. Wise et al. [3] presented acquisition routines lasting, 13.5 min-
utes (simultaneous) and 19.5 minutes (interleaved), while Bulte et al. [1], Gauthier
et al. [2] and Chapter 4 from this text present designs lasting 18 minutes. The
details of the duration of the individual respiratory stimulations also vary between
studies along with the concentrations of gas used.
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6.1.1 Reducing Acquisition Time
In order to make the dcFMRI protocol an appealing technique to implement in
clinical and research scan protocols it is necessary to produce reliable measures
of absolute CMRO2 and related physiological parameters in as short a scan time
as possible. Aside from the obvious advantages afforded by a shorter acquisition
such as reductions in valuable scan time, improvements in subject comfort and
realistic implementation in larger scanning protocols, it would also reduce the
susceptibility of the technique to motion related errors and there would be less
potential for change or drift in CBF and BOLD signals as well as the underlying
physiological parameters being measured.
However, reducing scan time must be done carefully as it is important to estab-
lish that the parameter measurements compare favourably with those made using
longer acquisition times. To understand where reductions in acquisition time can
feasibly be made the reasoning behind the current respiratory designs presented
in this study are discussed along with relevant details on elements of the post-
processing pipeline. Using data acquired in a previous study a number of analytical
approaches are then proposed to investigate if the acquisition time of the dual cali-
brated approach can feasibly be reduced and in what areas these reductions might
take place. The respiratory manipulations investigated in this work have been pre-
sented in Chapter 4 as the interleaved and simultaneous hypercapnic-hyperoxic
respiratory manipulations and data acquisition lasted 18 minutes in total.
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Figure 6.1: Interleaved and simultaneous hypercapnic-hyperoxic respiratory ma-
nipulations as presented by Wise et al. [3]
136
Chapter 6 ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Section 6.1
6.1.2 Interleaved Hypercapnic-Hyperoxic Respiratory Design
The design of the interleaved hypercapnic-hyperoxic respiratory manipulation was
based on that presented by Wise et al. [3], shown in Figure 6.1a, with some mod-
ifications. During the interleaved design, BOLD and CBF changes are measured
during periods of normocapnia and normoxia (baseline), hypercapnia and nor-
moxia (HC) and hyperoxia and normocapnia (HO). As can be seen in Figure 6.2
baseline and HO periods last one minute each and periods of HC last 2.5 minutes.
The reliance on arterial spin labelling (ASL) to measure changes in CBF is likely
to be a limiting factor in the dcFMRI routine as the measure of CBF using ASL
suffers from low SNR. It can also be seen from Figure 6.2 that changes in CBF are
only expected during periods of HC. In order to increase the accuracy of the ASL
measure of CBF change, the length of the HC blocks were increased in comparison
to HO where no CBF change need be detected. As no such SNR limitations are
placed on the detection of BOLD changes induced during periods of HO, more
frequent, shorter blocks of HO and baseline were used. The symmetry and inter-
leaved nature of the design, with baseline and HO blocks being bookended by long
blocks of HC, were also thought to be beneficial in dealing with any drift that may
occur during the long scan time duration.
6.1.3 Simultaneous Hypercapnic-Hyperoxic Respiratory Design
The concept of the simultaneous hypercapnic-hyperoxic respiratory design was
introduced by Wise et al. [3] and the design of the simultaneous hypercapnic-
hyperoxic respiratory manipulation used in this study was based on this, shown
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in Figure 6.1b, with some modifications. It involves modelling CBF and BOLD
changes during hyperoxic stimulation which is simultaneously modulated using
varying levels of hypercapnia (HC-HO) as well as measuring baseline periods con-
ducted during normocpania and normoxia. A schematic of the design used in this
study is shown in Figure 6.3. Using the simultaneous approach information about
the exponents, α and β, used in the BOLD signal model can be measured. α is the
exponent relating relative increases in CBF to blood volume and β is the exponent
relating deoxyhaemoglobin concentration to the relaxation rate R2∗. Both of these
model parameters are dependent on cerebrovasculature and have the potential to
change depending on the underlying physiology. To aid in extrapolating measure-
ments of these exponents from the simultaneously modulated CBF and BOLD
data, it was considered advantageous to have many levels of simultaneously vary-
ing HC-HO in the 18 minute time-course. It was also designed symmetrically to
counteract drift with baseline measures being conducted at the beginning, middle
and end of the respiratory protocol.
6.1.4 Block Averaging Time-Points
To increase the accuracy of the measurements made during each respiratory pe-
riod, block averaging was performed over designated window widths as shown in
Figure 6.2 and 6.3. This provided fewer points than fitting the CBF and BOLD
time-series on a volume by volume basis and improved accuracy of each CBF mea-
surement entered into the fitting in particular. The block averaging approach also
allowed periods of transition between conditions to be disregarded as the BOLD
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signal model assumes a steady state. In each respiratory block the first 30 seconds
was removed to allow the physiological measures reach such a steady state. From
observations of transitions of inspired gases during the experiments this was con-
sidered liberal and more than enough time to allow the effect of transitions to be
minimised.
6.1.5 Analytical Approach
Timecourse Splitting
The 18 minute interleaved and simultaneous respiratory manipulations were de-
signed symmetrically allowing the data acquired to be split into two, symmetrical 9
minute chunks which were used to provide estimates of the physiological variables
during these periods. This allowed a comparison of estimates of absolute CMRO2
and associated physiological parameters to be made using the 1st 9 minutes, 2nd 9
minutes and all 18 minutes of data.
Varying Block Average Window Sizes
As described above, block averaging was used to decrease the number of time-
points used in the fitting routine but increase the accuracy of these block averaged
data-points. The effect of decreasing time-points in each block averaged point on
the final variable estimates was investigated by making the window sizes smaller.
This leads to less data being averaged in each block averaged point decreasing
the SNR. By taking this approach we attempt to determine if a smaller window
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size would provide parameter estimates comparable to those made using the full
window size. In practice if a smaller window size was shown to produce compa-
rable estimates to a larger window size, the extra data used in the larger window
might be considered surplus and the length of that respiratory block could be
decreased.
Block Averaged Time-Point Resampling
The block averaged time-point resampling routine attempts to determine if the
acquisition time can be made shorter by acquiring fewer respiratory blocks. In
practice this is done by defining a number of time-based groupings for the in-
terleaved and simultaneous design which require a designated number of block-
averaged data-points of a certain type (baseline, HC, HO or HC-HO) as shown
in Figure 6.4. The designated number of block averaged data-points are then
randomly chosen from those available in the subjects time-series. The randomly
chosen BOLD, CBF and PETO2 block averaged data-points are then fitted with
the BOLD-signal model to determine absolute CMRO2 and related physiological
variables. This process is then repeated 1,000 times in each subject, for each time
based grouping giving a distribution of measured physiological parameters. By
comparing the distributions of parameters calculated in the time-based groupings
we can investigate at what stage enough block averaged data-points are used to
make reliable parameter estimates.
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Figure 6.2: Schematic of interleaved hypercapnic-hyperoxic respiratory challenge
used during the dcFMRI protocol. Details of the block averaging windows de-
scribed in Section 6.2.6 are shown with dotted lines marking the centre of the
respiratory block. BOLD, CBF and PETO2 block averaged data-points used in
the split design analysis described in Section 6.2.7 are detailed at the bottom.
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Figure 6.3: Schematic of simultaneous hypercapnic-hyperoxic respiratory chal-
lenge used during the dcFMRI protocol. Details of the block averaging windows
described in Section 6.2.6 are shown with dotted lines marking the centre of the
respiratory block. BOLD, CBF and PETO2 block averaged data-points used in the
split design analysis described in Section 6.2.7 are detailed at the bottom.
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Figure 6.4: Schematic detailing the time-based groupings and type of block av-
eraged data-points used in the block averaged time-point resampling analysis for
both the interleaved and simultaneous respiratory manipulations.
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6.2 Methods
The data used in this study is a subset of data presented in Chapter 4.
6.2.1 Participants
Eight normal healthy participants (aged 24 - 39; mean age 33.5 ± 5.0; 2 female)
were recruited and scanned having given written consent. Experimental procedures
were approved by the local institutional ethical review committee.
6.2.2 MRI
Scanning was performed on a 3T GE HDx MRI (GE Healthcare, Milwaukee WI)
with a body transmit coil and 8-channel head receive coil. All participants had
previous whole brain T1-weighted structural scans available (fast spoiled gradient
recalled echo, 1x1x1 mm voxels, TI/TR/TE = 450/7.8/3 ms).
Two dcFMRI protocols were performed in each subject on separate days allowing
the estimation of absolute CMRO2 and associated physiological variables. During
day one an interleaved respiratory manipulation was used and during day two a
simultaneous respiratory manipulation. These scans were conducted during rest
(eyes open, fixating on a cross hair on a black background) and details of the
interleaved and simultaneous respiratory manipulations are presented in Chap-
ter 4.
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Simultaneous perfusion and BOLD imaging data was collected for each dcFMRI
acquisition using a PASL proximal inversion and control for off-resonance effects
(PICORE), quantitative imaging of perfusion using a single subtraction (PICORE
QUIPSS II) [37] imaging sequence with a dual-echo gradient echo (GRE) readout
and spiral k-space acquisition (TE1 = 3 ms TE2 = 29 ms, TR = 2.2 s, flip angle
90◦, FOV 22 cm, matrix 64 x 64, 12 slices of 7 mm thickness with an inter-slice
gap of 1 mm acquired in ascending order, TI1 = 700 ms, TI2 = 1600 ms for the
most proximal slice and was incremented for the subsequent slices, tag thickness =
20 cm, adiabatic hyperbolic secant inversion pulse, 10 mm gap between labelling
slab and bottom slice, 10 cm QUIPSS II saturation band thickness). This resulted
in the acquistion of 488 volumes (244 tag - control pairs) for each of the dcFMRI
experiment. A separate single shot (M0) scan was acquired (TR=∞) with the
same parameters as the functional run to measure the equilibrium brain tissue
magnetisation for purposes of quantifying CBF. A minimum contrast image was
also acquired to correct for coil sensitivity.
6.2.3 Respiratory Manipulation
Respiratory challenges were administered using a system of end-tidal forcing [63]
which offers independent control of partial pressures of end-tidal oxygen and car-
bon dioxide (PETO2 and PETCO2 respectively). The end-tidal forcing system
comprised a laptop personal computer using BreatheDmx software (Department
of Physiology, Anatomy and Genetics, Oxford University, UK) to monitor end-
tidal expired gas levels and calculate the inspired partial pressures required to
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achieve the desired target. The gas mixtures were delivered at a total flow rate
of 30 litres per minute (lpm) through a fast gas mixing system connected to a
tight-fitting face-mask worn by the volunteer (Quadralite, Intersurgical, Woking-
ham, Berkshire, UK). The respiratory circuit included a reservoir on the expired
limb to permit re-breathing in the event that the instantaneous inspiratory rate
exceeded 30 lpm. Supplies of 10% CO2 (balance air), 10% O2 (balance N2), 100%
O2 and air were delivered from cylinders to the gas mixing chamber which was
placed as close as possible to the volunteer (on chest) to minimise delays in deliv-
ery. Gas delivery was controlled by four mass flow controllers (MKS Instruments,
Wilmington, MA, USA). Tidal gases were sampled from the volunteers facemask
and PETO2 and PETCO2 were measured using rapidly responding gas analysers
(AEI Technologies, Pittsburgh, PA, USA). During set-up PETO2 and PETCO2
were monitored for the volunteer. Resting PETO2 was used as the PETO2 tar-
get for normoxic periods and resting PETCO2 + 1mmHg was used as the target
PETCO2 for normocapnia to allow the end-tidal forcing system to provide control
of end-tidal CO2. Target profiles for PETO2 and PETCO2 are shown in Figures 6.2
& 6.3.
6.2.4 Preprocessing
All image time-series were motion corrected using 3dvolreg [74]. Time-series image
data acquired from the first echo of the PASL technique was used to calculate
CBF, while the data from the second echo was used to examine changes in BOLD
signal. Physiological noise correction (a modified RETROICOR), was applied
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with the first and second harmonics of both the cardiac and respiratory cycles
being regressed from the data along with the interaction term of the first cardiac
and respiratory harmonics [80, 81]. Interpolated surround subtraction of the ASL
tag and control image time-series was performed to yield a perfusion-weighted
time-series [43] which was corrected for coil sensitivity [82]. CBF images were
calculated using the M0 of blood, estimated from the cerebrospinal fluid signal
of the M0 image and the general kinetic model (GKM) [33]. The CBF estimates
were adjusted for the likely reduction of the T1 of arterial blood with increasing
plasma concentration of paramagnetic O2, according to the blood T1 values quoted
in Bulte et al. [51]. Interpolated surround averaging of the tag and control images
was performed to yield a BOLD weighted time-series.
6.2.5 ROI’s
Subject specific ROI’s of global grey matter (GM) were produced using FAST
segmentation on the high resolution structural images [83] and registered to the
native space of CBF and BOLD images using FLIRT [77]. Partial voluming of GM
was removed by thresholding the mask to include only voxels that were deemed to
contain all grey matter. Mean CBF and BOLD time-series for GM were produced
by averaging over the voxels in GM using the ROI mask.
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6.2.6 Block Averaging
Relative CBF ( CBF
CBF0
) and BOLD signal (∆S
S0
) timeseries were block averaged to
remove periods of transition from the analysis where the BOLD signal model is
not applicable. For the interleaved design, block averaging periods were calculated
for each final 30 second period of each 60 second respiratory block (normocapnia
with normoxia and normocapnia with hyperoxia) and 120 seconds of each 150
second block (hypercapnia with normoxia). The final 30 second period of each 60
second respiratory block was used when block averaging the simultaneous design.
The mean arterial oxygen content, CaO2, was calculated from the PETO2 data
for the same time periods. Periods of block averaging are shown in Figure 6.2 &
6.3.
6.2.7 Split Design Analysis
A split design analysis provided a crude way to investigate reducing scan time,
allowing data acquired in equivalent scan times to be compared. Due to the
symmetrical design of the respiratory manipulations this was possible. The relative
block averaged time-series were analysed in terms of the 1st 9 minutes, the 2nd 9
minutes and the full 18 minutes. For the interleaved design, CBF, BOLD and
PETO2 block averaged data-points from 1 to 8 were used for the 1
st 9 minutes,
8 to 15 for the 2nd 9 minutes and 1 to 15 for the full 18 minutes as shown in
Figure 6.2. For the simultaneous design block averaged data-points from 1 to 9
were used for the 1st 9 minutes, 10 to 18 for the 2nd 9 minutes and 1 to 18 for the
full 18 minutes as shown in Figure 6.3.
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6.2.8 Block Averaging using Varying Window Duration
The effect of reducing the amount of time-series data used to calculate each block
averaged time-point was investigated by varying the duration of the block average
windows. Block average windows of 100% duration are described in Section 6.2.6
and can be visualised in Figures 6.2 & 6.3. The block averaging windows were then
reduced by 10% increments down to 10% of the original block averaging window
size. All block averaging windows begin at the centre of the respiratory block
(dotted lines Figures 6.2 & 6.3). By decreasing the percentage size of the block
average windows, fewer time points are used to average before and after the dotted
line.
6.2.9 Block Averaged Time-Point Resampling
To demonstrate the effect the number of block averaged data-points has on pa-
rameter estimation a block-averaged time-point resampling routine was used. The
block averaged data-points calculated for the interleaved and simultaneous designs
using the 100% block averaging windows were used. For each subject block averag-
ing produced BOLD, CBF and PETO2 block averaged data-points made during 9
baseline (normocapnia and normoxia), 2 HC (hypercapnia during normoxia) and
4 HO (hyperoxia during normocapnia) in the interleaved design and 4 baseline
and 14 HC-HO (hypercapnia with hyperoxia of varying degrees) in the simulta-
neous design. Time-based groupings can be seen at the bottom of Figures 6.2 &
6.3.
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For the interleaved design the minimum requirement to estimate absolute CMRO2
are BOLD, CBF and PETO2 measures made at baseline (duration = 1 minute), HO
(duration = 1 minute) and HC (duration = 2.5 minutes). Summing the durations
of these three block averaged data-points gives a minimum acquisition time of 4.5
minutes using the block averaging technique defined in Section 6.2.6.
Seven time-based groupings related to length of acquisition were then defined.
For the interleaved design these were 4.5, 7, 9.5, 12, 13.5, 16 and 18 minutes.
The increasing group timings were achieved by incrementally introducing more
baseline, HO and HC block averaged data-points of BOLD, CBF and PETO2 as
described in the schematic in Figure 6.4.
Time-based groupings of 4, 7, 9, 12, 13, 16 and 18 minutes were used for the
simultaneous design to try to closely mirror the total times used in the groupings
of the interleaved design. Again the increasing group timings were achieved by
incrementally introducing more baseline and HO-HC block averaged data-points
of BOLD, CBF and PETO2 as described in the schematic in Figure 6.4.
Using these grouping definitions, a block averaged time-point resampling routine
was performed for each subject for both the interleaved and simultaneous design.
As defined in Figure 6.4 each grouping has a required number of block averaged
BOLD, CBF and PETO2 time-points made during a certain respiratory state which
is required. For example the interleaved 9.5 minute grouping requires 5 BOLD,
CBF and PETO2 block averaged data-points made during baseline (total duration
= 5 minutes), 2 during HO (total duration = 2 minutes) and 1 during HC (total
duration = 2.5 minutes). To perform the block averaged time-point resampling
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routine the BOLD, CBF and PETO2 block averaged data-points are randomly cho-
sen within the requirements of the time-based grouping. For the interleaved 9.5
minute example, 5 baseline points are randomly chosen from the 9 available, 2 HO
block averaged data-points are randomly chosen from the 4 available and 1 HC
block averaged time-point was randomly chosen from the 2 available. The physio-
logical measures made at these block averaged data-points were then concatenated
to make BOLD, CBF and PETO2 time-series containing information from 5 block
averaged time points made at baseline, 2 during HO and 1 during HC giving a time-
series taking 9.5 minutes to acquire. The BOLD, CBF and PETO2 block averaged
time-series were then used to estimate absolute CMRO2 and related physiological
parameters using the fitting routine described in Section 6.2.10. This was then
repeated 1,000 times in each subject for each grouping. During each iteration the
designated number of baseline, HC and HO block averaged data-points for that
grouping were randomly chosen from those available in the subjects physiological
time-series and absolute CMRO2 and related physiological variables recalculated
producing a distribution of parameter estimates.
The block averaged time-point resampling routine was the same for the simul-
taneous design with the simultaneous time-based groupings being described in
Figure 6.4 with block averaged data-points being randomly chosen from the base-
line and HC-HO block averaged data-points available in each subjects time-series
during each iteration and recalculated using the CMRO2 quantification routine
described in Section 6.2.10.
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6.2.10 Calculating Absolute CMRO2
The BOLD signal model described in [3] was fit to the global GM, mean CBF and
BOLD block averaged time-series produced from the different analysis approaches
described in Sections 6.2.7, 6.2.8 and 6.2.9. This was done using a simple bayesian
framework to yield estimates of M and SvO2 (interleaved) and M, SvO2, α and β
(simultaneous) at baseline permitting calculation of absolute CMRO2. α = 0.14
and β = 0.91 were chosen from [85] when fitting the interleaved design. Priors
for M and SvO2 were generated as normal probability density functions centred
around initial estimates of 0.08 and 0.5 with broad standard deviations of 0.02
and 0.1. When fitting for M, SvO2, α and β, normal probability density functions
centred around initial estimates of 0.3 and 1.4 with standard deviations of 0.1 and
0.2 were used as priors for α and β. By applying Bayes’ rule to the first block
averaged time points of ∆S
S0
, CBF
CBF0
and CaO2, posterior probability distributions of
the variables, M and SvO2 and M, SvO2, α and β, were generated after integrating
over the ranges 0.01− 0.15 (M), 0.2− 0.8 (SvO2), 0.1− 0.5 (α) and 0.8− 2.0 (β).
These were chosen to be beyond the extremes of physiologically plausible values.
The posterior distributions were used as the priors for calculations with the second
time points of averaged data and so on until a final posterior distribution for each
of the two variables was obtained. The maxima of these probability distribution
functions provided the estimates of M and SvO2 and M, SvO2, α and β for each
subject. Absolute CMRO2 was then calculated using:
CMRO2 = OEF · CBF · CaO2 (6.1)
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6.3 Results
6.3.1 Split Design Analysis
As described in Section 6.2.7 the CBF, BOLD and PETO2 block averaged data-
points were split into the 1st 9 minutes and 2nd 9 minutes to investigate if differences
could be detected between these measures and a full 18 minute acquisition in terms
of absolute CMRO2, CBF and SvO2 in GM at rest. The partitioning of the block
averaged data-points used to achieve these measures are shown at the bottom of
Figure 6.2 for the interleaved design and Figure 6.3 for the simultaneous design.
The group mean ± standard deviation CMRO2, CBF and SvO2 were calculated
in GM at rest from data partitioned into the 1st 9 minutes, 2nd 9 minutes and full
18 minutes and is presented in Figure 6.5. Similar data is presented in Figure 6.6
depicting intersubject coefficients of variation (CV) and Figure 6.7 showing ICC’s
to investigate the reproducibility of the measures being made using different data
partitioning. Background to the use of ICC’s for assessing reproducibility are
explained in Chapter 5.
6.3.2 Varying Window Duration Analysis
A comparison of the total amount of acquisition time used to calculate each window
size for both the interleaved and simultaneous designs is shown in Figure 6.8. The
100% acquisition times are less then 18 minutes as transitional periods have been
removed as discussed in the Section 6.2.6. Changes in group mean and standard
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Figure 6.5: Group mean ± standard deviation (N = 8) (Solid blue and red lines)
of absolute CMRO2, baseline CBF and SvO2 calculated for the 1
st 9 minutes,
2nd 9 minutes and full 18 minutes of the interleaved and simultaneous respiratory
manipulations as described in Figures 6.2 & 6.3 and Section 6.2.7. Measurements
for individual subjects are shown in the dashed blue and red lines.
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Figure 6.6: Intersubject CV’s ( = GroupStandardDeviation
GroupMean
) (N = 8) for absolute
CMRO2, baseline CBF and SvO2 calculated in GM from the 1
st 9 minutes, 2nd
9 minutes and full 18 minutes of the interleaved and simultaneous respiratory
manipulations.
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Figure 6.7: Intraclass correlation coefficient (ICC’s) calculated for 8 subjects be-
tween the 1st 9 minutes and full 18 minutes, 2nd 9 minutes and full 18 minutes
and the 1st 9 minutes and 2nd 9 minutes.
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deviation CMRO2, SvO2 and M with varying window size changes are presented
in Figure 6.9. Intraclass correlation coefficient’s (ICC) were calculated by testing
the parameter estimates at a given window size with those made at 100%.
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Figure 6.8: Amount of time used in block averages plotted as a function of window
size for both the interleaved and simultaneous respiratory designs. Each acquisition
took 18 minutes and periods used for block averaging to avoid transitions are shown
in Figure 6.2 & 6.3. Window sizes of varying duration (10 - 100%) all begin at
the dotted lines positioned at the centre of the respiratory blocks as shown in
Figures 6.2 & 6.3.
6.3.3 Block Averaged Time-Point Resampling
Results of the block averaged time-point resampling routine as applied to the inter-
leaved and simultaneous respiratory designs are presented in Figure 6.11. Subject
means were calculated from the 1,000 randomly sampled iterations at each time-
based grouping and the group mean and standard deviation was then calculated
from these means across subjects for CMRO2, SvO2 and M. The full 18 minute
time-based grouping does not demonstrate any variation as all block averaged
data-points were used to calculate the end physiological variables as the random
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Figure 6.9: Group mean ± standard deviation (N = 8) of absolute CMRO2, M
and SvO2 calculated for the interleaved and simultaneous respiratory manipula-
tions using block averaging windows ranging from 10% to 100% of those shown in
Figures 6.2 & 6.3.
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Figure 6.10: Intraclass correlation coefficients calculated by correlating across sub-
jects, the parameter estimates at a given window size with those made at 100%
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reordering of the block averaged data-points employed by the block averaged time-
point resampling routine does not influence the end result.
6.4 Discussion
BOLD, CBF and PETO2 block averaged time-series data was acquired in 8 sub-
jects during an interleaved and simultaneous hypercapnic-hyperoxic challenge on
separate days. Each scan lasted 18 minutes and was conducted at rest allowing
measurements of M, SvO2 and absolute CMRO2 to be made using both techniques.
Three separate analytical approaches were performed on the data to determine the
viability of a shortened acquisition time for quantification of absolute CMRO2 and
related physiological measures.
6.4.1 Split Design Comparison
The split analysis approach involved splitting the data collected for each 18 minute
acquisition into the 1st 9 minutes of data and the 2nd 9 minutes. The BOLD signal
model was fit to the portioned data to provide estimates of M, SvO2 and absolute
CMRO2.
From Figure 6.5, group mean CBF values are stable across all data portions.
Measurements of SvO2 appear to decrease in the 2
nd 9 minutes using the simul-
taneous design but appear to be stable using the interleaved design. This leads
to an increase in absolute CMRO2 detected between the 1
st 9 minutes and the
2nd 9 minutes of data when looking at the simultaneous design. The group aver-
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Figure 6.11: Group mean ± standard deviation (N = 8) of absolute CMRO2, base-
line CBF and SvO2 plotted as a function of the time based groupings shown in
Figure 6.4. For each time based grouping the mean of 1,000 iterations of the ran-
dom block averaged time-point resampling routine was calculated in each subject.
The mean and standard deviation of these means across the group was then cal-
culated and presented here. No variation is seen in the full 18 minute time-based
grouping as all block averaged data-points were used to calculate the physiolog-
ical variables and random reordering of the block averaged data-points does not
influence the end result.
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age CMRO2 value calculated for the 1
st 9 minutes of the simultaneous design is
unrealistically low (≈ 100 µmol/100g/min).
CV values for CMRO2, CBF and SvO2 presented in Figure 6.6 suggest intersub-
ject variation in the CMRO2 measure is mainly due to variation in SvO2 in the
interleaved design and variation in CBF in the simultaneous design.
ICC’s calculated between the 1st 9 minutes and full 18 minutes, 2nd 9 minutes and
full 18 minutes and the 1st 9 minutes and 2nd 9 minutes for both the interleaved
and simultaneous hypercapnic and hyperoxic challenges are presented in Figure 6.7.
Comparison with intrasession ICC values calculated in Chapter 5, (Interleaved:
CMRO2 = 0.68; CBF = 0.60; SvO2 = 0.57 and Simultaneous: CMRO2 = -0.01;
CBF = 0.88; SvO2 = -0.18 ) the interleaved design shows similar ICC values for
all comparisons in all physiological values. The simultaneous design demonstrates
generally lower ICC values but they are considerably higher than the intrasession
ICC values from Chapter 5.
Differences between the parameter measures made in the two 9 minute periods
may be due to changes occurring over the course of the 18 minute scan. Drift
in the BOLD and CBF signal may occur due to scanner instabilities or changes
in the underlying physiology causing differences in the parameters measured from
the 1st 9 minutes and the 2nd 9 minutes. Physiological changes may be caused by
acclimatisation of the subject to the respiratory tasks and to resting in the scanner.
Differences in parameter measures are also likely to be related to measurement
noise and repeatability which is investigated in Chapter 5.
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Although the approach of splitting the design into two 9 minute chunks allows a
like-for-like comparison, it is a crude way of investigating shorter acquisition times.
The varying window analysis and block averaged time-point resampling routines
provide more subtle approaches to determining appropriate shortened acquisition
routines.
6.4.2 Varying Window Size for Block Averaging
The total amount of time used to calculate the physiological variables as a function
of varying block-average window size is shown in Figure 6.8 for both the interleaved
and simultaneous design. The graph demonstrates that slightly less data is used in
the simultaneous design for all window sizes with the difference decreasing as the
windows get smaller. Total scan times using the 100% block average windows are
less than 18 minutes as data acquired during transitions was removed as described
in Section 6.2.6. After removing the transition periods and using the 100% block
averaged windows the interleaved design uses ∼ 10.5 minutes of data whereas the
simultaneous design uses ∼ 9 minutes.
Figure 6.9 shows the group mean ± standard deviation of CMRO2, SvO2 and M
calculated at varying block average window widths for both the interleaved and si-
multaneous designs. The same baseline CBF was used despite the varying window
width as this value was used to normalise the CBF trace before block averaging
was performed. Group standard deviations calculated for SvO2 and CMRO2 are
consistently smaller for all window sizes using the simultaneous design. Differ-
ences between group mean SvO2 and CMRO2 calculated using the interleaved and
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simultaneous design are discussed in Chapter 4 but differences between the two
measures remain consistent for all window sizes. This may be due to the fact that
all transitions were removed from the block averaged design and all block averag-
ing windows began at the same point at the centre of the respiratory manipulation
and the respiratory challenges were allowed to reach a steady state.
In both interleaved and simultaneous design reasonable estimates of SvO2 and
absolute CMRO2 are made even at the smallest window size (10%). The affect of
smaller window sizes was to underestimate group mean CMRO2 by a maximum of
∼ 15% for both approaches with group SvO2 being overestimated by a maximum
of ∼ 10% for the interleaved design and ∼ 5% for the simultaneous approach.
The interleaved and simultaneous designs achieve group parameter estimates that
agree well with those calculated using a 100% block averaging window at a window
duration of 50%. Estimates calculated using the interleaved design remain stable
for increasing window duration after this point. However considering estimates
calculated using the simultaneous design become unstable after this point, using
the simultaneous design with window sizes less than 80-90% of those currently be-
ing used could lead to unreliable parameter estimates. This can be put down to the
reduced accuracy of block averaged data-points using reduced window sizes.
For smaller window sizes, the group standard deviations for the interleaved design
remain around 20% higher than that calculated using the 100% block averaged
window. The group standard deviation only begins to converge to the lower value
measured using the 100% window at around 70% of it’s size. Group standard devi-
ations converge earlier with smaller window sizes for the simultaneous design.
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ICC’s presented in Figure 6.10 were calculated by correlating the parameter esti-
mates at a given window size with those made with 100% windows. From this it can
be seen that the parameter estimates are reliable when made with a window size
50% of the size currently being used. However simultaneous parameter estimates
are unreliable until they reach ∼ 90% of the width currently being used.
From this analysis the interleaved block averaging windows could be reduced to
50% of those currently being used and still produce comparable parameter esti-
mates to those made using 100% block-average windows. This would reduce the
overall scan time by ∼ 5 minutes meaning reliable parameter estimates could be
made in around 13 minutes. In this study 30 second periods were removed at the
start of each block to remove transition periods. This may be considered liberal
and by optimising the removal of periods related to transitions further savings in
scan time could be made. An alternative approach would be to modify the BOLD
signal model to account for transition periods.
The unreliable estimates produced using smaller window sizes in the simultane-
ous design may be due to a number of factors related to the CBF measurement.
For the simultaneous design, accurate measurements of CBF may be difficult to
achieve particularly with the smaller window sizes compared to the interleaved
approach and the rapidly changing nature of the design. The interleaved design
was purposely designed with large hypercapnic blocks to increase the accuracy of
the CBF measure giving a 2 minute continuous measure when a 100% window
is used and transitions were removed. Comparatively the simultaneous approach
uses block averaging of 30 seconds during periods of hypercapnia. By reducing
the window size below 90 % the accuracy of the block averaged CBF signal may
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decrease to a level where measurements are erratic leading to unreliable parameter
estimates when fitting with the BOLD signal model.
6.4.3 Block Averaged Time-Point Resampling
The block averaged time-point resampling routine attempts to determine how
many block averaged data-points are required to produce reliable estimates that
agree well with parameter estimates made using all the block averaged data points
from the full 18 minutes.
In Figure 6.11 each data point is the mean parameter estimate from 8,000 (1,000
x 8 subjects) randomly sampled time-series fitted with the BOLD signal model.
It can be seen that group mean differences between SvO2 and CMRO2 are still
present between the interleaved and simultaneous designs.
From Figure 6.11 it can be seen that the simultaneous design converges on a group
mean which deviates by ∼ 5% from the parameters calculated using the full 18
minutes of block averaged points using a time-based grouping of 9 minutes (1
baseline and 8 HC-HO block-averaged time-points) or more.
Applying a similar approach to the interleaved design reasonable parameter esti-
mates seem to be achieved at a time based grouping of 13.5 minutes. However it is
also interesting to note the effect of randomly choosing the hypercapnic block av-
eraged time-point versus including both hypercapnic block averaged data-points
for the interleaved design. This is represented in Figure 6.11 as triangular and
square data points respectively. By randomly choosing the hypercapnic block av-
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eraged time-point to be included, the standard deviation across the 8,000 samples
becomes larger. It is therefore suggested that reducing the acquisition time of the
interleaved design is best done using shorter respiratory blocks but keeping the
same number of blocks.
6.5 Conclusion
By using windows of varying sizes to block average the BOLD, CBF and PETO2
time-series it was found that reliable parameter estimates could be produced using
windows 50% the width of those currently being used in the interleaved design.
In practise the extra 50% of surplus data would not be acquired allowing a faster
acquisition and measurement of CMRO2. However this shortened acquisition still
requires experimental confirmation. This would allow reliable parameter estimates
to be produced using the interleaved approach with shorter respiratory blocks in
∼ 13 minutes.
Using the same analytical approach on the simultaneous respiratory design it was
found that reducing the duration of the respiratory challenge blocks in this manner
would not be advisable. However the block averaged time-point resampling routine
suggests that half the simultaneous design could be conducted using any of the
time-based groupings lasting 9 minutes or more. This would mean retaining the
size of the respiratory blocks currently being used but reducing the number of
respiratory blocks to shorten the acquisition.
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Future work to further shorten these acquisition routines should focus on min-
imising the amount of data disregarded due to transitions or alternatively adding
terms to the BOLD signal model to correctly model these transitions.
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Chapter 7
Investigation of Changes in OEF due to
Hypocapnia Induced by Voluntary
Hyperventilation Measured using Dual
Calibrated FMRI
7.1 Introduction
Regional measurements of oxygen extraction fraction (OEF) can be used to assess
compensatory responses made by the brain due to alterations in cerebral blood
flow (CBF). CBF plays a vital role in oxygen and metabolite delivery allowing the
brain to maintain proper function. In healthy brain tissue, CBF is closely matched
to the cerebral metabolic rate of O2 (CMRO2) with little regional variation in OEF.
In order to maintain acceptable oxygen levels within brain tissue, reductions in
CBF can lead to progressive increases in OEF. Severe reductions in CBF can
be implicated in chronic disease, brain trauma and particularly stroke [9] where
mismatches in OEF may mean that sufficient levels of oxygen are not maintained
leading to cell dysfunction and ischaemia.
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7.1.1 Dual Calibrated FMRI
Dual calibrated FMRI (dcFMRI) [1–3] allows mapping of venous oxygen satura-
tion (SvO2) across the brain. Assuming arterial blood is fully saturated, OEF can
be estimated as 1-SvO2 and absolute CMRO2 can be calculated from Fick’s prin-
ciple by combining OEF with a measure of CBF. This technique is non-invasive,
radioisotope free and is based on combining calibrated BOLD methodologies that
traditionally use hypercapnic [45] or hyperoxic [46] challenges allowing estimates
of relative change in CMRO2. To quantify SvO2, dcFMRI measures blood flow
and blood oxygen level dependent (BOLD) signal changes during hypercapnic and
hyperoxic respiratory manipulations in the same session and analyses the changes
using a BOLD signal model. As this technique provides a method to map SvO2,
and hence OEF throughout the brain it is well suited for a wide range of clinical
and research applications. However, to become a useful quantitative neuroimaging
tool the technique must demonstrate sensitivity in detecting disease or treatment
induced changes in SvO2.
7.1.2 Hyperventilation and Hypocapnia
Carbon dioxide (CO2) is a known vasodilator. Hypocapnia is a state of reduced
CO2 in blood which causes relative vasoconstriction and is known to globally lower
CBF [97–102]. It occurs when arterial partial pressure of carbon dioxide (PaCO2)
in blood is lower than normal. PaCO2 describes the amount of CO2 dissolved in
arterial blood and can be inferred by measuring the partial pressure of end tidal
CO2 (PEtCO2). Hypocapnia can be induced as a result of hyperventilation where
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the rate and quantity of CO2 ventilated from the body exceeds the amount of CO2
produced by the body therefore reducing PaCO2. This can be achieved voluntarily
by increasing the depth and frequency of breathing.
Hypocapnia is known to reduce CBF, decreasing the rate of delivery of oxygen
available to brain tissue in arterial blood. It is suspected that decreasing blood
flow is counteracted by an increase in OEF in an attempt to maintain acceptable
CMRO2 [103]. However it is unclear if CMRO2 changes during hypocapnia, as cur-
rent studies are complicated by the use of sedation/anaesthethia [104,105].
Hypocapnia presents a useful physiological state with which to evaluate changes
in cerebrovascular and cerebral metabolic function. By performing dual-calibrated
FMRI using a modified interleaved respiratory manipulation incorporating hyper-
ventilation, the sensitivity of the technique can be assessed with respect to detect-
ing decreases in SvO2 during a global decrease in CBF. This allows the suitability
of the technique for implementation in studies of chronic disease, brain trauma
and stroke to be investigated, where changes in regional OEF are of interest. This
study will also provide further insight into the behaviour of underlying physio-
logical variables, such as CMRO2 and maximum BOLD signal change (M), which
contribute towards the BOLD signal during hypocapnia and have previously been
the focus of investigation [102,106,107].
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7.2 Methods
7.2.1 Participants
Six normal healthy participants (aged 24-40; mean age 33.5 ± 5.7; 1 female) were
recruited and scanned having given written consent. Experimental procedures
were approved by the local institutional ethical review committee. All partici-
pants had previous experience performing respiratory manipulations during MR
scanning.
7.2.2 MRI
Scanning was performed on a 3T GE HDx MRI (GE Healthcare, Milwaukee WI)
with a body transmit coil and 8-channel head receive coil. All participants had
previous whole brain T1-weighted structural scans available (fast spoiled gradient
recalled echo, 1x1x1 mm voxels, TI/TR/TE = 450/7.8/3 ms). The scan ses-
sion lasted approximately one hour and consisted of two interleaved hypercapnic-
hyperoxic dcFMRI protocols similar to Chapter 4. The first dcFMRI protocol
was performed at baseline allowing measurements of SvO2 to be made at normal
baseline CBF. The second dcFMRI protocol was performed during hypocapnia,
providing a new low flow baseline from which changes in SvO2 could be compared
with the baseline scan. FMRI acquisition for each protocol lasted eighteen minutes
with an additional minute for calibration scans. During these protocols simulta-
neous perfusion and BOLD imaging data was collected using a PASL proximal
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Figure 7.1: Schematic detailing the acquisition strategy for normocapnic (blue)
and hypocapnic (red) dcFMRI acquisitions. Calibration (M0 and minimum con-
trast) scans were acquired prior to the ASL acquisition. Dual echo PASL was used
to simultaneously measure CBF and BOLD changes during an 18 minute mea-
surement. Target end tidal O2 and CO2 values for the respiratory manipulations
are shown. The normocapnic session was conducted with a system of end tidal
forcing. Hypocapnic baseline (PEtCO2 − 8 mmHg) was achieved using voluntary
hyperventilation and an EtCO2 feedback task. A manual forcing system was em-
ployed during the hypocapnic acquisition and was used to deliver the periods of
hyperoxia. A 30 second breath-hold (green) was introduced to aid recovery of
PEtCO2 from hypocapnic baseline back to normocapnia.
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inversion and control for off-resonance effects (PICORE), quantitative imaging of
perfusion using a single subtraction (PICORE QUIPSS II) [37] imaging sequence
with a dual-echo gradient echo (GRE) readout and spiral k-space acquisition (TE1
= 3 ms, TE2 = 29 ms, TR = 2.2 s, flip angle 90
◦, FOV 22 cm, matrix 64x64,
12 slices of 7 mm thickness with an inter-slice gap of 1 mm acquired in ascend-
ing order, TI1 = 700 ms, TI2 = 1600 ms for the most proximal slice and was
incremented for the subsequent slices, tag thickness = 20 cm, adiabatic hyperbolic
secant inversion pulse, 10 mm gap between labelling slab and bottom slice, 10 cm
QUIPSS II saturation band thickness). This resulted in a 490 volume acquistion
(245 tag - control pairs) for each of the dcFMRI acquisitions. The calibration scans
consisted of a separate single shot, M0 scan (TR=∞) with the same parameters
as the functional run to measure the equilibrium brain tissue magnetisation for
purposes of quantifying CBF and a minimum contrast image used to correct for
coil sensitivity [82].
7.2.3 Respiratory Manipulations
During the baseline condition scan the participant was told to fixate on a cross hair
overlaid on a black background allowing resting measures of CBF, SvO2, M and
CMRO2 to be made. The baseline interleaved hypercapnic-hyperoxic respiratory
manipulation paradigm is shown in Figure 7.1 highlighted in blue and was admin-
istered using a system of end-tidal forcing [63] which offers independent control
of partial pressures of end-tidal oxygen and carbon dioxide (PEtO2 and PEtCO2
respectively). Details of the respiratory circuit and gas concentrations used can be
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found in Chapter 4. At the beginning of the scan session the volunteer breathed
medical air only without control of PEtCO2 and PEtO2 allowing baseline PEtCO2
and PEtO2 to be measured. Target profiles for PEtO2 and PEtCO2 for the baseline
acquisition are also highlighted in blue in Figure 7.1.
The hypocapnic condition scan was performed by decreasing baseline PEtCO2 by
8 mmHg from that measured in the baseline condition described above. Periods of
normocapnia (PEtCO
base
2 ) and hypercapnia (PEtCO
base
2 + 8mmHg) in the baseline
conditioned scan correspond to periods of hypocapnia (PEtCO
base
2 − 8 mmHg) and
normocapnia (PEtCO
base
2 ) respectively in the hypocapnic conditioned scan. Target
profiles of PEtCO2 for the hypocapnic acquisition are shown in Figure 7.1 high-
lighted in red. Participants were given 2 minutes before the start of the hypocapnic
acquisition to reach hypocapnic baseline using voluntary hyperventilation.
In order to achieve a hypocapnic baseline of PEtCO
base
2 − 8 mmHg an EtCO2
feedback task, similar to that used by Pattinson et al. [108], was employed. The
participant’s PEtCO2 was displayed on a screen along with a target PEtCO2 shown
beside it. Target PEtCO2 corresponded to PEtCO
base
2 − 8 mmHg during periods of
hypocapnia and PEtCO
base
2 during periods of normocapnia as shown in Figure 7.1
red. To decrease displayed PEtCO2 participants were instructed to voluntarily hy-
perventilate by increasing the depth and frequency of breaths. It took participants
less than one minute of mild hyperventilation to achieve the hypocapnic baseline
(PEtCO
base
2 − 8 mmHg). It was noted during pilot testing that participants took a
considerable time, >5 minutes, to return back to normocapnia (PEtCO
base
2 ) after a
period of time at hypocapnic baseline. To increase scan time efficiency and main-
tain symmetry between the hypocapnic and baseline respiratory manipulations, 30
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second breathholds were introduced. Breath-holding offers a convenient method
for elevating PaCO2 by allowing CO2 levels in the lungs and blood to increase [109].
This facilitated a rapid return to normocapnia where participants were instructed
to resume normal breathing patterns. All participants were trained in EtCO2 ma-
nipulation by performing several test runs of the EtCO2 feedback task outside the
scanner until proficiency was proved. These testing sessions took place on separate
days prior to the scan session.
The gas delivery system was switched from the end-tidal forcing system to a man-
ually operated system of valves for the hypocapnic condition. This manual forcing
was performed as the end-tidal forcing system relies on the accurate detection of
inspired and expired breaths. Due to the complexity of the breathing patterns
introduced by the hypocapnic paradigm, increased frequency during hyperventi-
lation and periods of breathholding, the forcing system had difficulty accurately
detecting inspired and expired breathes. Medical air was delivered to the partici-
pants throughout the hypocapnic session and one minute blocks of hyperoxia were
delivered manually according to Figure 7.1. If participant’s struggled to maintain
normocapnia after breatholding a small amount of hypercapnic mixture (10% CO2,
balance air) was manually administered.
An interleaved rather than simultaneous hypercapnic-hyperoxic respiratory ma-
nipulation was chosen for this study as the complexity of the simultaneous design,
with varying levels of hypercapnia during hyperoxia, would have required a higher
level of training in participants and increased the likelihood of operator and subject
error in performing the respiratory manipulation correctly.
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7.2.4 Analysis
Preprocessing
All image time-series were motion corrected using 3dvolreg [74]. Time-series image
data acquired from the first echo of the PASL technique were used to calculate
CBF, while the data from the second echo were used to examine changes in BOLD
signal. Physiological noise correction (a modified RETROICOR), was applied by
regressing the first and second harmonics of both the cardiac and respiratory cycles
from the data along with the interaction term of the first cardiac and respiratory
harmonics [80, 81]. Interpolated surround subtraction of the ASL tag and con-
trol image time-series was performed to yield a perfusion-weighted time-series [43]
which was corrected for coil sensitivity [82]. CBF images were calculated using the
M0 of blood, estimated from the cerebrospinal fluid signal of the M0 image and
the general kinetic model (GKM) [33]. The CBF estimates were adjusted for the
likely reduction of the T1 of arterial blood with increasing plasma concentration
of paramagnetic O2, according to the blood T1 values quoted in [51]. Interpolated
surround averaging of the tag and control images was performed to yield a BOLD
weighted time-series.
Grey Matter Analysis
Subject specific ROI’s of global grey matter (GM) were produced using FAST
segmentation on the high resolution structural images [83] and registered to the
native space of CBF and BOLD images using FLIRT [77]. Partial voluming of
grey matter was removed by thresholding the GM segmented mask to include
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only voxels that were deemed to contain all grey matter. Mean CBF and BOLD
timeseries for GM were produced by averaging over the voxels in GM using the
ROI mask. Time averaged relative CBF ( CBF
CBF0
) and BOLD signal (∆S
S0
) were
block averaged to remove periods of transition from the analysis where the BOLD
signal model is not applicable. The interleaved design block averaging periods
were calculated for each final 30 second period of each 60 second respiratory block
(normocapnia with normoxia and normocapnia with hyperoxia in the baseline
acquisition and hypocapnia with normoxia and hypocapnia with hyperoxia for the
hypocapnic acquisition) and 90 seconds of each 120 second block (hypercapnia
with normoxia (baseline) and normocapnia with normoxia (hypocapnic)). The
periods of breath-holding were excluded from block averaging. The mean arterial
oxygen content, CaO2, was calculated from the PETO2 data for the same time
periods using Equation A11 from [3].
The BOLD signal model described in [3] was fitted to the global GM, mean CBF
and BOLD timeseries using a simple bayesian framework to yield estimates of M
and SvO2 for the baseline and hyperventilation conditions permitting calculation
of absolute CMRO2. α = 0.14 and β = 0.91 were chosen from [85]. Priors for M
and SvO2 were generated as normal probability density functions centred around
initial estimates of 0.08 and 0.5 with broad standard deviations of 0.02 and 0.1. By
applying Bayes’ rule to the first time points of averaged data ∆S
S0
, CBF
CBF0
and CaO2,
posterior probability distributions of the variables, M and SvO2, were generated
after integrating over the ranges 0.01− 0.15 (M) and 0.2− 0.8 (SvO2). These were
chosen to be beyond the extremes of physiologically plausible values. The posterior
distributions were used as the priors for calculations with the second time points
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of averaged data and so on until a final posterior distribution for each of the two
variables was obtained. The maxima of these probability distribution functions
provided the estimates of M and SvO2 for each subject. Absolute CMRO2 was
then calculated using the equation:
CMRO2 = OEF · CBF · CaO2 (7.1)
Whole Brain Analysis
Whole brain parameter maps of M, SvO2 and CMRO2 at normocapnia and hypocap-
nia, Figure 7.3, were produced by following the analysis pipeline and fitting routine
outlined. The whole brain CBF and BOLD timeseries were analysed on a voxel-
wise basis to obtain estimates of M, SvO2 and CMRO2 for each voxel.
Statistical Analysis
From the mean GM ROI measures in Table 7.1, tests for group decreases in
CBF and SvO2 between normocapnia and hypocapnia were performed using one-
tailed, paired t-tests as it was hypothesised that hypocapnia would cause global
decreases in both parameters. Tests for group differences between normocapnia
and hypocapnia in M and CMRO2 were performed using a two-tailed paired t-test.
Tests for regional differences between normocapnic and hypocapnic M, CBF, SvO2
and CMRO2 were performed using 3dttest++ [74]. This was achieved by regis-
tering the individual whole brain parameter maps of M, CBF, SvO2 and CMRO2
to MNI152 space (Montreal Neurlogical Institute) [76] through the hi-resolution
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structural image using FLIRT. T-statistic maps produced as a result of this anal-
ysis are presented in Figure 7.4.
7.3 Results
7.3.1 Hypocapnic PEtCO2
The mean group PEtCO2 for normocapnic baseline was 43.7 ± 1.9 mmHg and
hypocapnic baseline was 35.1 ± 2.6 mmHg. Normalised PEtCO2 ( PEtCO
measured
2
PEtCO
targetbase
2
) for
the hypocapnic run are shown in Figure 7.2. All six participants were successful in
using mild voluntary hyperventilation to reach and maintain hypocapnic baseline.
As noted the most difficult part of the task was returning to normocapnia. The
thirty second breath-holds introduced to speed up the transition from hypocapnia
worked well and participants who still struggled to return to normocapnia were
administered a small amount of hypercapnic mixture manually.
7.3.2 Global Grey Matter Analysis
Table 7.1 presents the whole brain grey matter CBF, M, SvO2 and CMRO2 mea-
sures made using dcFMRI at baseline normocapnia and hypocapnia. Group av-
erage values were calculated including and excluding an outlier which produced
unrealistic measures of SvO2 at rest. Excluding the outlier, significant differences
were detected with hypocapnia in all parameters except CMRO2.
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Figure 7.2: Mean normalised PEtCO2 (
PEtCO
measured
2
PEtCO
target
2
) (black) for the hypocap-
nic condition with standard deviation shown in red. The dips in transition be-
tween hypocapnia and normocapnia are due to the breath holds employed to aid
sharper transition back to normocapnia. These periods were excluded from block-
averaging. The mean, group target PEtCO2 for hypocapnic baseline was 35.3 ±
2.5 mmHg.
181
Chapter 7 ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Section 7.3
S
u
b
je
ct
M
S
v
O
2
C
B
F
ba
se
C
M
R
O
2
N
or
m
o
H
y
p
o
N
or
m
o
H
y
p
o
N
or
m
o
H
y
p
o
N
or
m
o
H
y
p
o
1
0.
04
±0
.0
0
0.
01
±0
.0
0
0.
64
±0
.0
7
0.
48
±0
.0
8
50
.0
31
.9
14
1.
3
12
9.
9
2
0.
04
±0
.0
0
0.
02
±0
.0
0
0.
49
±0
.0
5
0.
43
±0
.0
7
45
.4
36
.8
18
1.
6
16
3.
9
3
0.
06
±0
.0
0
0.
02
±0
.0
0
0.
43
±0
.0
5
0.
41
±0
.0
7
44
.8
35
.0
20
6.
8
15
7.
5
4
0.
05
±0
.0
0
0.
02
±0
.0
0
0.
51
±0
.0
5
0.
41
±0
.0
7
57
.6
45
.2
22
2.
0
20
9.
9
5
0.
05
±0
.0
0
0.
02
±0
.0
0
0.
52
±0
.0
7
0.
46
±0
.0
7
40
.0
33
.9
14
9.
9
14
2.
2
6
0.
05
±0
.0
0
0.
02
±0
.0
0
0.
85
±0
.0
0
0.
46
±0
.0
8
40
.0
30
.3
46
.5
12
7.
6
M
ea
n
±s
td
0.
05
±0
.0
1
0.
02
±0
.0
1
*
0.
57
±0
.1
5
0.
44
±0
.0
3
*
46
.3
±6
.7
35
.5
±5
.2
*
15
8.
0±
62
.9
15
5.
2±
30
.5
M
ea
n
±s
td
†
0.
05
±0
.0
1
0.
02
±0
.0
1
*
0.
52
±0
.0
8
0.
44
±0
.0
3
*
47
.5
±6
.6
36
.6
±5
.1
*
18
0.
3±
34
.9
16
0.
7±
30
.6
T
ab
le
7.
1:
C
om
p
ar
is
on
of
p
h
y
si
ol
og
ic
al
va
ri
ab
le
s
m
ea
su
re
d
d
u
ri
n
g
n
or
m
o
ca
p
n
ia
an
d
h
y
p
o
ca
p
n
ia
in
gl
ob
al
G
M
R
O
I’
s
fo
r
α
=
0.
14
an
d
β
=
0.
91
.
E
st
im
at
es
of
M
an
d
S
v
O
2
an
d
th
ei
r
m
ea
su
re
m
en
t
er
ro
r
w
er
e
m
ad
e
fr
om
th
e
p
os
te
ri
or
d
is
tr
ib
u
ti
on
s
p
ro
d
u
ce
d
b
y
th
e
fi
tt
in
g
ro
u
ti
n
e.
C
M
R
O
2
w
as
ca
lc
u
la
te
d
u
si
n
g
E
q
u
at
io
n
7.
1.
†=
su
b
je
ct
6
re
m
ov
ed
fr
om
gr
ou
p
an
al
y
si
s.
*
=
si
gn
ifi
ca
n
t
(p
<
0.
05
)
d
iff
er
en
ce
b
et
w
ee
n
n
or
m
o
ca
p
n
ia
an
d
h
y
p
o
ca
p
n
ia
w
er
e
te
st
ed
fo
r
in
th
e
ca
se
of
M
an
d
C
M
R
O
2
(t
w
o-
ta
il
ed
,
p
ai
re
d
t-
te
st
)
an
d
d
ec
re
as
es
w
er
e
h
y
p
ot
h
es
is
ed
in
th
e
ca
se
of
C
B
F
an
d
S
v
O
2
(o
n
e-
ta
il
ed
,
p
ai
re
d
t-
te
st
)
182
Chapter 7 ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Section 7.4
7.3.3 Whole Brain Parameter Maps
Group averaged (n = 6), whole brain parameter maps acquired at normocapnia
(left) and hypocapnia (right) using interleaved hypercapnic-hyperoxic respiratory
manipulations are presented in Figure 7.3. Target end tidal values for both res-
piratory manipulations can be seen in Figure 7.1. An end tidal forcing system
was used for the normocapnic session and manual forcing and an EtCO2 feedback
task was used during the hypocapnia session. Whole brain reductions in all four
parameters due to hypocapnia can be visualised and agree well with ROI measures
presented in Table 7.1. It is important to note that measures are limited to grey
matter as a result of limitations associated with measuring CBF using ASL.
T-statistic maps presented in Figure 7.4 were produced by voxelwise, paired t-
test analysis (normocapnia - hypocapnia) conducted between the normocapnic
and hypocapnic parameter maps. Grey matter structure is visible in the CBF
statistical map and to an extent in the CMRO2 and M statistical maps but no
clear pattern or structure is perceptible in the SvO2 statistical map.
7.4 Discussion
In this study we have investigated cerebrovascular and cerebral metabolic indica-
tors during normocapnia and hypocapnia. This was achieved by measuring M,
SvO2, CBF and CMRO2 using dcFMRI in both states. Normocapnic measures
were made using a system of end tidal forcing. The hypocapnic state was achieved
using an EtCO2 feedback task similar to that used by Pattinson et al. [108] and a
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Figure 7.3: Group averaged (n=6), whole brain parameter maps acquired at nor-
mocapnia (left) and hypocapnia (right) using interleaved hypercapnic-hyperoxic
respiratory manipulations.
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Figure 7.4: T-statistic maps produced as a result of the voxelwise, paired t-test
analysis (normocapnia - hypocapnia) conducted between the normocapnic and
hypocapnic parameter maps.
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manual forcing system to achieve a hypocapnic baseline of PEtCO
normocapnia
2 − 8
mmHg.
A regional analysis of global GM produced estimates of CBF, M, SvO2 and CMRO2
in all six participants during normocapnia and hypocapnia is shown in Table 7.1.
Tenable estimates were produced by the fitting routine for all but one participant.
It can be seen from Table 7.1 that subject 6 produced an unrealistic estimate of
SvO2 in normocapnia (0.85). This is considerably above the accepted range of
SvO2 values (0.7 - 0.55) and resulted in an unrealistic estimate of CMRO2 in grey
matter of 46.5 µmol/100g/min. Therefore group mean and standard deviations
for each variable including and excluding subject 6 are displayed at the bottom of
Table 7.1. Parameters estimated during normocapnia and hypocapnia, including
and excluding subject 6 were also tested for significant differences, in the case of
M and CMRO2 and decreases, in the case of SvO2 and CBF. Significant decreases
with hypocapania of M, SvO2 and CBF were detected including and excluding the
outlier. A non significant decrease (p = 0.06) in CMRO2 of 19.6 µmol/100g/min
(10.9%) was found when subject 6 was excluded from statistical testing. No sig-
nificant difference was present when the outlier subject was included.
CBF demonstrated a decrease of 2.9 ± 0.9 %/mmHg (subject 6 included) and
2.8 ± 1.0 %/mmHg (subject 6 excluded). These values agree well with those
reported in PET literature, with Ito et al. [99] reporting decreases in CBF of 3.5
± 0.6 %/mmHg with hypocapnia in the cerebral cortex and Yokoyama et al. [101]
reporting decreases of 3.0 ± 1.1 %/mmHg for the whole brain. An MRI based
study by Chen & Pike [102] reported larger decreases with hypocapnia of between
4.7 ± 0.8 %/mmHg and 5.2 ± 0.7 %/mmHg in GM using ASL.
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Estimates of SvO2 at normocapnia (0.52 ± 0.08) agree well with previous measures
made using the same interleaved respiratory manipulation in Chapter 4 and
Chapter 5. However as discussed in Chapter 4 and in reference [3] this technique
yields estimates of SvO2 that are on the low end of the spectrum when compared
to other dcFMRI studies by Bulte et al. (0.62) [1] and Gauthier & Hoge (0.65) [2].
SvO2 experienced a significant decrease from 0.52 to 0.44 excluding the outlier
subject who measured 0.85 at normocapnia. This is a 14.9 ± 8.0 % decrease in
SvO2 with an 8 mmHg challenge. In a previous investigation of hypocapnia with
MR, Chen & Pike [102] estimated whole brain SvO2 from venous blood T2 in the
jugular vein and reported decreases of 2.2 - 2.6 %/mmHg suggesting a 17.6 - 20.8
% decrease for an 8 mmHg decrease in PEtCO2.
Significant decreases in the maximum BOLD signal were observed with M decreas-
ing from 0.049 to 0.017 with hypocapnia. This is a large decrease of 63.9 ± 9.9 %
or 8 %/mmHg. M is related to baseline cerebral blood volume (CBV0) and deoxy-
hemoglobin concentration ([dHb]0) through the equation M = TEκCBV0[dHb]0
β
[45, 49]. If we consider that [dHb]0 = [Hb](1-SvO2) a drop in baseline SvO2 as
is the case with hypocapnia should result in an increase in [dHb]0. However in-
vestigations with PET [99] reported a decrease in CBV of 1.3±1.0 %/mmHg.
These observations do not explain the large decrease in M that is measured with
hypocapnia.
However M is also dependent on κ and β. These constants are both field dependent
with κ incorporating vessel geometry and susceptibility differences between vessels
and tissue and β incorporating vessel size and diffusion effects. If these presumed
constants vary due to hypocapnia these changes will not be accounted for in the
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model outside of M, as β is fixed and may manifest itself as a decrease in M. Further
investigation is needed to explore the effect of changes of κ and β in the model
and the effect this will have on the estimation of M. M may no longer represent
just the maximum BOLD signal change and may be better explained as simply a
fitting parameter capable of capturing several sources of physiological variation,
much in the same way as the new values of α and β are described by Griffeth et
al. [85]. It is also worth noting that if collinearity exists between α and β, changes
in α with hypocapnia could result in changes in M.
Excluding the outlying subject, group average CMRO2 estimates at rest agree well
with those already published using this technique. Resting measurements are high
relative to other MR and PET studies as a result of low estimates of SvO2 discussed
above. As previously noted a non-significant decrease (p = 0.06) in CMRO2 of 19.6
± 17.0 µmol/100g/min (10.4 ± 7.7 %) was detected due to hypocapnia leading to
a 1.3 %/mmHg decrease in CMRO2. Although the decrease in CMRO2 is not sig-
nificant the trend in decreasing CMRO2 with hypocapnia is apparent from Table
7.1 This noticeable effect of hypocapnia on CMRO2 is in contrast to the limited
reports of hypocapnia and CMRO2 in the literature. Chen & Pike [102] reported
a 2.2 - 3.5 %/mmHg increase in whole brain CMRO2 with hypocapnia using MRI.
Kety & Schmidt [97] reported a group average increase of 14 % in O2 consumption
using voluntary hyperventilation and a direct blood sampling technique. How-
ever this was over a much greater decrease in CO2 of 18 mmHg leading to an
increase in CMRO2 of 0.8 %/mmHg. McPherson et al. [104] reported no change
of CMRO2 in anaesthetised canines with hypocapnia using radio labelled micro-
spheres and a PET study by Gjedde et al. [103] which did not employ hypocapnia
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but instead used indomethacin, a non-steroidal anti-inflammatory drug, to reduce
CBF significantly by 34 % leading to a 8 % non-significant decrease in CMRO2.
EEG [110] and MEG [111] studies have also been used to measure negative DC-
shifts with hyperventilation, reflecting increased excitatory synaptic transmission
suggesting increases in CMRO2. Evidence from these studies point in the direc-
tion of increases in CMRO2 with hypocapnia. The results shown in this study of
decreasing CMRO2 with hypocapnia could be due to a bias in the BOLD signal
model. Refinement of the model is an area for future improvement, however it is
encouraging to see that the direction of change in SvO2 and CBF agree well with
what is expected. As has been suggested by results presented in [97, 102] there
may be a nonlinear relationship between the degree of hypocapnia and it’s effect
on the physiological variables measured. This could be further investigated using
the approach presented in this study by modifying the EtCO2 feedback task to
achieve hypocapnic baselines of different levels.
The T-statistic maps presented in Figure 7.4 were thresholded and clustered to
investigate if there were any obvious regional differences as a result of hypocapnia
induced changes in CBF, M, SvO2 and CMRO2. After thresholding and clustering
at a number of different p-values and cluster thresholds no evident regional change
was noticeable. It is interesting to note that grey matter structure is visible in
the CBF statistical map and to an extent in the CMRO2 and M statistical maps
but no clear pattern or structure is perceptible in the SvO2 statistical map. As
only 5 subjects are used in this analysis, a larger group size may be needed to
investigate if changes in the physiological parameters with hypocapnia have any
regional variation or bias.
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Further limitations are associated with the use of a task to achieve hypocapnia.
Neural activity caused by the performance of the EtCO2 feedback task may in-
fluence the measured physiological parameters. It is also worth noting that inac-
curacies may be present in the CBF measurement. The use of ASL with a single
imaging time may not accurately measure the CBF differences between the normo-
capanic and hypocapanic states if there are large enough differences in the arterial
arrival times (AAT) of these two states. This could be overcome using multi-TI
ASL approach to accurately model the discrepancies in AAT.
7.5 Conclusion
dcFMRI was used to successfully acquire measures of CBF, M, SvO2 and CMRO2
during normocapnia and hypocapnia in 5 of 6 participants. Decreases in all mea-
sured variables were detected in GM, with all but CMRO2 showing significant
differences. The data demonstrate a clear trend in CBF, M, SvO2 and CMRO2
between normocapnia and hypocapnia in global grey matter. This demonstrates
the sensitivity of the dcFMRI protocol to detect changes in OEF and suggests
that the technique is appropriate for clinical application in areas such as stroke or
vascular dysfunction in which flow is impaired.
190
Chapter 8 ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Section 8.1
Chapter 8
Comparison of Asymmetric Spin Echo
with Dual Calibrated FMRI using
Hypercapnic-Hyperoxic Respiratory
Challenges
8.1 Introduction
Oxygen metabolism is the principle form of energy production in the brain and
techniques allowing quantitative measurement of this process provide valuable in-
formation on neural energy consumption. Dual calibrated FMRI (dcFMRI) [1–3] is
a recent extension of the calibrated BOLD methodology [45,46]. Calibrated BOLD
utilises a single respiratory manipulation such as hypercapnia or hyperoxia to allow
relative, task related changes in the cerebral metabolic rate of oxygen (CMRO2)
consumption to be quantified. Similarly dcFMRI relies on relating changes in
cerebral blood flow (CBF) and blood oxygen level dependent (BOLD) signals dur-
ing respiratory manipulations to a BOLD signal model. However by using both
hypercapnic and hyperoxic challenges, quantification of absolute baseline CMRO2
191
Chapter 8 ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Section 8.1
can be made. dcFMRI offers a radioisotope free, noninvasive, MRI based tech-
nique that is capable of investigating the regional and spatial extent of cerebral
oxygen metabolism. By providing quantitative physiological measures that can be
tracked longitudinally, this technique broadens the appeal of FMRI making it a
more useful clinical and research based tool.
8.1.1 Hypercapnia
Hypercapnia was used in the original calibrated BOLD methodology which allowed
the estimation of relative changes in CMRO2 [45]. However a number of disadvan-
tages have been discussed in literature regarding the use of hypercapnia. Chiarelli
et al. [46] cited onset of breathlessness and the potential intolerability in distressed
or infirm subjects as some of the reasons for the introduction of the alternative
hyperoxic calibration methodology. Mohtasib et al. [112] made reference to the
hyperoxic calibration technique as being more comfortable and better tolerated
when implementing calibrated BOLD for studying an ageing population. Con-
cerns over the potential of a hypercapnic challenge to cause sensory stimulation
due to air hunger have also been expressed [113]. As a result it would be useful
to have an alternative calibration technique to use in conjunction with hyperoxia
in the dcFMRI framework to avoid the use of hypercapnia for the estimation of
absolute CMRO2.
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8.1.2 Relaxometry and Quantitative BOLD
A model for the quantification of the haemodynamic properties of the brain was
proposed by Yablonskiy et al. [114]. The method presented in this study relates
the reversible transverse relaxation rate (R′2) to cerebral blood volume (CBV) and
the deoxyhaemoglobin concentration ([dHb]) of the blood present. Techniques
measuring the time signal decay of a gradient echo (GE) and spin echo (SE) have
been able to utilise this mathematical model to estimate measures of venous oxygen
saturation (SvO2) and CBV in techniques dubbed quantitative BOLD (qBOLD)
[115].
However these techniques involve the fitting of a complex model to the time de-
pendent signal decay and it has been demonstrated through simulation and phan-
tom studies that these techniques require very high SNR in order to distinguish
between CBV and SvO2 as there is a strong interdependence between the two
parameters [116]. It has been pointed out that this interdependence of the two
parameters may require the independent estimation of one variable to determine
reliable values of the other [117].
The qBOLD approach has progressively become more complex with multi-parametric
approaches being employed to estimate relevant variables [118, 119] and more in-
tensive modelling being applied [120]. Blockley et al. [69, 121] has recently pro-
posed that qBOLD style techniques could be used for the estimation of the maxi-
mum BOLD signal change (M) and demonstrated the feasibility of this approach
through numerical simulation. M is the desirable parameter measured in a cal-
ibrated BOLD experiment which facilitates the quantitation of relative CMRO2
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changes. Subsequently M is a key parameter requiring estimation in the dcFMRI
methodology allowing calculation of absolute CMRO2. Although M is dependent
on CBV and SvO2 its estimation doesn’t require the independent determination
of either parameter and can instead be measured together in one grouped term.
This overcomes the problem of trying to disentangle two interdependent variables
from the data.
The aim of this chapter is to evaluate the use of R′2 relaxometry for the measure-
ment of maximum BOLD signal change (MR′2) and compare it to maximum BOLD
signal change determined by hypercapnic calibrated BOLD (Mhc) and hyperoxic
calibrated BOLD (Mho) as well as the M measured using dcFMRI (MdcFMRI).
MR′2 is then integrated into the hyperoxic calibrated BOLD technique allowing
measures of absolute CMRO2 in grey matter (GM) to be made in a manner anal-
ogous to dcFMRI. The results are then compared to a more traditional dcFMRI
approach using an interleaved hypercapnic-hyperoxic set up, the details of which
are presented in Chapter 4. The Background and Theory section (Section 8.2)
introduces the original BOLD signal model proposed by Davis [45] and Hoge [49].
The derivation of M is demonstrated and the simplification of the model in the case
of individual hypercapnic and hyperoxic calibrations is presented. The combina-
tion of hypercapnic and hyperoxic challenges for dual calibration is then discussed
allowing the measurement of SvO2 and in turn absolute CMRO2. Finally the re-
lationship of R′2 with M is considered and a framework for measuring SvO2 and
in turn absolute CMRO2 is proposed by combining MR′2 and hyperoxic calibrated
BOLD.
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8.2 Background and Theory
FMRI is a well established technique most frequently used to investigate regions of
increased task related, neuronal function. This is performed by measuring relative
changes in BOLD signal from an unquantified baseline state. The magnitude of
BOLD signal change is a function of underlying physiological processes, CBF and
CMRO2, as well as being dependent on the unknown baseline state defined by
[dHb]0 and CBV0. Subscript 0 is used in this case to denote the baseline state of
the given physiological variable. As a result of the non-quantitative nature and
complicated dependence on the previously described physiological variables the
interpretation of BOLD signal changes can become difficult.
8.2.1 Calibrated BOLD
The calibrated BOLD methodology was introduced to improve interpretability of
task related changes in BOLD. This is achieved by estimating M for the current
baseline state allowing estimates of relative change in CMRO2 to be inferred from
task related changes in BOLD and CBF. To measure M, a calibration scan is per-
formed where BOLD signal changes are induced by increasingg venous [dHb]. This
can be done by inducing mild hypercapnia [45] or hyperoxia [46] in the participant.
The respiratory challenges are considered to be isometabolic and as such do not
alter brain metabolism [102]. Hypercapnia involves increasing inspired CO2 caus-
ing an isometabloic increase in CBF. Hyperoxia is an increase in inspired O2 and
increases the arterial oxygen content (CaO2). The induced BOLD signal changes
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can then be interpreted using a simple BOLD signal model derived by Davis et
al. [45] and Hoge et al. [49].
BOLD signal changes depend on changes in [dHb]. Due to it’s paramagnetic nature
and presence in blood vessels, deoxyhaemoglobin (dHb) creates a susceptibility
difference with surrounding brain tissue resulting in local signal decreases due to
the enhanced relaxation rate. This is dependent on the amount of dHb present
and can be related to R∗2, the transverse relaxation rate. R
∗
2 is also dependent on
the volume of blood present described as CBV by [29]. Considering a voxel with
a normal resting R∗2, removing all dHb from that voxel causes a change in R
∗
2 that
can be described by δR∗2, Equation 8.1, where constants κ and β are both field
dependent constants and β is dependent on vessel size and geometry.
δR∗2 = κCBV0[dHb]
β
0 (8.1)
Maximum BOLD signal change (M) can then be calculated as:
M = TE · κCBV0[dHb]β0 = TE · δR∗2 (8.2)
Changes in BOLD signal can be described as ∆R∗2:
∆R∗2 = κCBV [dHb]
β − κCBV0[dHb]β0 (8.3)
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Small changes in ∆R∗2, such as those that are experienced during an FMRI exper-
iment can be approximated by Equation 8.4 where ∆S
S0
is the fractional increase
in BOLD signal which takes the echo time (TE) of the acquisition sequence into
account.
∆S
S0
= e−TE∆R
∗
2 − 1 ≈ −TE∆R∗2 (8.4)
Substituting Equation 8.3 for ∆R∗2 in Equation 8.4 gives:
∆S
S0
= TEκCBV0[dHb]
β
0
(
1−
(
CBV
CBV0
)(
[dHb]
[dHb]0
)β)
(8.5)
Substituting Equation 8.2 into Equation 8.5 the term for maximum BOLD signal
change can be incorporated into the model:
∆S
S0
= M
(
1−
(
CBV
CBV0
)(
[dHb]
[dHb]0
)β)
(8.6)
In the case of hypercapnia Equation 8.6 reduces to Equation 8.7 where increases
in inspired CO2 are assumed to cause isometabolic CBF changes. α is the Grubb
constant [50], a value taken from literature, and relates changes in CBF to changes
in CBV as [ CBF
CBF0
]α = [ CBV
CBV0
].
∆S
S0
= M
(
1−
(
CBF
CBF0
)α−β)
(8.7)
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In the case of hyperoxia an isometabolic increase in CaO2 is assumed to have no
effect on CBF and Equation 8.6 is simplified to:
∆S
S0
= M
(
1−
(
1− ∆CaO2
φ[Hb] (1− SvO2)
)β)
(8.8)
Both equations can then be solved for M with all other parameters being measured
or assumed. However it is important to note that hyperoxic calibration requires a
value for SvO2 to be assumed.
8.2.2 Dual Calibrated FMRI
dcFMRI uses a two point calibration, inducing BOLD and CBF changes by hyper-
capnic and hyperoxic respiratory manipulations which are performed in the same
session. In it’s simplest form, as described by Bulte et al. [1], M can be calcu-
lated using the hypercapnic calibrated BOLD approach, meaning SvO2 no longer
needs to be assumed in the hyperoxic calibration. Instead the equation can now be
solved for SvO2. Assuming arterial blood is fully saturated the oxygen extraction
fraction can be calculated as OEF = 1 − SvO2 and CMRO2 measured using Fick’s
equation:
CMRO2 = OEF · CBF · CaO2 (8.9)
The approach of Gauthier et al. [2] and Wise et al. [3] to dcFMRI differ only in
the application of the BOLD signal model. Instead of estimating M independently
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using hypercapnic calibration and determining SvO2 using hyperoxic calibration,
the Davis/Hoge model (Equation 8.6), is expanded to accommodate simultaneous
modulations of CBF and CaO2. The model reduces to the hypercapnic (Equa-
tion 8.7) and hyperoxic (Equation 8.8) based models when arterial oxygen levels
and CBF are held constant respectively. However M and SvO2 are estimated by
simultaneously optimising these parameters to the data through the expanded
model. The approach taken by Bulte et al. [1] suggests that if M is known, SvO2
and in turn absolute CMRO2 can be measured using a hyperoxic calibration tech-
nique and it is this approach that we exploit in this chapter.
8.2.3 R′2
[dHb] can also be inferred by directly quantifying the relaxation properties of brain
tissue. As noted above dHb present in blood vessels causes a susceptibility differ-
ence with surrounding tissue resulting in attenuation of the transverse relaxation
rate, R∗2. R
∗
2 can be expressed as the sum of reversible (R
′
2) and irreversible (R2)
dephasing with relation to spin echo refocussing (Equation 8.10). R′2 is dephasing
caused by local magnetic field inhomgeneities that can be refocused by a spin echo
whereas R2 is dephasing due to the thermal motion of molecules, referred to as
spin-spin interactions, and cannot be refocused by a spin echo.
R∗2 = R
′
2 +R2 (8.10)
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Yablonskiy et al. [114] demonstrated that R′2 can be related to CBV0 and [dHb]0.
From Equation 8.1, R∗2 describes the amount of dHb present in blood vessels and
is given by:
R∗2 = κCBV0[dHb]
β
0 (8.11)
Assuming that BOLD effects are solely described by R′2 and reversible transverse
relaxation, Equation 8.10 becomes:
R∗2 = R
′
2 (8.12)
Substituting Equation 8.12 into Equation 8.11 gives:
R′2 = κCBV0[dHb]
β
0 (8.13)
From Equation 8.2, M can now be described in terms of R′2 as:
M = TE ·R′2 (8.14)
However effects contributing to BOLD signal change (∆R∗2) are not considered
to be solely reversible. As suggested by simulations irreversible components may
contribute towards the signal [122], however further simulations suggest BOLD
signal changes can be directly scaled with R′2 [69].
200
Chapter 8 ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Section 8.2
Asymmetric Spin Echo (ASE) for Measuring R′2
A single shot ASE can be implemented to provide a measure of R′2. In a traditional
spin echo experiment a 180◦ refocusing pulse is applied at TE
2
and a re-phased spin
echo is formed at TE where the signal is acquired. In an ASE experiment the
signal is still acquired at TE but the 180◦ refocusing pulse is shifted by τ
2
so that
the re-phased echo is shifted by TE − τ with respect to the centre of the signal
acquisition window, as shown in Figure 8.1.
Figure 8.1: Comparison of a spin echo (SE) and asymmetric spin echo (ASE) pulse
sequence. In the ASE approach the 180◦ refocusing pulse is shifted asymmetrically
by τ
2
with respect to the SE refocusing pulse.
The signal refocused by a symmetric SE at a given TE can be described by Equa-
tion 8.15 where S0 is the signal acquired at TE = 0 and is dependent on R2, the
irreversible decay.
SSE = S0e
−TE·R2 (8.15)
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By shifting the refocused spin echo by −τ with respect to the acquisition time
(TE), the signal attains additional attenuation due to R′2 dephasing. The signal
acquired using ASE at TE has an extra attenuation term which describes the R′2
dephasing, that occurs during time τ , as a result of shifting the refocusing pulse
by τ
2
:
SASE = S0e
−TE·R2e−τ ·R
′
2 (8.16)
To ensure that measures of R′2 are localised to the dephasing occurring as a result
of susceptibility differences between blood vessels and brain tissue due to dHb,
attenuation of the ASE signal due to larger scale magnetic field inhomogeneities
must be accounted for. These larger scale magnetic field inhomogeneities occur
because of susceptibility differences at tissue/air and tissue/bone interfaces and
can be corrected. This can be done by acquiring high-resolution field maps and
calculating the frequency difference across voxels in the slice direction (∆ω). Al-
though there is the potential for in plane dephasing to also occur, these signal
attenuations were deemed to be small when compared to through slice dephasing
due to the relative strength of the gradients used.
∆ω = γGz∆z (8.17)
An attenuation correction factor for differences due to large scale magnetic field
inhomogeneities can then be corrected using a τ dependent sinc function:
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F (τ) = sinc(
τ∆ω
2
) (8.18)
For single shot ASE, TE doesn’t change and therefore R2 weighting is constant.
Once SASE is corrected for additional signal decay by multiplication with F(τ),
changes in SASE with τ can be used to calculate R
′
2 of the resting baseline state of
the brain (Equation 8.16) and used to calculate M (Equation 8.14). MR′2 can then
be used within the hyperoxic calibration to allow Equation 8.8 to be solved for
SvO2. If we consider the approach taken by Bulte et al. [1] to dcFMRI, MR′2 effec-
tively replaces Mhc allowing absolute CMRO2 to be calculated using Equation 8.9.
This means that a dcFMRI approach can be performed without the need for a hy-
percapnic respiratory manipulation. This allows measures of absolute CMRO2 to
be made without the drawbacks associated with hypercapnic respiratory challenge
such as air hunger, intolerability and sensory stimulation. This demonstrates a
practical improvement for the implementation of the dcFMRI approach and aids
in the transition of the technique to a clinical setting.
8.3 Methods
8.3.1 Participants
Eight normal healthy participants (aged 24 - 39; mean age 33.5 ± 5.0; 2 female)
were recruited and scanned having given written consent. Experimental proce-
dures were approved by the local institutional ethical review committee. All par-
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ticipants had previous experience of performing respiratory manipulations during
MR scanning.
8.3.2 MRI
Scanning was performed on a 3T GE HDx MRI (GE Healthcare, Milwaukee WI)
with a body transmit coil and 8-channel head receive coil. All participants had
previous whole brain T1-weighted structural scans available (fast spoiled gradient
recalled echo, 1x1x1 mm voxels, TI/TR/TE = 450/7.8/3 ms). The data presented
in this study is a subset of data acquired during a scanning session that lasted
approximately an hour. Only the details of relevant acquisitions to this study are
presented from here on. Throughout the scan session participants were presented
with a cross hair overlaid on a black background and instructed to keep their eyes
open for the duration of the scan.
Dual Calibrated FMRI
An interleaved hypercapnic-hyperoxic dcFMRI protocol was performed lasting
eighteen minutes with an additional minute for calibration scans. Details of the
dual-echo spiral EPI sequence used to collect simultaneous perfusion and BOLD
imaging data can be found in Chapter 4 alongside details of the interleaved
hypercapnic-hyperoxic respiratory manipulation used.
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Asymmetric Spin Echo
The same anatomical area / prescription was scanned using a single shot ASE-EPI
sequence with different asymmetric or τ weightings. An SE (τ = 0 ms) was first
acquired followed by asymmetric SE’s at τ = 20, 25 and 30 ms. The τ times
were chosen to be greater than 15 ms in order to stay in the monoexponential
regime of the signal model [69]. A single-echo, gradient echo (GRE) readout with
spiral k-space acquisition was used (TE = 44 ms, TR = 3.0 s, flip angle 90◦) with
one interleave being acquired. The anatomical prescription used during the dual-
calibrated FMRI was copied to ensure that the same brain regions were covered.
In-plane resolution was kept the same as before (FOV 22 cm and matrix 64x64)
but 32 slices with 2 mm thickness and an inter-slice gap of 1 mm were acquired.
The smaller slice thickness was used to reduce the effect of B0 inhomogeneities
while conserving good signal-to-noise ratio as demonstrated in [119, 123]. Each τ
acquisition took 1 minute 6 seconds with two dummy pulses followed by 20 vol-
umes being acquired. Although spiral image acquisition helps overcome some of
the signal loss and image distortion caused by the presence of B0 inhomogeneties
the use of a spiral in/out [124] or spiral in/in [125] acquisition or other multiple
spiral acquisitions, such as that presented by Brewer et al. [126], would ideally
minimise macroscopic field dephasing effects. To calculate the attenuation correc-
tion function, F(τ), two GRE acquisitions were used with the same prescription
as the single shot SE acquisition described previously. The GRE’s were collected
at TE = 7 and 9 ms with phase maps for each echo time being output from the
raw data.
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8.3.3 Analysis
All image time-series were motion corrected using 3dvolreg [74].
MR′2, ASE
Each of the four τ shifted ASE acquisitions were averaged over the 20 volumes
acquired to give the mean signal map (SASE). 3D phase unwrapping was per-
formed using PRELUDE, (part of the FSL toolbox) on the phase maps acquired
for the GRE acquisition (TE = 7 and 9 ms) and the phase difference (rads/s) was
calculated by subtracting the unwrapped phase maps on a voxel by voxel basis.
The difference image was then demeaned and smoothed using a 2 mm Gaussian
smoothing kernel. The demeaned difference images were taken into MATLAB us-
ing the AFNI MATLAB toolbox [74] and phase difference was calculated in the
slice direction using the ”diff.m” function. This provided the frequency difference
across each voxel in the slice direction (∆ω) and allowed the attenuation correction
function F(τ) to be calculated individually for each τ (Equation 8.18). The signal
intensity, SASE, for each τ was corrected for signal attenuation due to macroscopic
field inhomgeneity. Voxels with signal attenuations greater than 10% (i.e. F <
90 %) were not included in further analysis and thresholded out. This threshold-
ing was considered liberal and was done to ensure the influence of macroscopic
magnetic field inhomogeneity was removed from the measured R′2.
Subject specific ROI’s of global grey matter (GM) were produced using FAST
segmentation on the high resolution images [83] and registered to the native space
of each τ image using FLIRT [77]. Mean GM signal was calculated across these
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ROI’s for each of the four attenuation corrected and thresholded τ weighted ASE
images.
Four M values were calculated using Equations 8.16 and 8.14. Individual estimates
of M were made using the GM averaged signal at each of the three τ shifted ASE
acquisitions (τ = 20, 25 and 30 ms) and the symmetric SE (τ = 0). These estimates
are referred to as Mτ=20ms, Mτ=25ms and Mτ=30ms. A fourth estimate of M was
made by estimating a value for R′2 from all the ASE data acquired in a subject. A
line was fit (− log(Sτ20,25,30
S0
) vs. τ) to estimate R′2 and Mτfit was determined from
this.
Respiratory Manipulated FMRI
The first and second echo time-series image data acquired by the dual-echo PASL
sequence during the dcFMRI protocol was corrected for physiological noise us-
ing a modified RETROICOR approach. The first and second harmonics of both
the cardiac and respiratory cycles were regressed from the data along with the
interaction term of the first cardiac and respiratory harmonics [80, 81]. The first
echo acquired was used to calculate CBF, while the data from the second echo was
used to examine changes in BOLD signal. Interpolated surround subtraction of the
ASL tag and control image time-series was performed to yield a perfusion-weighted
time-series [43] which was corrected for coil sensitivity [82]. CBF images were cal-
culated using the M0 of blood, estimated from the cerebrospinal fluid signal of the
M0 image and the general kinetic model (GKM) [33]. The CBF estimates were
adjusted for the likely reduction of the T1 of arterial blood with increasing plasma
concentration of paramagnetic O2, according to the blood T1 values quoted by
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Bulte et al. [51]. Interpolated surround averaging of the tag and control images
was performed to yield a BOLD weighted time-series.
The subject specific ROI’s of global GM produced by FAST segmentation were
registered to the native space of CBF and BOLD images using FLIRT [77]. Partial
voluming of GM was removed by thresholding the mask to include only voxels that
were deemed to contain all GM. Mean CBF and BOLD timeseries for GM were
produced by averaging over the voxels in GM using the ROI mask. Time averaged
relative CBF ( CBF
CBF0
) and BOLD signal (∆S
S0
) were block averaged to remove periods
of transition from the analysis where the BOLD signal model is not applicable.
The interleaved design, block averaging periods were calculated for each final 30
second period of each 60 second respiratory block (normocapnia with normoxia
and normocapnia with hyperoxia in the baseline acquisition ) and 120 seconds of
each 150 second block (hypercapnia with normoxia). The mean arterial oxygen
content, CaO2, was calculated from the PETO2 data for the same time periods
using Equation A11 from [3].
M, Calibrated BOLD
The data acquired for the dcFMRI acquisition was divided up in such a way as
to allow the calculation of Mhc and Mho using the calibrated BOLD approach.
For the calculation of M using the hypercapnic approach (Mhc), Equation 8.7 was
used. From the block averaged data, periods of hypercapnia and normoxia were
used to estimate CBF and BOLD increases from baseline. During the hyperoxic
calibration (Mho) no change in CBF was assumed. Periods which were hyperoxic
and normocapnic were used to estimate BOLD and CaO2 changes from baseline.
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Constants assumed in Equation 8.8 are SvO2 = 0.3 [46], φ = 1.34 ml/g and Hb
= 0.15 g/ml. In both cases baseline was calculated from periods of normocapnia
and normoxia.
Dual Calibrated FMRI
The BOLD signal model described in [3] was fitted to the block averaged global
GM, mean CBF and BOLD timeseries using a simple bayesian framework to yield
estimates of MdcFMRI and SvO2 permitting calculation of absolute CMRO2. α =
0.14 and β = 0.91 were chosen from [85]. Priors for M and SvO2 were generated as
normal probability density functions centred around initial estimates of 0.08 and
0.5 with broad standard deviations of 0.02 and 0.1. By applying Bayes’ rule to
the first time points of averaged data ∆S
S0
, CBF
CBF0
and CaO2, posterior probability
distributions of the variables, M and SvO2, were generated after integrating over
the ranges 0.01 - 0.15 (M) and 0.2 - 0.8 (SvO2). These were chosen to be beyond
the extremes of physiologically plausible values. The posterior distributions were
used as the priors for calculations with the second time points of averaged data and
so on until a final posterior distribution for each of the two variables was obtained.
The maxima of these probability distribution functions provided the estimates of
M and SvO2 for each subject. Absolute CMRO2 was then calculated using:
CMRO2 = OEF · CBF · CaO2 (8.19)
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8.3.4 ASE-R′2 and Hyperoxic Calibrated BOLD
Using the same subset of BOLD data described for the hyperoxic calibrated BOLD
approach, M measured using ASE can be substituted into Equation 8.8 and the
problem can be solved for SvO2. Combining SvO2 with a baseline measure of CBF,
absolute CMRO2 can be estimated using Equation 8.19.
8.4 Results
8.4.1 ASE Signal Attenuation Correction, F(τ)
To help correct for macroscopic magnetic field inhomogeneities and ensure that
measurement of R′2 can be directly related to [dHb] the signal attenuation factor F,
described as a function of τ in Equation 8.18, is used to correct the signal intensity
of the ASE images acquired at different τ . F was further thresholded at 90%
effectively excluding any voxel signals which differed from their measured value by
more then 10% due to signal distortion. This was an arbitrary thresholding value
that was considered cautious. Details of F thresholding in terms of voxel exclusion
are given in Table 8.1. It can be seen that the number of voxels removed increases
with τ as expected.
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Total voxels GM Thresholded voxels GM % Thresholded
τ = 20 ms 14776 ± 703 4220 ± 1084 29 ± 7 %
τ = 25 ms 14471 ± 711 5407 ± 1117 37 ± 7 %
τ = 30 ms 14163 ± 732 6171 ± 1034 44 ± 7 %
Table 8.1: The signal attenuation factor F(τ) (Equation 8.18) was thresholded to
remove voxels which were attenuated by more then 10% due to macroscopic field
distortions. Values presented are the mean ± standard deviation across the group
(n = 8). For each τ the total number of voxels in GM before thresholding, after
thresholding and the percentage of voxels removed is given.
8.4.2 Characterisation of MR′2 with τ
R′2 was calculated in each subject using the signal attenuation corrected, ASE
images acquired at each of the three asymmetric τ ’s as well as an estimate of R′2
determined by fitting the data to all four signals. This was done using Equa-
tion 8.16. Using Equation 8.14 the calculated R′2 was multiplied by the TE of the
second echo used for BOLD acquisition in the dcFMRI protocol (TE = 29 ms).
This provided four estimates of MR′2 . These were Mτ=20ms, Mτ=25ms, Mτ=30ms and
Mτfit and results are shown in Figure 8.2. A consistent trend of increasing M with
τ is demonstrated.
8.4.3 Comparison of Haemodynamic Variables Measured using Cali-
brated BOLD, dcFMRI and ASER′2
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Figure 8.2: Subject specific (grey) and group mean (black) MR′2 values calculated
using four different τ weightings are shown above. MR′2 is calculated for a TE = 29
ms which corresponds to the dual echo acquisition used in the dcFMRI protocol.
Maximum BOLD Signal Change, M
M was measured using three different categories of technique. As described in the
previous section, M was estimated by measuring the reversible transverse relax-
ation properties of the brain using ASE. This category, MR′2 , provided four esti-
mates of M as detailed above. M was also estimated using single point, calibrated
BOLD methodologies. This provided estimates of M calculated from hypercapnia
and hyperoxia referred to as Mhc and Mho respectively. Finally M was estimated
from the dcFMRI protocol giving MdcFMRI . Group mean ± standard deviation
for M calculated in GM are presented in Table 8.2. MdcFMRI offers the lowest
estimate of maximum BOLD signal change with MR′2 varying with τ as would
be expected from Figure 8.2. Figure 8.3 shows scatterplots of the M estimates
made using ASER′2 techniques compared to the calibrated BOLD techniques in all
8 subjects. Intraclass correlation (ICC) was used to test the reproducibility of the
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ASER′2 measures, when compared to the other techniques, the results of which can
be found in Table 8.3.
M in Grey Matter
dcFMRI
MdcFMRI 0.046 ± 0.014
calibrated BOLD
Mhc 0.096 ± 0.031
Mho 0.099 ± 0.073
ASER′2
Mτ=fit 0.105 ± 0.012
Mτ=30ms 0.109 ± 0.011
Mτ=25ms 0.099 ± 0.014
Mτ=20ms 0.078 ± 0.019
Table 8.2: Group mean ± std, maximum BOLD signal change measured in GM
for dcFMRI, calibrated BOLD and R′2 measured using ASE.
Mτ=20 Mτ=25 Mτ=30 Mτ=fit
MHC -0.22 -0.07 0.02 -0.02
MHO 0.20 0.18 0.18 0.18
MdcFMRI -0.13 -0.13 -0.05 -0.08
Table 8.3: ICC coefficient calculated for the relations shown in Fig. 8.3 (n = 8).
Comparison of SvO2 and CMRO2 Measured using dcFMRI and ASER′2
with hyperoxic calibrated BOLD
Group mean estimates of SvO2 and CMRO2 in GM made using dcFMRI (inter-
leaved hypercapnic-hyperoxic design) are shown on the first line of Table 8.4(i).
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Figure 8.3: Scatter plots comparing GM measures of M made using ASER′2 to
calibrated BOLD and dcFMRI techniques (n = 8).
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Group mean CBFbaseline in GM was the same with both techniques presented as
the ASL data used for each calculation is a subset of the dcFMRI acquisition.
Group mean SvO2 and CMRO2 values in GM calculated from the combination of
MR′2 and the hyperoxic calibrated BOLD data subset are presented in Table 8.4(ii).
It can be seen that SvO2 varies with τ , as would be expected from Table 8.2 where
MR′2 is shown to vary with τ .
SvO2 CMRO2
(µmol/100g/min)
(i) dcFMRI
Hypercapnia-Hyperoxia 0.54±0.10 182.7±75.5
(ii) ASER′2 + Hyperoxic calibrated BOLD
Hyperoxia - Mτfit 0.50±0.14 188.8±36.6
Hyperoxia - Mτ=30ms 0.48±0.14 197.2±37.4
Hyperoxia - Mτ=25ms 0.53±0.14 178.4±37.6
Hyperoxia - Mτ=20ms 0.63±0.14 139.8±35.4
CBFbase = 49.5 ± 10.1. ml/100g/min
Table 8.4: Group mean SvO2 and CMRO2 values in GM for dcFMRI (i) and MR′2
+ hyperoxic calibrated BOLD (ii). The M values calculated for the multiple τ
weighted ASE images are presented. CBFbaseline is the same for both techniques
Figure 8.4 shows scatterplots of the SvO2 (top line) and CMRO2 (bottom line)
estimates comparing dcFMRI and ASER′2 + Hyperoxic calibrated BOLD in all 8
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subjects. ICC was used to test the reproducibility of the measures between both
techniques the results of which can be found in Table 8.5.
0.2
0.85
S v
O
2 
dc
−F
M
RI
R2=0.1 R2=0.2 R2=0.2 R2=0.2
90 360
90
360
HO−M
τ=20
CM
RO
2 
dc
−F
M
RI
R2=0.1
90 360
HO−M
τ=25
R2=0.1
90 360
HO−M
τ=30
R2=0.1
90 360
HO−M
τ=fit
R2=0.1
Figure 8.4: Scatter plots comparing GM measures of SvO2 and CMRO2 between
dcFMRI and ASER′2 + Hyperoxic calibrated BOLD (HO - MR′2) for various mea-
sures of R′2 using different τ weighted ASE’s (n = 8).
HO-Mτ=20 HO-Mτ=25 HO-Mτ=30 HO-Mτ=fit
SvO2 dcFMRIINT -0.36 -0.43 -0.45 -0.44
CMRO2 dcFMRIINT -0.26 -0.26 -0.22 -0.24
Table 8.5: ICC coefficient calculated for the relations shown in Fig. 8.4 (n = 8).
8.5 Discussion
In this study we investigate the use of ASE to measure R′2 and in turn M as
suggested by Blockley et al. [69, 121]. These measures of maximum BOLD sig-
nal change are then compared to respiratory manipulated FMRI calibration ap-
proaches. Finally we propose a substitution of R′2 derived M into the hyperoxic
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calibrated BOLD approach, in an extension of dcFMRI, for the estimation of
SvO2 and absolute CMRO2. By combining the two techniques we allow hyper-
capnia to be replaced in the dcFMRI protocol and circumvent problems experi-
enced in qBOLD style modelling associated with the interdependence of SvO2 and
CBV.
8.5.1 ASE Signal Attenuation Correction, F(τ)
The attenuation factor used to correct the ASE signal for macroscopic field in-
homogeneities was thresholded cautiously in order to ensure voxels were excluded
where through slice macroscopic gradients were large. From Table 8.1 the num-
ber of voxels removed due to thresholding increase with τ . This is an expected
behaviour and can be explained by considering the effects of increasing τ . As τ
increases, the 180◦ refocusing pulse is moved closer to the preparation pulse effec-
tively refocusing the echo further away from the optimal imaging time at TE. This
allows more time for signal attenuations due to B0 inhomogenities to enhance sig-
nal dephasing and manifest as signal attenuation at the time of image acquisition.
This could be a potential source of bias as different sets of voxels are used in the
calculation of M from different τ ’s due to the thresholding. Considering the worst
case the different sets of voxels would have different OEF’s for each τ . However
this is unlikely as PET studies have shown that OEF is reasonably uniform across
the brain.
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8.5.2 Characterisation of MR′2 with τ
It can be seen from Fig 8.2 that the measurement of M depends on τ . This effect
was also noticed in a study using a gradient echo sampling of spin echo sequence
(GESSE), similar in principle to ASE, to measure R′2 in the brain [127]. They
noticed that the measurement of R′2 was dependent on SE time (what is referred
to in this study as τ). This effect was attributed to the multicomponent structure
of brain tissue. If each component has a different R2 relaxation time the fractional
weighting contributed to the signal from that component is different at different
τ ’s. These findings have previously led to the introduction of a multicompart-
ment model used in the qBOLD approach [115] where main tissue, cerebrospinal
fluid/interstitial fluid and intravascular compartments have been incorporated into
the signal model to account for their separate contributions to R′2 relaxation.
8.5.3 Comparison of Haemodynamic Variables Measured using Cali-
brated BOLD, dcFMRI and ASER′2
Maximum BOLD Signal Change, M
From Table 8.2 group average estimates of M made in GM using the dcFMRI
technique are considerably lower than those made using calibrated BOLD or ASE.
For the ASE derived measurements of M, estimates calculated at a τ of 25 ms
agree best with both hypercapnic and hyperoxic calibrated BOLD approaches. It
can be seen in all ASE measures of M that standard deviation across subjects in
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all τ iterations is considerably lower than that measured using calibrated BOLD
and equivalent to that using dcFMRI.
Scatterplots presented in Figure 8.3 compare M values derived from ASE to those
measured using calibrated BOLD and dcFMRI techniques for each subject. Again
it can be seen that values of M determined by dcFMRI are lower then ASE derived
M’s. From visual inspection of the scatterplots it would appear the measures of
M made using hypercapnia and hyperoxia are the noisier measurements when
compared to MASE as they have a larger spread and obvious produce outliers in
the case of MHO.
The ICC coefficients calculated in Table 8.3 test the reproducibility between tech-
niques. Low ICC values (<= 0) indicate that M measures vary greatly between
the two techniques with high ICC values (0.5 - 1) indicating the values measured
using the two techniques are more agreeable. All techniques are shown to be in
poor agreement with relation to subject reproducibility across techniques but ASE
measures agree best with M’s calculated using hyperoxic calibrated BOLD. A lack
of true underlying biological variability as well as uncertainty in the measurement
could contribute heavily towards the poor ICC’s which show no appreciable cor-
respondence.
Comparison of SvO2 and CMRO2 Measured using dcFMRI and ASER′2
with Hyperoxic Calibrated BOLD
Estimates of SvO2 and CMRO2 made using dcFMRI and ASER′2 with hyperoxia
calibrated BOLD are compared in Table 8.4. Best agreement with ASE for SvO2
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and CMRO2 occur at τ = 25 ms. Scatterplots (Figure 8.4) and ICC coefficients
(Table 8.5) show poor correlation between both methods for both measurements.
This is not surprising considering the poor correlations between M values presented
in Figure 8.3 and Table 8.5. When considering these comparisons it is important
to note that the estimates of SvO2 and CMRO2 are low and high respectively when
made using dcFMRI and compared to literature as discussed by Wise et al. [3] and
in Chapter 4.
The potential influence of varying compartmental R′2 relaxation on M measured
at different τ ’s can also be seen in Table 8.4. As τ increases so does the estimate
of M. This has the effect of decreasing SvO2 and therefore increasing CMRO2 as
all other components of Equations 8.8 and 8.9 remain constant.
It must be noted that group average values of SvO2 and CMRO2 are reasonable
if not a bit high in all cases except τ = 20 ms when compared to expected values
in GM. An analogous approach was attempted using ASER′2 with hypercapnic
calibrated BOLD. Instead of using Equation 8.7, a BOLD signal model presented
by Wise et al. [3] was used which introduces an SvO2 term into this relation.
However estimates of SvO2 were unrealistic (0 >SvO2 >1). This was probably as a
result of the dual calibrated model [3] reducing to Equation 8.7 and their not being
enough information from the isometabolic CBF change induced by hypercapnia to
delineate a unique value for SvO2. In light of this ASER′2 with hyperoxia calibrated
BOLD is viewed as promising. Another important benefit is that the technique
requires CBF to be measured only at normocapnia. This removes any limiting
factors associated with measuring CBF changes with respiratory manipulations
which are present in the dcFMRI hypercapnic-hyperoxic approach.
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Limitations and Further Work
The method and results in this study should be viewed as an intermediary step
to developing a quick and effective measure of cerebral metabolism. However to
make this technique a realistic option for providing quantitative, parametric maps
of absolute CMRO2 further investigation into a number of areas is required.
In this study the limiting factor to producing whole brain, parametric maps is the
ASE measure of R′2. The calculations of R
′
2 are cautiously thresholded to ensure
that the measured R′2 can be attributed to mesoscopic magnetic field inhomo-
geneities. By introducing a multiple spiral acquisition [124–126] more confidence
could be put in the estimates of R′2 by reducing macroscopic magnetic field in-
homogeneities. Previous studies have demonstrated the application of ASE to
measuring R′2 on a voxel by voxel basis [128].
Further work would be required to prove the sensitivity of R′2 to global and regional
changes in physiology such as continuous visual and motor tasks (Chapter 4) or
hypocapnia (Chapter 7) as has been done with the dcFMRI protocol. How-
ever previous studies measuring changes in R′2 with hypercapnia are promising
[128].
Localisation of R′2 for measurement in the appropriate compartments for use in
the hyperoxic calibrated BOLD model requires further consideration. This could
be done by investigating diffusion weighting to suppress signal from intravascular
flow [128] or by using more complex, compartmental style modelling analogous to
the qBOLD approach [115] where main tissue, cerebrospinal fluid/interstitial fluid
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and intravascular compartments have been incorporated into the signal model to
account for their separate contributions to R′2 relaxation.
8.6 Conclusion
In this study we investigate the relationship between single-shot ASE, calibrated
BOLD and dcFMRI techniques for the measurement of maximum BOLD sig-
nal change, M. From this a framework for calculating SvO2 and in turn abso-
lute CMRO2 using qBOLD style relaxometry and calibrated BOLD is presented.
Measurements of R′2 are made using ASE allowing M to be known in a hyperoxic
calibrated BOLD experiment. This then leaves SvO2 to be estimated from the
calibrated BOLD model. The technique can be viewed as an extension of the
dcFMRI methodology where the hypercapnic respiratory manipulation is replaced
by a relaxometry measure.
ASER′2 with hyperoxic calibrated BOLD is a promising technique which allows
problems associated with qBOLD modelling and measurement of SvO2 from cali-
brated BOLD to be solved in a multi parametric approach. Group average mea-
sures of SvO2 and CMRO2 in GM compare well with dcFMRI results. The concept
and techniques used have the potential for a fast and effective method of produc-
ing whole brain, absolute CMRO2 maps in a short scan time without hypercapnia.
However further investigation of R′2 measurement techniques is required to de-
termine it’s global and regional sensitivity to changes in baseline haemodynamic
state and localisation of the signal to relevant compartments for integration into
the calibrated BOLD model.
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Chapter 9
Discussion and Conclusions
Brain function and health are intrinsically linked to oxygen metabolism. As a
result, MR methods such as dcFMRI which provide detailed parametric maps of
CMRO2 consumption are desirable in both a research and clinical setting. dcFMRI
is capable of producing a non-invasive, radioisotope free, easily implementable
routine for measuring absolute CMRO2 and as such offers a competitive alternative
to the current gold standard PET techniques. It offers an absolute, quantitative
measurement of oxygen metabolism which can be monitored longitudinally.
As such, dcFMRI has many prospective applications in basic neuroscience research
and the research and clinical investigation of disease. The relationship between
brain function and oxygen utilisation is important for the understanding of normal
human brain function [129] and a measurement of CMRO2 has the potential to
provide a measure more tightly coupled with neural activity than the BOLD signal.
Measurements of oxygen metabolism are of interest when investigating pathophysi-
ology of stroke [130], particularly in the delineation of the ischemic penumbra [16].
Oxygen metabolism measurements are also of importance for the evaluation of
hypoxia within tumours of the brain and other organs where hypoxia is related
to tumour resistance to therapies [131–133]. Neurodegenerative disorders such as
Alzheimer’s disease [134–136], Huntingtons disease [137], Parkinsons disease [138]
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and other neurological disorders [13,139,140] also demonstrate marked changes of
cerebral oxygenation. In a similar manner, dcFMRI could provide a non-invasive
biomarker of efficacy and inform stop signals in the process of drug discovery and
development for the treatment of such diseases [141].
This thesis aims to further develop the dcFMRI approach in terms of feasibility
and application, aiding the transition of dcFMRI into research and clinical appli-
cations.
In Chapter 3, a dual-echo PASL and single-echo PCASL acquisition were com-
pared to determine the optimal technique available in our imaging centre for im-
plementation in the dcFMRI protocol. The detection of simultaneous task related
changes in CBF and BOLD was chosen as the assessment criterion. The dual-echo
PASL sequence was chosen as the optimal ASL acquisition available for imple-
mentation in all dcFMRI protocols throughout this thesis. When compared to a
single-echo PCASL acquisition, the dual-echo PASL technique offered improved
CBF sensitivity, higher temporal resolution and a greater correspondence between
CBF and BOLD signal changes. It was also largely insensitive to errors in CBF
calculation caused by velocity dependent tagging efficiency errors.
Although such a technique is not currently available in our centre, a dual-echo
PCASL technique has the potential to offer improved perfusion signal SNR with
optimised echo times. However, PCASL tagging efficiency has been shown to
decrease with the administration of a hypercapnic challenge and further work is
required to accurately reduce velocity dependent tagging efficiency errors. This
could be achieved by relating phase contrast measures and PCASL tagging sim-
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ulations, similar to the work presented by Aslan et al. [73] and O’Gorman et
al. [142].
A more relevant improvement, currently available in our centre, is multi-TI ASL.
This may better characterise CBF and overcome any AAT issues that may arise.
However the implementation of this technique reduces the temporal resolution of
the acquisition leading to lower SNR.
In Chapter 4, a dcFMRI framework was introduced and used to investigate re-
gional changes in absolute CMRO2. dcFMRI provides measures of oxygen metabolism
related parameters by measuring CBF and BOLD signal changes in the brain us-
ing an ASL acquisition and modelling these changes using a simple BOLD signal
model. Regional elevations in absolute CMRO2 were produced using continuous
visual and motor stimulation. Two different respiratory manipulations were as-
sessed: an interleaved hypercapnic-hyperoxic challenge allowing the estimation of
[M and SvO2] and a simultaneous hypercapnic-hyperoxic challenge allowing the
estimation of [M, SvO2, α and β].
When compared to an interleaved design, the simultaneous hypercapnic-hyperoxic
respiratory manipulation was capable of detecting significant increases in absolute
CMRO2, induced by continuous visual and motor stimulation as well as agreeable
estimates of absolute CMRO2 in grey matter. This demonstrates the sensitivity
of dcFMRI to detect focal alterations in oxygen metabolism.
In Chapter 5, the repeatability of oxygen metabolism related parameters, made
at rest using dcFMRI, were assessed using both interleaved and simultaneous
hypercapnic-hyperoxic respiratory manipulations in a dcFMRI protocol. This was
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achieved by using the data acquired in Chapter 4 alongside an additional in-
terleaved and simultaneous hypercapnic-hyperoxic dcFMRI protocol performed at
rest on a separate day.
Physiological parameters measured at rest using interleaved and simultaneous de-
signs were compared for intrasession and intersession repeatability using ICC’s.
The interleaved design results in more reproducible measures of CMRO2. How-
ever, questions remain over the sensitivity of the interleaved technique to detect
changes in oxygen metabolism and associated parameters.
Further investigation into the repeatability of oxygen metabolism parameters made
using dcFMRI is required. A larger, more structured repeatability study resem-
bling that used by Liu et al. [91] to investigate the repeatability of TRUST may
better characterise the repeatability of the dcFMRI measures. In Chapter 5,
a rest and task measure was made within session and a single rest measure was
repeated in a separate session. Repeatability may be better characterised by per-
forming multiple within session measures and repeating this routine in several
separate sessions on separate days. Repeatability of regional and global changes
detected in oxygen metabolism could also be investigated by taking the same ap-
proach to performing multiple rest and task measures within session and in sepa-
rate sessions. However, as the current acquisition time is relatively long (18 mins),
these studies become quite time intensive and tedious. Acquisition time savings
offered in Chapter 6 may improve this. It may also be worth investigating if
further improvements in repeatability can be gained through optimisation of the
BOLD signal model similar to the approach taken by Griffeth et al. [85].
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In Chapter 6, a retrospective analysis was performed on the interleaved and
simultaneous hypercapnic-hyperoxic dcFMRI acquisitions to investigate the feasi-
bility of acquiring shorter datasets for absolute CMRO2 quantification. This was
performed on the resting datasets acquired as part of Chapter 4.
The retrospective analysis demonstrated, in theory, that an interleaved respiratory
manipulation used for quantification of absolute CMRO2 in a dcFMRI protocol
could be shortened by acquiring less data during each respiratory block. When
using a simultaneous design, it was shown that acquisition was better shortened
by using less respiratory blocks as opposed to shortening each block individually.
This leads to reliable dcFMRI oxygen metabolism measures in ∼ 9 to 13 minutes.
Further acquisition-time improvements could be made by reducing the amount of
disregarded data during the transition times. Appropriate modelling of the CBF
and BOLD signal during transitions would aid this.
In Chapter 7, dcFMRI was used to measure CBF related changes in OEF during
voluntary hyperventilation. Resting measures were acquired using the previously
established method of interleaved dcFMRI presented in Chapter 4. Subjects then
used voluntary hyperventilation and an end-tidal CO2 feedback task to achieve a
new low flow baseline allowing changes in OEF to be measured.
dcFMRI detected significant changes in CBF and SvO2 measured in global grey
matter due to hypocapnia. This demonstrates the sensitivity of the dual calibrated
FMRI protocol to detect changes in OEF and suggests that the technique is ap-
propriate for clinical application in areas such as stroke or vascular dysfunction in
which flow is impaired. However, it is important to note that reliable estimates of
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SvO2 were not achieved in one of the six subjects scanned. Further improvement
of this study could be achieved by increasing the number of subjects and by per-
forming varying levels of hypocapnia to investigate if there is a linear effect on the
oxygen metabolism and related parameters.
In Chapter 8, hypercapnic respiratory manipulations were replaced in the dcFMRI
framework by relating a measure of R′2, made using ASE, to maximum BOLD sig-
nal change, M. This allowed hypercapnia free measures of absolute CMRO2.
Using ASE to measure R′2 and to infer M alongside a hyperoxic calibrated BOLD
technique has the potential to provide regional measures of SvO2 and absolute
CMRO2. This is an extension of the dcFMRI protocol which circumvents issues
associated with hypercapnia and may have the potential to provide whole brain
maps in a short scan time. More work is required to optimise the measure of
M from R′2 which may include investigating other acquisition techniques or more
sophisticated signal modelling. As this technique is closely related to the qBOLD
class of techniques, a lot can be gained from the advancements made in this field.
An in-depth review of this field has recently been published, Yablonskiy et al. [143],
and provides a good basis for further optimisation.
In conclusion, dcFMRI is a promising technique which has demonstrated regional
and global sensitivity to changes in oxygen metabolism related parameters. Fur-
ther work will improve the repeatability of the technique with proposed time saving
improvements resulting from reduced scan duration and the introduction of ASE
measures of R′2. This will help drive the adoption of this technique in clinical set-
tings, offering a radioisotope free alternative to established PET methods.
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Appendix A
The following derivation applies to Section 2.4 and was taken from Wise et al.
[3].
Starting from the Davis/Hoge model (Equation 2.14), which describes fractional
BOLD signal changes ∆S
S0
in terms of changes in CBF (related to CBV through the
Grubb coefficient, α) and deoxyhaemoglobin concentration [dHb] from baseline
(subscript 0):
∆S
S0
= M
(
1−
(
CBF
CBF0
)α(
[dHb]
[dHb]0
)β)
(A.1)
M is the maximum possible BOLD signal change and is given by:
M = TE · κ · CBV0 · [dHb]β0 (A.2)
A and β are constants that depend on vessel size and geometry as well as magnetic
field strength. The is to find an expression for
(
[dHb]
[dHb]0
)
. According to Fick’s
principle the cerebral rate of oxygen consumption is give by:
CMRO2 = (CaO2 − CvO2) · CBF (A.3)
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where CaO2 and CvO2 are the arterial and venous oxygen contents respectivley and
CBF represents blood flow to the tissue bed in which oxygen is extracted.
It is assumed that CMRO2 is unaltered during hypercapnia and hyeproxia chal-
lenges compared to the baseline condition, therefore:
(CaO2|0 − CvO2|0) · CBF = (CaO2 − CvO2) · CBF (A.4)
The venous oxygen content can be calculated from that bound to haemoglobin
and that dissolved in the plasma:
CvO2 = φ · [Hb] · SvO2 + PvO2 ·  (A.5)
where SvO2 is the venous blood oxygen saturation,  is the coefficient of solubility
of oxygen in blood (0.0031 ml O2/(dlblood mmHg)) and φ is the O2 carrying capacity
of haemoglobin (1.34 ml O2/gHb). In practice, the dissolved oxygen (PvO2 ·) is
negligible in venous plasma. The concentration of haemoglobin is assumed to be
[Hb] = 15 g Hb dl−1blood.
Substituting Equation A.5 into Equation A.4:
CBF0
CBF
=
CaO2 − (φ · [Hb] · SvO2)
CaO2|0 − (φ · [Hb] · SvO2|0) (A.6)
and the venous deoxyhaemoglobin concentration is given by:
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[dHb] = [Hb](1− SvO2) (A.7)
Substituting Equation A.7 into Equation A.6:
CBF0
CBF
=
CaO2 − φ([Hb]− [dHb])
CaO2|0 − φ([Hb]− [dHb]0) (A.8)
Rearranging Equation A.8 gives an expression for venous deoxyhaemoglobin con-
centration with respect to baseline (normoxia and normocapnia) when arterial
oxygen content is increased and/or CBF is altered:
[dHb]
[dHb]0
=
CBF0
CBF
− 1
[dHb]0
(
1
φ
(
CaO2 −
(
CBF0
CBF
)
CaO2|0
)
+ [Hb]
(
CBF0
CBF
− 1
))
(A.9)
for which the arterial oxygen content,
CaO2 = φ · [Hb] · SaO2 + PaO2 ·  (A.10)
can be calculated using the relationship between oxygen partial pressure (PaO2)
and arterial oxygen saturation (SaO2), (the Severinghaus equation):
SaO2 =
(
1
23400
(PaO2)3+150(PaO2)
+ 1
)
(A.11)
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Equation A.9 is then substituted into Equation A.1 and fit for M and SvO2|0 where
[dHb]0 = [Hb](1 - SvO2|0). Baseline rate of cerebral oxygen consumption is given
(in mlO2/100g/min) by:
CMRO2|0 = (CaO2|0 − CvO2|0) · CBF0 = CaO2|0 ·OEF0 · CBF0 (A.12)
allowing OEF0 also to be calculated once SvO2|0 is estimated. Together Equa-
tion A.9 and Equation A.1 characterise the BOLD signal and incorporate the
parameters α and β. Experimental data acquired with simultaneous modulation
of CBF and arterial oxygen content allowed α and β to be estimated from the full
signal model (Equations A.9 and A.1) in addition to M and SvO2|0 and therefore
OEF0 and CMRO2|0. In the specific case of increased arterial oxygen content on
top of increased CBF induced by hypercapnia a relationship can be formulated,
based on the ratio of oxygen related BOLD signal changes at different levels of
CBF, which can be used to constrain estimates of α and β in combination with
data acquired from interleaved hypercapnia and hyperoxia.
We begin with Equation A.1 expressed for the ith level of hypercapnia,
∆Si
Si
= TE · A · CBVi · [dHbi]β0
(
1−
(
CBFi
CBFi|0
)α(
[dHbi]
[dHbi]0
)β)
(A.13)
considering i = 1 for one level of hypercapnia e.g. normocapnia and i = 2 for a
different level of hypercapnia. The ratio of oxygen-related signal changes where
there is no CBF change with hyperoxia is given by:
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∆S1 · S2
∆S2 · S1 =
CBV1
CBV2
· [dHb1]
β
0
[dHb2]
β
0
1−
(
[dHb1]
[dHb1]0
)β
1−
(
[dHb2]
[dHb2]0
)β
 (A.14)
where [dHbi]0 and [dHbi] represent deoxyhaemoglobin concentrations for the ith
level of hypercapnia at baseline and elevated PaO2.
The ratio of deoxyhaemoglobin concentrations can be expanded using a binomial
series assuming that the arterial hyperoxia related change in [dHb] is small, namely(
[dHb]−[dHb]0
[dHb]0
)
<< 1
(
[dHbi]
[dHbi]0
)β
=
(
1 +
[dHbi]− [dHbi]0
[dHbi]0
)β
= 1 + β
(
[dHbi]− [dHbi]0
[dHbi]0
)
+ ...
Substituting the first two terms into Equation A.14
∆S1 · S2
∆S2 · S1 =
CBV1
CBV2
· [dHb1]
β−1
[dHb2]β−1
(
[dHb1]− [dHb1]0
[dHb2]− [dHb2]0
)
(A.15)
Then assuming that the hyperoxia related changes in BOLD signal are small,
namely S1 ∼= S2 and for a pure change in CBF, [dHb1]0[dHb2]0 ∼= CBF2CBF1 , then
∆S1
∆S2
=
(
CBF1
CBF2
)α
· (CBF2)
β−1
(CBF1)β−1
(
[dHb1]− [dHb1]0
[dHb2]− [dHb2]0
)
(A.16)
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During experimentation, [dHbi] - [dHbi]0 is not directly measured. However, for an
increase in arterial oxygen content during hyperoxia, under the assumption that
oxygen metabolism is unchanged, the extra-arterial oxygen appears as a change in
venous deoxyhaemoglobin concentration. Namely, [dHbi] - [dHbi]0 is proportional
to ∆CaO2|i = CaO2|i,hyperoxia - CaO2|i,normoxia, the difference in arterial oxygen
content induced by hyperoxia at the ith level of CBF. Therefore,
∆S1,O2
∆S2,O2
=
(
CBF1
CBF2
)1+α−β
(A.17)
where ∆Si,O2 =
∆Si
∆CaO2|i
is the hyperoxia-induced BOLD signal change normalised
to the hyperoxia-induced change in total arterial oxygen content, administered at
the ith hypercapnic (CBF) level. This gives us a relationship which can be used
with the experimental data from combined hypercapnia and hyperoxia estimate
(1+α - β)
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